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Abstract 
 
Duchenne muscular dystrophy (DMD) with an average global incidence of 
1:5000 is an X-linked recessive disease, caused by mutations in the DMD gene 
encoding dystrophin. Lack of dystrophin isoforms results in progressive muscle 
weakness and cardiomyopathy, leading to loss of ambulation and premature 
death secondary to cardiac/respiratory complications. At present, there is no 
curative treatment. However, implementation of standards of care has 
significantly shifted life expectancy and the natural history of DMD has 
considerably evolved.  Moreover, a number of promising therapeutic approaches 
are under development, some reaching phase II-III clinical trials. These 
experimental therapies will further contribute to the transformation of the 
disease trajectory. 
The projects of my thesis intended to address specific research questions, which 
have an impact not only on the clinical care of DMD patients, but also advice on 
clinical trial design. I studied the effect of steroid therapy on the motor function 
in DMD boys >7 years, more specifically profiling benefits and side effects of the 
most commonly used regimens: intermittent and daily prednisolone. I analysed 
the impact of starting steroids at an earlier age than what is standard of care. I 
explored the role of different dystrophin gene (DMD) genotypes in the motor 
progression of the disease, further defining the genotype-phenotype correlations.  
All results obtained are of particular interest for clinical trials of pharmaco-gene 
therapies targeting specific DMD mutations.  
Dystrophin isoforms also play an important role for the CNS and their lack 
causes morbidity in DMD.  My investigations expanded the genotype-phenotype 
profile specifically in relation to neuropsychiatric co-morbidities in DMD. In 
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conjunction with the CNS profile of DMD, I characterized abnormalities of 
retinal function and developed electroretinography as a potential and non-
invasive CNS endpoint for future clinical trials.  
Addressing the non-ambulant DMD population, I studied quantitative magnetic 
resonance imaging and novel functional measures of the upper limb.  These 
results allow for the first time to evaluate disease progression and response to 
treatment in non-ambulant DMD. All the results obtained in this thesis therefore 
enlarge our knowledge of the disease evolution under current standard 
treatment and contribute to trial readiness by developing new endpoints. 
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CHAPTER 1: INTRODUCTION TO DUCHENNE MUSCULAR DYSTROPHY 
 
Duchenne muscular Dystrophy (DMD, OMIM 310200) is the most common fatal 
childhood-onset condition, with a global prevalence of 1.7-4.2 per 100,000.1, 2  
DMD is an X-linked recessive condition, caused by mutations in the dystrophin 
encoding DMD gene. Lack of dystrophin products results in progressive muscle 
weakness, leading to loss of ambulation and premature death secondary to 
cardiac and respiratory complications. At present, there is no curative treatment. 
 
Revised incidence  
The commonly reported average incidence of DMD is 1:3500 live males.3 
However, these figures have recently been revised, supporting that the average 
global DMD incidence is now closer to 1:5000 live males,4-7 with the drop being 
attributed to both reproductive planning within DMD families and medical 
advances since the 1990s.5 
  
Clinical features 
Affected children are diagnosed between 4 and 5 years of age,8-10 with some 
children being diagnosed as late as 9 years of age, figure which has changed little 
over the last 3 decades. The classic clinical presentation includes the following: 
delayed gross motor milestones, frequent falls, abnormal gait, calf hypertrophy, 
frequent falls and muscle cramps. These features may present in isolation or in 
combination with language delay, intellectual disability, and/or behavioural 
problems. The classic manoeuvre, which reveals the underlying proximal 
weakness is known as “Gowers manoeuvre” and describes the compensatory 
mechanism of climbing on their legs when getting up from the floor (figure1).  
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Figure 1. Gowers manoeuvre 
 
Figure 1. Gowers manoeuvre (Gowers WR. Clinical lecture on pseudohypertrophic 
muscular paralysis. Lancet 1879;ii,73-5.) 
 
However, children may be symptomatic under three years of age, even if signs 
are subtle, showing gross motor and/or language delay when compared to their 
peers.11-13 Recent studies suggests that while there are gains in motor skills in the 
early years, when compared to their peers, even infants and young boys with 
DMD may be losing ground and show less maturational improvement with 
age.11-13 In addition, many boys with DMD have social deficits, which are 
generally appreciated at school age. However it has been demonstrated on 
objective clinical evaluator assessments, those DMD boys younger than three 
show lower average performance on measures of cognitive and social emotional 
development. 
The diagnosis can be suspected following abnormal laboratory result: such as 
elevated creatine kinase (CK), or transaminases (ALT/AST), discovered 
incidentally during investigations for other on-going illness. Table 1 summarises 
various presentations of DMD. 
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Table 1. Various presentations of DMD 
 
Motor presentations 
 Walking delayed beyond 18 months 
Frequent falls 
Toe walking 
Foot posture deformities 
Waddling gait 
Difficulty running, jumping and 
hopping 
Difficulties rising from the floor 
Non-motor presentation  
 Global developmental delay 
Severe intellectual disability 
Neurodevelopmental disorders  
Failure to thrive 
Myoglobinuria  
Malignant 
hyperthermia-like reaction to 
general anaesthetic 
Incidental elevated CK 
Incidental elevated transaminases 
(ALT/AST) 
Positive family history 
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Diagnosis 
a. Creatine Kinase 
Serum creatine kinase (CK) is extremely elevated, 10 to 100 times the upper limit 
of normal (normal levels 2-251 U/L ) since birth, and should be the first 
investigation when DMD is suspected. These CK values may fall to much lower 
levels during the later stages of the condition, as a result to muscle wasting and 
decreased muscle activity. A normal CK at presentation generally excludes the 
diagnosis, however maybe an exceptional finding in patients with X-Linked 
dilated cardiomyopathy or Becker Muscular dystrophy,14 which are the mildest 
end of the dystrophinopathies spectrum. Other liver enzymes, such as aspartate 
transaminase (AST) and alanine transaminase (ALT) can also be 10 to 20 times 
above the upper limit of normal (ALT normal levels 5-30 U/L; AST normal 
levels 0-41 U/L) due to their production also in skeletal muscle. 
 
 c. Molecular genetics 
Confirmation of diagnosis by molecular genetics provides the clinical 
information for genetic counselling, prenatal diagnosis and considerations for 
mutation specific therapies/clinical trials. Approximately two-thirds of the 
affected patients have large deletions in two mutational hot spots of the gene, 
which can be detected by multiplex PCR. 15 For more in-depth analysis 
Multiple Ligation dependant Probe Amplification (MLPA)16, 17 and multiplex 
amplifiable probe hybridization,16 which recently have become more available, 
will cover all exons and detect all deletions and duplications. If MLPA testing is 
negative, and diagnosis highly suspected, DMD gene sequencing should be 
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performed to look for point mutations, or small deletions/insertions, which are 
found in about 13% of DMD patients.18  
Of note, the different types of mutations, such as missense, nonsense, splice-site 
mutations, single base deletions, larger deletions and duplications or rarer 
intronic rearrangements, are spread across the whole DMD gene.19, 20 
Advances in molecular genetics now also allow precise evaluation of the carrier 
status of the relevant females in a family.  
 
 
d. Histopathology 
A muscle biopsy is not necessary if a genetic diagnosis has been established.21 
Nevertheless, the correlation between genotype and phenotype is approximately 
90%19 and therefore if a more precise correlation is required especially for 
patients with mutations that have been associated with different phenotypes, a 
muscle biopsy may be indicated in these cases for a more firm diagnosis. 
For example, some patients do not follow the reading frame rule, therefore out-of 
frame mutations predicted to be associated with a DMD phenotype may present 
with an intermediate/Becker  phenotype, and vice-versa,  in-frame mutations can 
be associated with DMD in up to 7% of cases.22, 23 In such circumstances, a muscle 
biopsy can elucidate if residual protein is expressed, resulting in a milder 
phenotype.  
Tests performed on muscle biopsy include immunohistochemistry and 
immunoblotting of dystrophin. 
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Figure 2. Muscle biopsy images 
 
 
a)   
 
b)    c)   
 
d)   e)  
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f)   
 
 
Figure 2. H&E staining of a normal muscle (a).  H&E staining of a young DMD 
boy showing fibrosis, necrotic and basophilic fibres (b), fat infiltration, 
hypertrophic and atrophic fibres (c). Dystrophin immunohistochemistry: normal 
dys 3 labelling in control (d) and absent dys 3 labelling in DMD (e). Western blot-
sarcomeric α-actinin (f): normal control (A), DMD subjects (C,F) and BMD 
subjects (B,E). Red arrow: α-actinin; blue arrow: normal dystrophin, green 
arrows: dystrophin of reduced molecular weight in BMD. 
 
(Curtsey of Lucy Feng and Silvia Torelli, Dubowitz Neuromuscular centre, UCL 
Institute of Child Health London.) 
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Dystrophin is a rod-shaped protein localised at the inner side of the sarcolemma 
and is part of a complex of (glycol-)proteins: the dystrophin-associated protein 
complex (DAPC) (figure 3). Many muscle proteins, such as α-dystrobrevin, 
syncoilin, synemin, sarcoglycans, dystroglycan, and sarcospan, colocalize with 
dystrophin at the costamere and are believed to share signal pathways.  The role 
of dystrophin is yet not entirely understood, however it is undisputable that it is 
a key protein in the striated muscles, which offers a mechanical support and 
stability to the muscle fibre.  When dystrophin is disrupted this leads to an 
increase in muscle fibre fragility, in part due to the loss of mechanical connection 
between the sarcolemma and the actin cytoskeleton, but possibly also secondary 
to a disturbance in calcium homeostasis resulting in fibre degeneration. 24 
Furthermore, it is now recognised that DMD patients because of the lack of 
dystrophin which harbours a nNOS binding site fail to localise nNOS to the 
sarcolemma. This leads to nNOS mis-localization the cytosol and to pathological 
nitrosylation of the ryanodine receptor resulting in increased calcium leakage 
into the cytosol.25 In addition, lack of functional nNOS at the sarcolemma adds to 
an abnormal regulation of blood flow within exercising muscles.26 Much remains 
unknown, however, of the different factors contributing to the specific clinical 
pattern of the disease.  
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Figure 3. Dystrophin-glycoprotein complex. 
 
 
Figure 3. The dystrophin-associated protein complex.  (Source: Fairclough, Wood 
and Davies, Nature Genetics 2013.) Dystrophin is a rod shape protein that links 
intracellular cytoskeleton network to transmembrane components, which include 
dystroglycan, sarcoglycans, and sarcospan. Neuronal nitric oxide synthase 
(nNOS) binds to alpha-syntrophin and in the rod domain of the protein.   
 
 
Progression 
Following an initial period of apparent stability in relation to muscle weakness, 
as they become older, DMD boys become progressively weak. Muscle weakness 
is more pronounced in the hip extensors, as a result the pelvis becomes unstable. 
Contractures also develop, most commonly affecting the Achilles tendons (TA) 
and the iliotibial bands (ITB). The disease evolves into muscle atrophy, and loss 
of ambulation, historically between 6-12 years of age. With the progressive 
weakness affecting also the upper body, DMD patients will develop progressive 
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scoliosis, secondary to weakness of the para-spinal muscles, which also affect 
respiratory function. Before ventilation was introduced in the late 1970s, death 
occurred in the late teens or early twenties in 90% of patients secondary to 
respiratory complications, and 10% of patients secondary to dilated 
cardiomyopathy (figure 4).27 28 
 
Management 
Despite the major advances in understanding the underlying pathogenic 
mechanisms of the disease, no cure is currently available for DMD. However, life 
expectancy for DMD patients has now shifted well into adulthood with reported 
age of death in the 30s-40s,29-31 as a result of the implementation of internationally 
agreed standardised guidelines of clinical care.32, 33 The standards of care for 
DMD encompass a multidisciplinary medical, surgical and rehabilitation 
approach of the multiple symptoms of the disease.  The key interventions, which 
have profoundly altered the disease course, include respiratory support, surgery 
for scoliosis,31 physiotherapy and intervention with glucocorticoids.34, 35  
 The fundamental pillars of the multidisciplinary approach are summarised in 
the table below: 
1) Orthopaedic management and rehabilitation 
a. Preventive measures for the progressive contractures include 
mobilization, stretching and ankle-foot orthoses mostly worn at 
night-time.36, 37  
b. Prolongation of ambulation for 6-8 months can also be achieved 
with knee-ankle-foot-orthoses.38 
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c. Regular clinical surveillance of scoliosis is imperative;39 and an 
anterio-posterior radiograph is warranted if the curvature is >15o. 
A multidisciplinary team approach is required in establishing 
suitability for scoliosis surgery in patients who are non-ambulant 
and the curvature is >20o. Fortunately, glucocorticoid therapy has 
considerably reduced incidence of scoliosis, hence the need for 
surgical intervention.40, 41  
 
2)  Glucocorticoid therapy 
The use of chronic glucocorticoid therapy in the ambulant phase is 
endorsed by the standards of care documents, and supported by an 
extensive Cochrane review.42 There is evidence that steroids improve 
muscle strength,42, 43 prolong ambulation and function,35, 43 prevent 
scoliosis41, 44 and delay the onset of respiratory failure43-45 and possibly 
that of cardiac dysfunction.44, 46, 47 Steroid therapy, including regimens, 
doses and side effects will be further discussed in the following chapter. 
 
3) Respiratory Management 
Guidelines for the respiratory management include the use of cough 
assist and timely intervention with non-invasive ventilation.48 
Surveillance of respiratory function with spirometry and with sleep 
studies when required is imperative.48  Since the introduction of 
ventilation alone, life expectancy has shifted to 30 years.29  
Furthermore, immunization with 23-valent pneumococcal polysaccharide 
vaccine and annual immunization with inactivated influenza vaccine is 
indicated.33  
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4) Cardiac Management 
Lack of dystrophin in the myocardium invariably leads to a subclinical 
cardiomyopathy, which develops into a progressive dilated 
cardiomyopathy and/or arrhythmia from the second decade onwards. 49 
Cardiomyopathy is the leading cause of death in DMD. Regular 
surveillance of cardiac function is essential. Current management 
includes symptomatic treatment with angiotensin-converting-enzyme 
inhibitors (ACE-I), and if required beta-blockers and diuretics.50  A recent 
US study showed significant benefit when an aldosterone antagonist, 
eplerenone, as an adjuvant therapy.51 Encouraging results from Phase I 
and Phase II studies support treatment with ACE-I for the prevention of 
cardiomyopathy. 52  Furthermore, a retrospective study showed that the 
combination of an ACE inhibitor and a beta-blocker had a beneficial effect 
on long-term survival of DMD patient, suggesting a potential role also for 
prevention. 53    A Phase III randomised placebo-controlled multicentre 
clinical trial is currently on-going in the UK to establish efficacy of 
preventative therapy.  
 
5) Endocrinological management 
Endocrinological aspects have been increasingly gathering the attention 
of clinicians especially to address glucocorticoid therapy associated side 
effects.54 
a. Promoting bone health and preventing steroid induced osteopenia 
is imperative. Guidelines recommend close surveillance of bone 
density with yearly DEXA scans while on steroids, and 
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monitoring for vertebral compression fractions.55-57 Furthermore it 
is recommended to keep the levels of 25-OH-vitamin D within 
normal ranges with chronic prophylactic supplementation. 57 
b. Delayed puberty is invariably observed in steroid treated patients. 
Induction of puberty with testosterone injections is often 
practised, however there is no published data on the long-term 
outcomes.54  
c. Short stature secondary to steroid-induced reduced growth 
velocity is well recognised. Therapeutic options include growth 
hormone IGF-1, however the evidence of IGF-1 as a beneficial 
therapy remains sparse,58 whilst a short stature can possibly 
provide advantage to motor function.59  
d. Finally, there is increased awareness of steroid-induced glucose 
intolerance. Metformin, an insulin sensitizing agent, can be 
considered in selected cases.54 
 
6) Nutrition 
a. The major concern with decreased mobility and steroids is 
excessive weight gain.  Individualised dietary advice on caloric 
intake and appetite control is very important.54 
b. Decreased function of visceral smooth muscle is recognised in 
DMD.60-62 When symptoms of constipation are present many 
patients use iso-osmotic laxatives to facilitate transit. With the 
progression of the disorder pharmacological intervention may be 
required to manage constipation and gastro-oesophageal reflux. 
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Gastrostomy tube may be placed to prevent aspiration and 
optimise nutrition.33  
 
7) Exercise 
Promoting exercise in DMD has been controversial. It is widely 
recognised that high resistive eccentric contractions are damaging for the 
dystrophic muscle fibres, whilst beneficial effects have been reported for 
low-intensity training.63 However, further research is needed to establish 
the optimal exercise training, which does not confer detrimental effects on 
the muscle in the long term as well as on the heart.  
 
8) Psychosocial management 
The medical care of DMD would not be complete without the appropriate 
psychosocial support. Psychosocial adjustment at diagnosis and during 
disease progression require careful considerations.64, 65 Furthermore, there 
is a growing body of literature detailing the cognitive impairment and 
neuropsychiatric comorbidities of DMD, which require prompt 
interventions. 66-68 69-71 70, 72, 73  
 
Evolving natural history and novel frontiers of therapy 
Undoubtedly the natural history of Duchenne muscular dystrophy has 
considerably evolved in the past decades, with a mean age of loss of ambulation 
in the mid-teens and life expectancy reaching mid-40s.29, 32, 33  A schematic 
representation on its evolution is illustrated in figure 4. The natural history of 
DMD continues to be a moving target. With the implementation of the standards 
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of care and the rapidly growing attention to the multifaceted aspects of the 
disease, life expectancy will shift even further and quality of life is also likely to 
improve. 
In the past decades a number of promising potential therapeutic approaches 
have been developed, some have now reached phase II-III clinical trial trials74-82.   
With the emergence of novel therapies there has also been a need to develop and 
sharpen skills for the design of clinical trials, especially challenging for a rare and 
progressive disorder such as DMD.  Moreover, these novel experimental 
therapies will further contribute to the transformation of the disease trajectory 
and will generate yet new questions to be addressed also as part of the standards 
of care.  
 
The projects of my thesis intend to address specific research questions, which 
have an impact not only on the clinical care of DMD patients, but also advise on 
the clinical trials design. 
 
In Chapter 2 I will discuss the impact that steroid therapy had on the motor 
function in DMD boys over 7 years of age, more specifically profiling benefits 
and side effects of the most commonly used regimens, intermittent 10 days on 
and days off and daily prednisolone. 
 
In Chapter 3 I will report the impact of starting steroids at an earlier age than 
what has been generally practiced in clinic. Furthermore I will discuss the role 
that genotypes play in the progression of the disease, further defining the 
genotype-phenotype associations.  This is particularly of interest for the clinical 
trials of emerging pharmaco-gene or gene therapies.  
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In Chapter 4 I will discuss the role of dystrophin and its different isoforms in the 
central nervous system (CNS), more specifically profiling the neuropsychiatric 
co-morbidities in DMD. 
 
In Chapter 5 I will expand on the CNS role of dystrophin more specifically 
related to retinal function and discuss the potential use of electroretinography 
(ERG) as an explorative endpoint in clinical trials 
 
In Chapter 6 I will discuss magnetic resonance imaging (MRI) and novel upper 
limb outcome measures in the non-ambulant population. Assessments of the 
upper-limb in patients who are no longer ambulant offer the opportunity to 
monitor disease progression beyond the loss of ambulation. Furthermore MRI 
offers an alternative and non-invasive method to monitor disease progression 
and therapeutic response in a context of clinical trials.  
 
In the final Chapter, I will discuss the challenges of clinical trials design and 
potential future avenues.    
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Figure 4. Schematic representation of the natural history of DMD 
 
 
(Adapted from Bushby & Connor, Clin. Invest. 2011) 
 
Figure 4. Evolution of the natural history of DMD from no intervention, to the 
introduction of the standards of care, which include steroid therapy, ventilation, 
physiotherapy, orthotics and spinal surgery. * Bushby et al. Lancet Neurol 2010 (1 
&2) 
 
Notes on the history of the disease 
The disorder has been eponymically attributed to the renowned French 
Neurologist  Guillaume Benjamin Amand Duchenne (1803-1875). In 1858 he 
studied the case of a 9-year-old boy who could not walk due to muscle wasting. 
In his seminal publications of 1861 and 1868 and his second edition of De 
L’Electrisation localisee 83 Duchenne describes the disease in considerable detail, 
which crystallises all the essential features including the histopathology findings 
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which he obtained by use of his invention, the “harpoon” to perform 
percutaneous muscle biopsies. In his publication, he proposed the name of 
“hypertrophic paraplegia of infancy” based on the presenting symptoms. He 
described the male predominance, waddling gait, the progressive course, loss of 
ambulation, pseudo-hypertrophy of the calves, and on muscle biopsy he 
described the loss of muscle fibre striation, hyperplasia of fibrous connective 
tissues, fat infiltration, and fascicular atrophy.  
 
However, the first historical account of DMD was reported by the Neapolitan 
physician Giovanni Semmola in 1834 and Gaetano Conte in 1836.84 They 
described 2 brothers with progressive weakness starting at age 8 years and 
enlarged calves, who subsequently developed contractures. The older brother 
died of cardiac failure. At the time, it was thought that this clinical profile was 
perhaps due to tuberculosis of the muscles. 
 
About 10 years before Duchenne, Edward Meryon, an English physician, had 
described at the Royal-Medico-Chirurgical Society a family of four affected 
brothers and six healthy sisters. Meryon was the first to carry out a systemic 
clinical family and pathological study of the disease.  He was the first to 
recognise that this condition was a primary disease of muscles; subsequently on 
autopsy he described the granular degeneration of the tissue, and disruption of 
the sarcolemma, whilst the spinal cord was intact, and he showed that the 
disease was familial, with boys the only affected.85, 86  
 
In his own works, Duchenne refers on several occasions to the papers published 
by Meryon, however he raised concerns that Meryon had mistakenly described 
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his cases as progressive muscular atrophy.83 This misconception about Meryon’s 
description was fuelled by other renowned physicians, such as Lockhart Clarke, 
who was in close contact with Duchenne and co-authored with Gowers a case of 
a young boy identified to have the “pseudo-hypertrophic paralysis” described by 
Duchenne, and at autopsy degeneration of nerve-cells in the grey matter, which 
was in contrast with the normal findings of Meryon.87  
The term “pseudo-hypertrophic dystrophy” was established when William 
Gowers, an English neurologist, gave a series of lectures to the students of 
University College Hospital describing 21 personal cases and 139 cases 
previously described in the literature.88 These lectures where subsequently 
published in the Lancet.88 William Gowers also described the classical 
manoeuvre by which affected children get up from the floor.88  
Since then, important milestones in the history of DMD include the identification 
of elevated serum creatine kinase (CK) in affected individuals and female 
carriers;89 mapping of the dystrophin gene to Xp21;90 the identification 
localization and functional role of the protein dystrophin;91-93  and finally the 
recognition and description of Becker muscular dystrophy as the allelic and less 
severe variant to DMD.94  
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CHAPTER 2: STEROID THERAPY IN DMD   
 
 
Glucocorticoids in DMD: Setting the scene 
Glucocorticoids  (GC) have been used in DMD for about four decades. As early 
as 1974, Dracham et al. observed in an uncontrolled study on 14 DMD patients 
aged between 3 and 10 years that GC had an effect in slowing progression of the 
disease.95 This observation, however, was not supported by a controlled study 
conducted by Siegel et al. over 24 months in a small cohort of 7 Duchenne boys 
aged 6-9 years compared with 7 matched controls. The authors reported no value 
in GC therapy.96   
Despite Drachman’s promising initial observation, no further systematic studies 
were conducted until much later. In 1987 Brooke et al. set up the first multicentre 
open study of 33 DMD patients aged between 5 and 15 years. The authors 
reported overall improvement when compared to natural history controls with a 
The work contained in this chapter has given rise to the following publication: 
Ricotti V, Ridout D, Scott E, Quinlivan R, Robb S, Manzur AY, Muntoni F, on 
behalf of NorthStar Clinical Network. 
Long term benefits and adverse effects of intermittent versus daily glucocorticoids in 
boys with Duchenne Muscular Dystrophy. J Neurol Neurosurg Psychiatry. 2013 
Jun;84(6):698-705. PMID: 23250964. 
 
My contribution to this work consisted of the following: I oversaw the design 
and conduct of the study, and analysis. I oversaw and contributed to data 
collection. I supervised and organised the inclusion of patients from Great 
Ormond Street Hospital into the database.  I led the analysis of the data in 
collaboration with the statistical department at UCL, ICH. I wrote the first 
draft of the manuscript, and I contributed to the revision of the manuscript. 
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dose of 1.5 mg/kg; muscle strength, joint contractures, timed functional tests, 
functional ability, and pulmonary function were measured at the beginning and 
6 months later at the end of the treatment period.97, 98 At the same time, De Silva 
reported long-term benefits in 20 DMD boys in relation to age of loss of 
ambulation, when compared to historical controls.99 
The first randomised controlled trial was a US multicentre study including 103 
subjects aged 5 to 15 years over 6 months, comparing two different regimens of 
prednisone 0.75 mg/kg/day and 1.5 mg/kg/day vs placebo.100 The authors 
reported that improvement was observed as early as one month and peaked by 
three months. At six months the high-dose group (i.e. 1.5 mg/kg/day) when 
compared to the placebo group showed improvement (p<0.001) in the time rising 
from the floor from supine (3.4  and 6.2 sec respectively), the time to walk 9 m 
(7.0  and 9.7 sec respectively), in the time to climb four stairs (4.0  and. 7.1 sec 
respectively), in strength measured as lifting a weight (2.1 and 1.2 kg 
respectively), and in respiratory function measured as forced vital capacity (1.7 
and 1.5 litres respectively). The most frequent side effects observed during the 
study included: excessive weight gain, Cushingoid appearance, and excessive 
hair growth. Given the profile of side effects observed in a short time frame of 
therapy, the authors concluded that GC could not be recommended for long-
term palliative therapy until studies assessing prolonged treatment were carried 
out.101  
The same group of patients was further evaluated to compare alternate-day and 
daily dosing of prednisone with respect to benefits and adverse effects. 102 The 
placebo arm was started on alternate-day prednisone therapy, and the treatment 
group regimens were changed to equivalent doses of alternate-day prednisone. 
At the end of 6 months, the group that was changed from daily to alternate-day 
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GC had declined in strength back to levels observed at baseline. The group in 
which alternate-day therapy was started showed a significant improvement in 
strength at 3 months, not dissimilar to the response of boys treated with daily 
therapy. However, their strength declined significantly afterwards. The 
frequency of side effects was not significantly different for alternate-day therapy 
compared with daily therapy. The authors concluded that alternate-day 
prednisone therapy effectively increases strength but does not sustain the 
improvement to the same extent as daily therapy nor does it mitigate side 
effects.102  
The same research group carried out a study to establish the optimal therapeutic 
dose of prednisone by comparing 0.75 mg/kg/day and the lower dose 
0.3mg/kg/day vs placebo over 6 months in a cohort of 99 patients aged 5-15 
years. 103 At the 3-month visit, the boys in the group receiving 0.75 mg/kg of 
prednisone were stronger than those in the group given 0.3 mg/kg of 
prednisone. At 6 months, more severe side effects occurred in the group treated 
with the higher dose, whilst excessive weight gain was the only side effect 
reported in the group treated at the lower dose of 0.3 mg/kg. 103 
These results were the first to establish a therapeutic window for DMD. 
Moreover, Fenichel et al. reported about the benefits of GC therapy after 3 years 
of treatment. The same cohort of boys earlier recruited in the 6-month 
randomised double-blind controlled trials (n=93) were treated for two additional 
years. At the time of their last visit most of the boys in addition to maintaining 
their strength and their performance in lifting kilogram weights, had also 
improved in some timed function tests. 104 
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In an editorial published in 1991 Dubowitz105 commented the recent studies on 
steroids and recommended an intermittent regimen as a potential avenue to  
avoid the side-effects of prolonged GC therapy (Table 2). Given the clinical rapid 
improvement in muscle strength within 10 days even on low dosage, Dubowitz 
proposed short repeated periods of low dosage daily steroids, with intervals of 
no treatment in between. The periods of treatment would have to be short 
enough to avoid adrenal suppression and associated difficulty in withdrawing 
the drug. One simple regime suggested in the editorial was prednisone 0.75 
mg/kg/day for 10 days at the beginning of each calendar month, followed by no 
treatment for the remaining 20 days of the calendar month.      
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Table 2. Adverse effects associated with chronic systemic glucocorticoid use 
 
Metabolic/endocrinologic effects  Hypokalemia 
 Hyperglycemia 
 Hyperlipidemia 
 Adrenal Suppression 
 Growth Suppression 
 Delayed Puberty 
 Excessive Weight gain 
 Diabetes mellitus 
 Cushingoid Habitus 
Musculoskeletal effects  Osteoporosis 
 Vertebral compression fractures 
 Aseptic necrosis of bone 
 Myopathy 
Dermatologic effects  Dermal thinning and striae 
 Increased skin fragility 
 Acne 
 Hirsutism 
Ophthalmological effects  Cataracts 
 Glaucoma 
Immunologic effects  Diminishing IgG levels 
 Loss of delayed-type 
hypersensitivity 
 Potential for increased risk of 
opportunistic infection, 
reactivation of latent TB, or severe 
varicella infection 
Haematological effects  Lymphopenia 
 Neutrophilia 
Cardiovascular effects  Hypertension 
 Atherosclerosis 
Psychological/neurologic effects  Mood swings 
 Steroid withdrawal syndrome 
 Idiopathic intracranial 
hypertension 
 Psychosis 
 
Table 2: Adverse effects associated with chronic systemic glucocorticoid use as 
reported in Nelson Textbook of Paediatrics, 17th Edition (Saunders editors). 
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An open trial was conducted on 32 DMD subjects close to loss of ambulation, and 
at 6 months demonstrated that this regimen had a positive effect on some 
individuals when strength was measured, however this was followed by a slow 
decline at 12 and 18 months. 106   Weight gain and other side effects observed 
with a continuous regimen were less severe in this group of patients.106   
In 2005, Beenaker et al. designed a study that focused on the initial proposed 
intermittent regimen.107 The authors studied 17 ambulant DMD patients aged 5-8 
years in a randomized, placebo-controlled, crossover trial with 6 months of 
treatment: prednisone or placebo (0.75 mg/kg daily) during the first 10 days of 
each month. After a washout period of 2 months, patients received the other 
regimen for an additional 6 months. Timed functional testing were the primary 
outcome measures, which showed significant difference from placebo; this 
included the time-required-to-run-9-metres (p=0.005) and to climb 4 standard-
sized stairs (p=0.02). The authors concluded that intermittent prednisone slowed 
deterioration of muscle function and muscle force in ambulant patients with 
DMD. 107  Subsequent to the initial suggestion of 10 days-on and 20 days-off 
therapy, in order to increase efficacy such intermittent regimen was modified to 
give prednisolone 0.75 mg/kg/day 10 days on and 10 days off. Encouraging 
long-term results were presented on a case series of 4 boys.108, 109   
An alternative intermitted regimen has been proposed by Connoly et al.: twice 
weekly oral prednisone was given each Friday and Saturday given as 
5mg/kg/dose.110 A cohort study was reported in 2002 suggesting improvement 
in grip strength in 20 treated boys at 12 months, when compared with historically 
untreated cohorts; however growth and weight did not differ from the historical 
controls, suggesting less side effects.  
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Furthermore, deflazacort has also been proposed as an alternative to 
prednisolone/prednisone. One randomised controlled trial comparing 
deflazacort to prednisolone has been published by Bonifati in 2000; 111 the study 
included 18 patients and compared daily regimens of prednisolone and 
deflazacort. The outcomes showed similar benefits over one year; however the 
boys treated with deflazcort did not show the same degree of excessive weight 
gain.  
The complete list of studies on GC in DMD up to 2008 is reported in the updated 
Cochrane Review: Glucocorticoid corticosteroids for Duchenne muscular 
Dystrophy.34 The authors concluded that the most effective regimen appears to 
be prednisolone 0.75mg/kg/day or the equivalent Deflazacort 0.9 mg/kg/day. 
However, on published data, the authors could not evaluate long-term effects of 
GC and different regimens, given the short term nature of the published studies.  
The main limitations of the studies appraised by the Cochrane Review relate to 
the number of patients evaluated, the duration of the studies and the selection of 
outcomes measures.  
With the exception of the studies reported by Mendell et al.101 and  Fenichel et al. 
102,  which included 103 DMD patients (two daily doses vs placebo)101  and 
subsequently followed-up 102 boys (daily vs alternate days), 102 most of the early 
studies included between  15-60 patients.  Griggs et al.103 studied a total of 99 
DMD boys, however only 70 of those were ambulant, and in the same study 
different doses were evaluated. With the current knowledge, it is recognised that 
response to therapy varies between subjects, and also according to the stage of 
the disease; therefore a sample size of even 100 patients  spanning from 5-15 
years of age, from ambulant to non-ambulant and evaluating different 
doses/regimens, is largely underpowered.  Furthermore, the duration of these 
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studies was relatively short. Only 2 randomised studies were conducted for 24 
months. 96, 112 The study reported by  Siegel et al. 96  however only evaluated 7 
DMD boys, hence not surprisingly the 2 year  results were inconclusive.  Pradhan 
et al. 112 also conducted a study over 2 years, however targeting a DMD 
population in a more advanced stage and close to losing ambulation (mean age 
8.5 years).  Despite the general consensus that a response to steroids can be 
clinically observed as early as 3 months, in order to evaluate long-term effects 
and side effects, short-duration studies are not adequate.  Moreover, none of 
these early studies were immune to selection bias, and the authors did not 
address this point. Furthermore, most of these early studies did not evaluate 
response to treatment with validated functional scales or outcome measures (e.g. 
the NorthStar ambulatory assessment), but relied on manual muscle strength 
measurements, which can be operator-dependant, or timed tests (i.e. time taken 
to rise from the floor), which can be motivation-dependant.  Finally, the 
intermittent regimen 10 days on/off suggested by Dubowitz105 and now widely 
used in the UK was only evaluated on 4 DMD boys by Kinali et al.108 
Most recent work include the study by Mazzone et al.113, which evaluated 
functional changes in a national cohort of 106 steroid treated patients using 
validated outcome measures (e.g. 6-minute walk test and NSAA) as primary 
endpoints. 113 Furthermore, a recent randomised-blinded clinical trial compared 
high dose weekend prednisone (10 mg/kg/week) vs standard daily dose (0.75 
mg/kg/d) over 12 months in 64 DMD boys.114, 115 The study provided evidence 
measuring both force and function that high dose weekend prednisone is equally 
effective in preserving muscle strength/function, while the side effect profile was 
similar in the two regimes.  
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A study published in 2015 by Bello et al. for the first time reported on the long-
term effects of deflazacort therapy in 80 DMD patients, showing that the use of 
daily deflazacort was associated with prolonged ambulation when compared to 
any prednisolone regimen; however Cushingoid features, growth retardation 
and cataracts were more frequent.116   
Finally, a very recent study for the first time systemically evaluated upper-limb 
function in steroid treated non-ambulant DMD boys, supporting the current 
consensus among clinicians that GC should not be discontinued after loss of 
ambulation.117  
Table 3 summarises the key prospective studies that evaluated GC therapy. 
 
 
 
 
Table 3. Prospective published studies on prednisolone treatment: design, 
sample size glucocorticoids regimen and duration of treatment. 
 
STUDY GC regimen Design Duration Number of 
patients 
Mendell 1989 Daily Randomised 
double blinded 
6 months 103 
Fenichel 1991a Alternate 
days/daily 
Randomised 6 months 102 
Griggs 1993 Daily Randomised 18 months 99 
Bonifati 2000 Daily Randomised 12 months 18 
Pradhan 2006 Daily Randomised 24 months 67 
Rahman 2001 Daily Randomised 6 months 19 
     
Griggs 1991 Daily Randomised 
double blinded 
6 months 99 
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Drachman 
1974 
Alternate days Open 3- 28 months 14 
Siegel 1974 Alternate days Double-blind 24 months 14 
Brooke 1987 Daily Open 6 months 33 
DeSilva 1987 Daily first then 
alternate daily 
Open 1-11 months 16 
Beenakker 
2005 
Intermittent Randomised 
double blinded 
6 months 17 
Backman 1995 Daily Randomised 
double blinded 
6 months 41 
Parriera 2007 Daily/ 
Intermittent 
Cohort 14 months 32 
Yilmaz 2004 Alternate days Cohort 3 years 66 
Fenichel 
1991b 
Daily Open 2 years 93 
Sansome 1993 Intermittent Open 6-18 months 32 
Kinali 2002 Intermittent Open 5 years 4 
Connolly 2002 Weekend high 
dose 
Open 22 months 20 
Mazzone 2011 Intermittent and 
daily 
Cohort 12 months 106 
Escolar 2011 Daily vs 
weekend high 
dose 
Randomised 
blinded 
12 months 64 
Bello 2015 14 different 
regimens 
Cohort 4 years 340 
Pane 2015 Daily/ 
Intermittent 
Cohort 12 months 91 
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Mechanism of action of glucocorticoids 
The precise mechanism of action of GC in dystrophic muscles remains largely 
poorly understood. In unaffected subjects the most prominent change in skeletal 
muscle following GC treatment is a mixed atrophy affecting type II fibres more 
severely than type I fibres.118 Studies have consistently shown that steroids 
increase number of mitochondria in both sub-sarcolemmal and inter-myofibrillar 
loci, and this alteration is expected to be beneficial in dystrophies, since 
mitochondrial increase should confer prolonged activity and fatigue resistance.119  
The precise mechanism of their action is unknown, but prednisolone- treated 
DMD muscle has shown a significant anti-inflammatory effect. Mononuclear cell 
analysis showed significantly fewer T cells, cytotoxic/suppressor T cells and less 
muscle fibres focally invaded by inflammatory cells, compared with muscle 
biopsies from the placebo group.120  
In addition it has been shown that prednisolone enhances myogenesis in 
dystrophin-deficient skeletal muscle of the dystrophic animal model: the mdx 
mouse. It has been hypothesized that GC reduce muscle necrosis and stabilise the 
muscle fibre membrane.121 In mdx dystrophic mice, RNA profiling studies 
identified over-expression of metabolism, proteolysis and structural protein 
genes. 121  And finally, Fischer et al. demonstrated that skeletal muscle gene 
expression profiles of mdx mice, treated with prednisolone when compared with 
control mice at 1 and 6 weeks showed a differential expression of calcium 
metabolism genes.122 At both time points, overexpression of a cohort of genes 
relating to metabolism and proteolysis was apparent, alongside the differential 
expression of genes relating to calcium metabolism. In the treated mdx soleus 
muscle, the percentage of slow fibres was significantly lower compared with 
untreated controls after 6 week of treatment.  
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All of these results show how complex the GC action is upon dystrophic muscle, 
and how many different pathways are likely involved in conferring benefit to 
dystrophin-deficient tissue. 
 
Note on glucocorticoids 
Prednisone is an ester pro-drug that is converted to the active prednisolone in the 
liver through the action of 11-beta-hydroxydehydrogenase. Both prednisone and 
prednisolone have equipotent GC effect. Deflazacort is a methyloxazoline 
derivate of prednisolone: 1.2 mg of Deflazacort is equivalent to 1 mg of 
prednisolone. 
 
A study on long term benefits and adverse effects of intermittent 
versus daily glucocorticoids in boys with Duchenne muscular 
dystrophy 
In my study I analysed data collected through the NorthStar clinical network for 
paediatric neuromuscular disease (NSCN), from January 2004 to September 2011. 
We focused on clinical outcomes from different GC regimens and analysed 
outcome measures and side effects in the largest steroid-treated cohort of DMD 
boys studied to date.  
Methods 
The NorthStar Clinical Network and database 
The NSCN was established in the United Kingdom at the end of 2003, with the 
objective of optimising the care and acquiring longitudinal natural history data 
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on DMD boys treated and assessed according to a specified standardised 
protocol, including GC.32, 33 Currently there are 21 participating specialist 
paediatric neuromuscular centres. A full list of participating centres is available 
on line http://www.northstardmd.com/study-centres.html and in the appendix. 
A secure web-based database has been set up with the collaboration of CERTUS 
technology, and is currently used for data collection since 2006. Prospective data 
are uniformly and systematically collected across centres facilitating national 
audits. Physicians and physiotherapists complete standardised forms biannually.  
A national training programme was implemented to ensure standardisation of 
physiotherapy data collection across centres and a national coordinator assures 
standardised re-training across the network. Baseline information is recorded at 
registration (table 4). At each follow-up, medical and physiotherapy data are 
documented including steroid regimen, side effects, outcome measures, and a 
management plan (table 4).  
The NorthStar database collects clinical information on DMD boys with an out-
of-frame mutation in the DMD gene, confirmed by DNA diagnostic technique 
covering all DMD gene exons, including but not limited to Multiplex Ligation-
dependent Probe Amplification.  Where DMD deletions or duplications were not 
identified, all 79 exons and the adjacent introns were analysed through PCR 
amplification and direct sequencing, although the search for point mutation was 
not available uniformly throughout UK. Mutations are classified according to the 
Leiden Muscular Dystrophy database.123  
Boys with no confirmed mutation but absent dystrophin in muscle biopsy (<5% 
on immunohistochemistry) are also included in the database. Information is 
recorded with signed parent/guardian informed consent. The data is linked-
anonymised and each subject is assigned a unique NorthStar ID number. 
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Table 4. Key medical and physiotherapy information recorded on the database 
 
Baseline information 
 
Medical information at  
follow-up 
Outcome measures at  
follow-up 
Demographic data  Date of starting GC Ambulation status and 
mobility aids 
Genetic mutation§ Current dose and regimen 
of GC  
Age at loss of independent 
ambulation  
Maternal carrier status§  Adverse behavioural 
changes 
Respiratory status (FVC, 
FVC%)  
Date of diagnosis Gastrointestinal 
symptoms 
Echocardiogram (LVFS%) 
Features of the muscle 
biopsy ǂ 
Increased appetite NorthStar Ambulatory 
Assessment score 
Family and social history History of infections Time rising from the floor 
from lying 
 Height and weight Timed 10 metre run 
 Blood pressure Manual muscle testing 
 Cushingoid features Joint range 
 Bone density 
measurements  
Spinal posture 
 Long bone fractures and 
vertebral fractures 
 
 Cataracts  
 Hirsutism  
 Delayed puberty  
 Other therapeutic 
interventions 
 
 Adjustment in GC 
dose/regimen  
 
 
Table 4: Key medical and physiotherapy information recorded on the database  
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§Genetic diagnosis and maternal carrier status confirmed by a state-of-the-art 
DNA diagnostic technique covering all DMD gene exons. ǂ Dystrophin 
expression observed on muscle biopsy by immunohistochemistry with 
monoclonal antibodies dys1, dys2, dys3 (i.e.: complete absence, traces).   
GC = Glucocorticoid corticosteroids; LVSF% = Left Ventricular Shortening 
Fraction percentage; FVC% = Forced Vital Capacity percentage. 
 
 
 
Patient population  
At the time of my data analysis in September 2011, 500 patients were registered 
on the NorthStar database. Prospectively collected longitudinal data were 
available for 360 DMD boys between 2004-2011 (figure 5, table 5) ranging from 
age 3-17. Longitudinal data was available only for boys treated with GC, who 
represent the large majority of DMD boys in the age range studied. GC therapy is 
systematically offered and only exceptionally refused by parents. We classified 
boys according to the GC regimen: daily prednisolone (daily), intermittent 
prednisolone 10-days-on/10-days-off (intermittent), alternate days prednisolone, 
and deflazacort-treated. Some boys changed regimen of GC between daily and 
intermittent or vice-versa (switchers). All patients included were treated 
according to the integrated multidisciplinary standard of care,32, 33 and assessed 
by specialised neuromuscular physiotherapists. 
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Figure 5. Flow-chart of boys included in the study 
 
 
Figure 5: Flow of patients from registration in the database to enrolment in the 
study §Data with missing key medical information refers to essential data 
required for statistical analysis (e.g.: dose of glucocorticoids, date of birth of the 
patient, date of assessment).  
†Assessments saved in draft format were not confirmed, therefore excluded from 
the analysis.   
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Table 5. NorthStar patients’ breakdown by centre 
Neuromuscular Centre No. of 
patients 
No of subjects 
recruited  
Birmingham Heartlands 
Hospital 
52 44 
Frenchay Hospital, Bristol 11 2 
University Hospital of Wales, 
Cardiff 
14 14 
Kings Cross Hospital, 
Dundee 
9 6 
Evelina Children’s Hospital 16 14 
Royal Hospital for Sick 
Children, Glasgow 
9 0 
Great Ormond Street 
Hospital, London 
142 122 
Leeds 35 26 
Alder Hey Hospital, 
Liverpool 
34 27 
Royal Manchester Children’s 
Hospital 
36 24 
International Centre for Life 
Newcastle upon Tyne  
66 41 
University Hospital, 
Nottingham 
4  
Orthopaedic & District 
Hospital NHS Trust, 
Oswestry  
24 16 
Preston Royal Hospital 12 6 
Sheffield Children’s Hospital 19 15 
Southampton General 
Hospital 
15 3 
Morriston Hospital, Swansea 2 0 
Total 500 360 
52 
 
Table 5. NorthStar patients’ breakdown by centre, completion percentage of data 
entry and number of patients recruited in the analysis as of September 2011. 
NorthStar Clinical Network Study centres are listed on the following website: 
http://www.northstardmd.com/study-centres.html. 
 
 
Physiotherapy outcome measures 
The NorthStar Ambulatory Assessment (NSAA) is a validated composite scale to 
measure function in ambulant DMD boys.124, 125 It is widely used in the UK, 
internationally, and in clinical trials.126 79, 81 This scale has recently been confirmed 
by Rasch analysis to be a psychometrically robust scale.127 The assessment 
consists of 17 items (table 6), with three ordered response categories (maximum 
score 34). Items can be scored 2 (activity carried out normally with no obvious 
modification), 1 (goal achieved independently with modified method), or 0 (task 
cannot be performed independently). Clear instructions are described in the data 
entry form. The scale is completed in 20 minutes and contains a number of timed 
tests: timed 10-metre-run-test (10mRT), timed rising from the floor from lying 
(Gowers’ manoeuvre).  
 
Side effects 
Side effects recorded include objective evaluations carried out during clinical 
appointments (i.e.: weight, height, blood pressure, whole spine bone density 
measurements, vertebral fractures), and adverse events reported by the 
families/boys and logged by the physician as mild, moderate or severe (i.e.: first 
presentation or aggravation of behavioural problems, insomnia, abdominal 
pains, gastroesophageal reflux, increased appetite, history of infections) 
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according to the instructions provided in the clinical forms, which were 
discussed and agreed at national consensus meetings organised at the inception 
of the network. 
 
 
 
Table 6. The 17 items of the NorthStar Ambulatory assessment 
 
NorthStar Ambulatory 
Assessment 
Stand 
Walk  
Stand up from chair 
Stand on right leg 
Stand on left leg 
Climb box step -right leg 
Climb box step -left leg 
Descend box step -right leg 
Descend box step -left leg 
Gets to sitting 
Rise from the floor 
Lift head 
Stand on heels 
Jump 
Hop – right leg 
Hop –left leg 
Run (10 metres) 
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Statistical methods 
I described the general patient characteristics for each GC regimen. As this is an 
observational study and some patients switched regimens throughout the course 
of their treatment, comparisons between regimens were analysed in three ways: 
1. as per initial treatment, daily vs intermittent; 2. by majority of treatment, daily 
vs intermittent, as defined by the overall majority of time treated with one 
regimen (≥ 60% of time); 3. by removing switchers. Results for these three 
approaches were very similar for all analyses; therefore, we have presented final 
results for the most clinically relevant “majority of treatment” (daily or 
intermittent).  Switchers were too heterogeneous to be grouped as one cohort of 
patients for the purposes of the analysis.  
For the time to loss of ambulation (LOA) a Cox regression model was used to 
compare the effect of daily versus intermittent. An adjustment was made for 
random centre effects and hence the hazard ratio is presented along with a 95% 
CI, derived using robust standard errors. For the main longitudinal functional 
outcome measure NSAA score, a running line smoother (i.e. lowess smoother) 128 
was used to provide a graphical representation of a locally weighted regression 
of a dependent variable (i.e. age) on a predictor variable (i.e. NSAA) . This 
revealed a definite change in the relationship after about age 7, which was in line 
with what observed clinically and reported before.113, 129  A piecewise linear 
spline128 with a single knot (changing point) at age 7 was used to allow for this 
effect: in other words we fitted a function defined by 2 sub-functions (one under 
boys age 7 and another function for boys above age 7.  The spline, which is a 
smooth linear function,128  was incorporated into a two level multilevel model 
with the random effect of patient nested within random centre. This allowed 
comparing the longitudinal effect of age between daily and intermittent, both 
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before and after age 7 years, by fitting two interaction terms for age and regimen. 
We fitted a similar model for 10mRT and the timing for the Gowers’ manoeuvre; 
as this data was skewed, a log transformation was used. The longitudinal models 
were adjusted for the length of time on steroids prior to entry to the database.  
Additionally, we hypothesised that BMI may be related to outcome and therefore 
explored the models adjusting for BMI z-score. As BMI data was unavailable for 
some observations (13%) we used multiple imputation with the method of 
chained equation  to generate five imputed data sets, so rather than a single value 
being imputed for every missing value, each missing value is imputed in a series 
of imputed data sets and these are combined together.130 This was done 
assuming the data was missing at random, which means that the probability that 
a value is missing depends only on observed values and not on unobserved 
values.130 Estimates obtained from the multiple imputations were pooled to 
obtain a single set of results. 
We compared the NSAA total score in boys who started GC before age 5 versus 
after age 5 with a multilevel model adjusting for treatment. For respiratory and 
cardiac outcome measures a linear multilevel model was used to investigate the 
relationship of Forced Vital Capacity percentage predicted (FVC%) and Left 
Ventricular Shortening Fraction percentage (LVSF%) respectively, with age and 
the interaction with treatment regimen. 
Side effect profiles reported by families and, where possible measured during the 
consultation, were compared as proportions by χ2 analysis. The BMI was 
calculated from height and weight. Height, weight and BMI centiles for gender 
and age were derived against the British 1990 Growth Reference and converted 
to z-scores (LMS Growth Calculator).131 BMI z-scores were described as mean 
and 95% CI. At time of latest follow-up, differences between intermittent and 
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daily BMI, height and weight z-score means were compared by regression 
analysis adjusted for length of time on steroids. Single measurements at last 
follow-up were used for patients on treatment more than one year. BMI z-score 
means were compared for intermittent and daily at baseline using a two-sample 
t-test. Baseline included pre-GC single measurement to a maximum of three 
months into treatment. Hypertension was defined as a blood pressure >95th 
percentile. 
For all tests, a p-value of ≤0.05 was considered statistically significant. The 
statistics package Stata132 was used for the analysis.  
 
Results 
Longitudinal data on 360 patients were included in the analysis (figure 5, table5). 
Seventy-two percent of the patients registered in the database were recruited in 
the study. The mean age of starting GC was 6.4 years (range 3.4, 9.8) and mean 
duration of treatment and follow-up was 3.9 years (range 0.5, 8.5).  Intermittent 
(n=154) and daily (n=136) were the most common regimens, used in 73% of boys 
on GC; additionally 70 of 72 switchers were treated with daily or intermittent 
prednisolone (table 7B). The general characteristics of intermittent, daily and 
switchers were similar in relation to age starting steroids, mean dose of GC, 
duration of treatment, duration of follow-up as NSCN registered patients (table 
7A). The mean dose of GC was an overall group mean through the full period of 
treatment, which included dose adjustment in line with weight and tolerability. 
A total of 28 boys discontinued GC.  
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Table 7. General characteristics of patients 
A. 
 Age of 
diagnosis 
(years) 
mean, range 
Age of 
starting GC 
(years) 
mean, range 
Duration of 
treatment 
(years) 
mean, range 
Dose of GC  
(mg/kg/day) 
mean, range 
Duration of 
follow-up  
(years) 
mean, range 
IP (n=154) 4·4 (0·3-9·4) 6·5 (4·2-9·6) 3·6 (0·5-8·5) 0·6 (0·3-0·8) 2.5 (0.2-5.4) 
DP (n=136) 4·3 (0·3-9·4) 6·2 (4·2-9·8)  4·3 (0·5-7·5)  0·5 (0·3-0·8) 2.7 (0.3-7.8) 
SW (n=72) 4·2 (0·2 -8·6) 6·3 (3·4-9·2) 4·1 (0·7-7·8) 0·6 (0·3-0·8) 3.2 (0.4-6.9) 
DFZ (n=19) 5·5 (0·5-8·7) 7·0 (5·2-9·3) 4·4 (0·6-7·9) 0·6 (0·4-0·9) 2.8 (0.6-7.0) 
AD (n=15) 4·4 (1·3-8·2) 6·3 (4·4-9·0) 5·0 (2·4-7·5) 0·6 (0·3-0·8) 2.0 (0.2-3.9) 
Not on GCs 
(n=32) 
3·3 (0·9-6·9) ---- ---- ---- ---- 
 
 
B. 
 IP DP DFZ AD 
Starting regimen 57 12 2 1 
Majority of treatment 37 33 1 1 
Age of switching 
regimen mean, 
ranges (years) 
8·4 
(5·6-12) 
8·5 
(7·3-9·3) 
 
---- 
 
---- 
 
 
Table 7: General characteristics of patients  
(A) Summary of patients’ characteristics (n=428) with mean and ranges: age of 
diagnosis, age of starting steroids, duration of treatment, dose of steroids during 
the whole duration of treatment, and duration of follow-up since registration on 
the database. (B) Switchers (n=72): In the analysis 70 switchers were included as 
per majority of treatment for intermittent and daily.  
GC = Glucocorticoid corticosteroids; IP = intermittent prednisolone 10-
dayson/10-days-off, DP =daily prednisolone, SW =switchers, DFZ =deflazacort; 
AD =prednisolone on alternate days.  
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Figure 6. Survival curve on loss of ambulation 
 
 
 
 
Figure 6: Kaplan-Meier analysis estimates for loss of ambulation and Cox 
regression 
Loss of ambulation was reported in 48/176 intermittent prednisolone, and 
36/165 in daily prednisolone.  Median loss of ambulation intermittent =12 years, 
daily =14.5 years. Hazard ratio 1.57 (95% CI 0.87, 2.82) p=0.13. 
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Outcome measures 
Loss of ambulation (LOA) was reported in 51/184 intermittent and 39/168 daily 
(figure 6). Two boys were never ambulant and excluded from this part of the 
analysis; ambulation status was unknown for the remaining six. Median LOA 
was 12 years for intermittent and 14.5 years for daily. Hazard ratio for 
intermittent versus daily was 1.57 (95% CI 0.87, 2.82; p=0.13) and the mean age 
for LOA did not differ. The longitudinal analysis of NSAA total score showed a 
difference in the relationship with age between the two regimens after 7 years of 
age (figure 7). Daily showed the slowest decline, with the difference between the 
2 regimens increasing by 1.58 units per year, 95% CI 1.04, 2.11; p<0.001. This 
result was consistent when adjusting additionally for BMI z-score.  Adjusting the 
NSAA total score model for severe learning difficulties, we observed an overall 
difference in means (2.74 NSAA points, 95% CI 0.37, 5.10; p=0.02), such that 
patients with learning difficulties performed worse. There was little change in 
the relationship with age between intermittent and daily (coefficient 1.36, 95% CI 
0.79, 1.94; p<0.001), compared with the model without learning difficulties. 
Comparison of the NSAA total score between patients who started GC over and 
under age 5 years, after adjusting for regimens, demonstrated an overall motor 
function improvement  in favour of children who started early treatment 
(difference =3.04, 95% CI 0.15, 6.23; p=0.06). For the 10mRT outcome, there was 
evidence of a difference in the relationship over time between the two regimens 
after age 7 years, favouring daily (figure 8A). The difference increased by 6% per 
year on average, 95% CI 3%, 9%; p<0.003. A similar clinical observation was 
found for time rising from the floor (Gowers’ manoeuvre) with a difference after 
age 7 of 6% per annum, 95% CI 0%, 12%; p=0.06 (figure 8B). After adjusting for 
BMI z-score the size of this effect decreased for both outcomes. 
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We also described the slope of decline for respiratory and cardiac function. 
Respiratory and cardiac outcomes were not different between intermittent versus 
daily regimens (Figure 9). The entire cohort (daily and intermittent together) was 
then analysed as one group. Within the age range of the cohort, mean values 
remained within normal limits. However, there was a significant progressive 
decline in the FVC% by 2.2% per annum (p<0.001) after age 10 years; and in the 
LVSF% by 1% per annum (p<0.001) after 12 years old.      
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Figure 7. North Star Ambulatory Assessment total score intermittent versus 
daily prednisolone 
A      B 
 
C 
 
 
 
Figure 7: North Star Ambulatory Assessment total score intermittent (blue) 
versus daily (red) prednisolone 
(A) NSAA total score running line smoother for daily and (B) intermittent 
prednisolone. NSAA decline began at 7 years in the daily group and at 6 years in 
the intermittent group. (C) A fitted multilevel model and interaction for the 
NSAA total score was calculated comparing intermittent and daily. There were 
862 episodes. There was a definite change in the relationship after 7 years of age: 
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< 7 years interaction coefficient -0.81 (95% CI 0.42, 2.04), p=0.2;  ≥7 years 
interaction coefficient -1.58 (95% CI  1.04, 2.11) p<0.001. Intermittent deteriorates 
faster than daily after 7 years of age. For each additional year, the difference in 
NSAA total score between the 2 regimens increases by 1.58 points.  
 
 
 
 
Figure 8. 10 metres run time and time rising from the floor: intermittent 
versus daily prednisolone 
 
 
 
 
Figure 8: 10 metres run time (A) and time rising from the floor (B) intermittent 
versus daily prednisolone (log secs)  
Daily prednisolone (in red) shows a slower progression in both timed tests 
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Figure 9. Left Ventricular Shortening Fraction percentage and Forced Vital 
Capacity percentage: intermittent versus daily prednisolone 
 
 
 
 
Figure 9:  Left Ventricular Shortening Fraction percentage (LVSF %) and Forced 
Vital Capacity percentage (FVC %): intermittent versus daily prednisolone 
(A) Left Ventricular Shortening Fraction percentage running line smoother for 
intermittent and (B) daily prednisolone.  There were 683 episodes. There was no 
evidence for a difference in slopes between regimens (p=0.11). The relative 
reduction was 1% per annum (p< 0.001) for both groups. (C) Forced Vital 
Capacity percentage running line smoother for intermittent and (D) daily 
prednisolone. There were 964 episodes. There was no evidence for a difference in 
slopes between regimens (p=0.16). The relative reduction was 2.2% per annum 
(p< 0.001) for both groups. 
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Side effects 
 
Side effects were summarised for intermittent and daily prednisolone, assigning 
switchers by “majority of treatment” (table 8). 
Moderate and severe side effects were more frequently observed in daily GC. 
Statistically significant differences were found in daily/intermittent respectively: 
Cushingoid features 33%/15%, hyperactivity 23%/15%, gastro-intestinal 
symptoms 14%/6%, and hypertension 22%/5%. Severe side effects alone were 
not significantly higher in the daily group. Baseline BMI did not differ between 
intermittent and daily (figure 10 A), both groups gaining excessive weight (figure 
10 D), however the mean height z-score, adjusted for length of time on steroids 
was significantly lower in daily, with a mean difference of 1.09 (95% CI 0.78, 1.40; 
p<0.001) (figure 10 C). The overall effect at latest follow-up was a significant 
increase from baseline in BMI in both regimens, but daily more severely affected 
than intermittent with a mean difference 0.43 (95% CI 0.11, 0.74); p<0.01 (figure 
10 B). Bone health was compromised in both intermittent and daily GC (table 9): 
BMD z-scores ≤-2.5 on DEXA scan were observed in 5 % in intermittent 8% in 
daily. Vertebral fractures were defined by the NSCN as vertebral wedging on 
lateral spine radiography.57  
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Table 8. Moderate to severe side effect breakdown 
 
SIDE EFFECTS Intermittent n (%) Daily n (%) χ2 p-value 
Temper tantrums 54 (28%) 67 (40%) 0·02* 
Mood swings 56 (29%) 64 (38%) 0·08 
Aggressiveness 41 (21%) 49 (29%) 0·09 
Hyperactivity 29 (15%) 39 (23%) 0·05* 
Emotional 
liability 
23 (12%) 32 (19%) 0·06 
Insomnia 8 (4%) 19 (11%) 0·01* 
Cushingoid 
features 
28 (15%) 56 (33%) < 0.01* 
GI symptoms  12 (6%) 23 (14%) 0·01* 
Increased 
appetite 
73 (38%) 78 (46%) 0.1 
Hypertension 10 (5%) 38 (22%) < 0·01* 
Vertebral 
fractures 
8 (4%) 14 (8%) 0·1 
Long bone 
fractures 
13 (7%) 9 (5%) 0·5 
§BMD z-score ≤ -
2.5 
9 (5%) 14 (8%) 0·1 
Cataracts 2 (1%) 4 (2%) 0·3 
Hirsutism 19 (10%) 24 (14%) 0·2 
Easy bruising 5 (3%) 7 (4%) 0·4 
 
Table 8: Moderate to severe side effect breakdown, χ2 analysis (intermittent 
prednisolone n=191; daily prednisolone n=169). 
§BMD z score = lumbar spine  
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Figure 10. BMI, height and weight: intermittent versus daily prednisolone 
 
 
 
Figure 10: BMI, height and weight: intermittent versus daily prednisolone: 
(A) BMI z-score (mean, ± 95% CI) at baseline: there was no significant group 
difference between BMI. Intermittent (n=67) baseline mean z-score 0.62 (95% CI 
0.39, 0.85), daily (n=32) baseline mean z-score 0.88 (95% CI 0.50, 1.27), p=0.2. (B) 
At maximum period of treatment§ there was a group difference in BMI favouring 
intermittent (n=99) versus daily (n=102): Intermittent BMI mean z-score 1.51 
(95% CI 1.27, 1.75), daily 1.99 (95% CI 1.79, 2.19), p=0.002. (C) Height restriction 
was significant in daily (n=104) but there was no group loss of height for 
intermittent (n=101): Intermittent height mean z-score -0.70 (95% CI -0.90, -0.49), 
daily -1.77 (95% CI -2.00, -1.53), p<0.001. (D) Weight z-score (mean, ± 95% CI) at 
maximum period of treatment: intermittent (n=123) weight mean z-score 0.79 
(95% CI 0.57, 1.01), daily (n=122) 0.50 (95% CI 0.29, 0.71) p=0·06.  
§Maximum period of treatment= single measurement at last follow-up of patients 
at least one year into treatment.  
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Discussion 
Here I report the largest prospectively collected multicentre longitudinal clinical 
data of ambulant DMD boys treated with GC according to internationally agreed 
standards of care. In particular, I describe the long-term efficacy and tolerability 
of intermittent versus daily prednisolone in 360 UK-treated DMD boys, on 
treatment for a mean of 4 years. In this study I included 191 boys on intermittent 
and 169 boys on daily prednisolone. Switchers (n=70) did not affect results, and 
were analysed by “majority of treatment” regimen. 
Survival analysis of median LOA favoured daily treatment (14 years) with two 
years advantage compared to intermittent (12 years). However, the hazard ratio 
was not statistically significant because the mean ages were not different. DMD 
boys lose ambulation by the end of the first decade if untreated,45, 133 however 
daily therapy has been shown to prolong ambulation beyond 13 years of age.42, 45 
Additionally, the implementation of the international standards of care endorsed 
by the NSCN and NICE, through addressing the multi-system requirements of 
DMD, may also significantly contribute to prolongation of ambulation.  
I demonstrated that the two regimens equally gain function until 6 years but after 
age 7, boys on intermittent GC decline more rapidly with an incremental 
difference (NSAA score 1.58 per annum). There was also a faster decline in the 
10mRT and Gowers’ manoeuvre: 5% and 6 % respectively per annum. Boys with 
severe learning difficulties performed worse on motor assessments, but this was 
not affected by steroid regimen. Our data indicate a clinically significant benefit 
in starting GC early, fuelling the on-going debate on how early treatment should 
be started.134 A recent long-term case series of four DMD boys treated between 
age 2-4 reported prolonging ambulation beyond 16 years.135 In my study, boys 
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who began treatment before 5 years of age showed a trend towards slower 
functional decline.  
Despite the relatively young age of the cohort, in the second decade respiratory 
and cardiac outcomes showed a decline of LVSF% by 1% and FVC% by 2.2% per 
annum, irrespective of treatment regimen. 
A larger proportion of patients on daily GC reported moderate to severe side 
effects. Cushingoid features (33% vs 15%), behavioural problems (40% vs 29%) 
and hypertension (22% vs 9%) were significantly higher in daily GC treatment. 
We highlighted a significantly increased BMI in daily (mean z-score 1.99) versus 
intermittent (mean z-score 1.5), and severe height restriction in daily (mean z-
score -1.77) compared to intermittent treatment (mean z-score -0.70).  
Long-term use of GC is a recognised and well-described risk factor for decreased 
bone mineral density and increased incidence of vertebral fracture in DMD.54, 55, 
57, 136 In our studied population, symptomatic vertebral fractures were seen in 8% 
on daily and 4% on intermittent. A prevalence of up to 32% has previously been 
reported in smaller series of chronically GC-treated DMD boys.137 Asymptomatic 
vertebral fractures are possibly less likely to be ascertained by the NSCN 
database.  NSCN DEXA scan data (table 4) suggest that applying the standard of 
care reduces osteopenia, affecting only 8 % of boys on daily prednisolone. 
Nascent and evolving guidelines on bone protection in DMD recommend: 
normalisation of serum 25-hydroxyvitamin-D3 with oral supplements at 
diagnosis, close surveillance while on GC, annual DEXA and intravenous 
bisphosphonates for symptomatic vertebral fractures.57 Furthermore, 
osteopenia/Z-scores ≤-2.5 require a lateral spine radiograph looking for vertebral 
deformity, which may require bisphosphonate treatment.57 The NSCN aims to 
incorporate these recommendations for the future. 
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A number of prospective studies have been published on GC treatment in DMD, 
ranging from cohort studies to randomised-double-blinded clinical trials (see 
table 3). Only two studies compared daily with intermittent GC in the short-
term.113, 114 A recent randomised-blinded clinical trial compared high dose 
weekend prednisone (10 mg/kg/week) vs standard daily dose (0.75 mg/kg/d) 
over 12 months in 64 DMD boys.114 The study provided evidence that high dose 
weekend prednisone is equally effective in preserving muscle function for some 
of the outcome measures, but with increased linear growth and lower BMI.114 
A recent longitudinal multicentre cohort study reported NSAA changes over 12 
months on 106 ambulant DMD boys.  A clear slope of change was observed at 
the age of 7, also confirmed by our findings; above age 7 (n=71), a slower rate of 
decline was reported in boys on continuous GC.  No randomised controlled 
study has previously reported data on LOA in DMD boys treated with an 
intermittent regimen.113 
Our study has several limitations: incomplete and partially missing data, 
adjusted for in the statistical analysis; outcome measures and side effect profile 
were analysed collectively and not as single patient trajectories; side effects were 
assessed in clinic and included parental reports; there was no validated quality of 
life information; there were no validated measures for learning difficulties and 
behavioural problems; and analysis did not adjust for severity of phenotype at 
enrolment. Furthermore, it is difficult to account for the effect of GC treated boys 
whose parents did not consent, or for incomplete data. Finally, we could not 
compare outcomes with an untreated cohort, as almost invariably families would 
agree on starting GC.  Following this study, a more rigorous definition of side 
effects will be introduced in the NSCN, particularly concerning behavioural 
problems, using validated psychometric evaluations. Nevertheless, for the first 
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time our analysis provides long-term outcome data from diagnosis to LOA in a 
large sample representative of the ambulant DMD population in the UK. These 
data offers evidence for a functional benefit of intermittent prednisolone, 
possibly more so if initiated early, delaying median LOA to 12 years. This 
contrasts to the very modest effect of intermittent GC given to older boys.42 The 
intermittent regimen was overall better tolerated with fewer adverse effects.  
Although multiple randomised controlled clinical trials (RCTs) remain the gold 
standard in determining therapeutic safety and efficacy, there is an increasing 
recognition of the importance of observational studies.138-141 A robust well-
designed and properly analysed secure database containing prospectively and 
systematically acquired data can be a valuable tool for guiding evidence based 
decisions in relation to treatment and in designing future controlled trials.142 Our 
study provides a framework for consultation when starting treatment, however 
does not offer a definite answer on which GC regimen should be used, and a 
long-term RCT of intermittent vs continuous GC is required. The NSCN is 
collaborating in an international clinical trial of different steroid regimes funded 
by the National Institutes of Health (FOR-DMD: Finding the Optimum Regimen 
of Corticosteroids for DMD), which will compare daily prednisone/deflazacort 
regimens versus intermittent in a young steroid-naïve population in a 
randomised controlled trial.143 
A future challenge will be to assess the efficacy and safety profile of continuing 
GC administration in the non-ambulant population.  With the implementation of 
multidisciplinary interventions, in particular respiratory management, life 
expectancy has shifted to the third/fourth decades compared with the 
second/third decades for steroid-naïve patients.29 GC in DMD is likely to further 
prolong life. Longitudinal analysis is required to evaluate survival and quality of 
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life in DMD, and determine the optimal treatment protocol in continuing GC 
treatment beyond LOA.  
In conclusion, our study comparing benefits and tolerability of the most widely 
used GC regimens in the UK addresses one of many facets of a multi-system 
disorder, which is evolving.  Further prospective collection of clinical data with a 
robust and refined tool can significantly facilitate monitoring and improving the 
standards of care for this common genetic disease.   
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CHAPTER 3: VARIABILITY OF PHENOTYPE IN DMD: IMPLICATIONS 
FOR CLINICAL CARE AND CLINICAL TRIAL DESIGN 
 
 
Experimental therapies in DMD 
In recent years a number of experimental therapeutic approaches have been 
developed. These can be divided in three major groups:  
 
1) Those aiming at restoring the absent dystrophin protein in muscles, and 
mostly targeting specific mutations of the dystrophin gene. These 
therapeutic approaches include:  
 exon skipping mediated by antisense oligomer nucleotides,78-81  
 read-through of intragenic stop codon mutations by small molecules,144, 145  
 
2) Other non-mutation dependent therapeutic approaches include: 
The work contained in this chapter has given rise to the following publication: 
Ricotti V, Ridout D, Scott E, Mayhew A, Main M,  Manzur AY, Muntoni F, on 
behalf of NorthStar Clinical Network . The Northstar ambulatory assessment in 
Duchenne muscular dystrophy:  considerations for the design of clinical trials  J 
Neurol Neurosurg Psychiatry. 2015 Mar 2. [Epub ahead of print]. PMID: 
25733532  
 
My contribution to this work consisted of the following: I oversaw the design 
and conduct of the study, and analysis. I led the analysis of the data in 
collaboration with the statistical department at UCL, ICH. I wrote the first 
draft of the manuscript, and I contributed to the revision of the manuscript. 
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 ibedenone, a potent antioxidant, which proved to be effective in 
stabilising pulmonary function in non-ambulant subjects in a phase 3 
trial;146  
 tadalafil, which through the  inhibition of the nitric oxide –cyclic 
guanosine 39,59-monophosphate pathway promotes muscle blood flow, 
and proved to alleviate functional muscle ischemia in a small cohort of 
DMD boys.147 Currently in a phase III clinical trial;  
  up-regulation of utrophin by a novel small molecule; utrophin is a close 
evolutionary relative of dystrophin. Up-regulation of this protein with 
SMT C1100, an orally available small molecule in animal models proved 
to compensate for the lack of dystrophin in skeletal muscle in the mdx 
mouse.148 Currently a phase Ib clinical trial is on-going. 
 
3) And finally viral-mediated gene therapy, which can be used as 
replacement therapy, for example using a mini-dystrophin149-151 or to 
correct specific mutations, for example through U7- or U1-mediated exon 
skipping.152-154 
 
Mutation specific therapeutic approaches 
Approximately 70% of dystrophin mutations are deletions that affect the normal 
splicing of the dystrophin RNA transcript into mRNA. As a result the normal 
dystrophin mRNA open reading frame is disrupted leading to a prematurely 
truncated dystrophin protein. The abolished production of a functional protein is 
the underlying cause of the disease. 
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Mutations in the DMD gene are also found in Becker Muscular Dystrophy 
(BMD), however characterised by a much milder phenotype when compared to 
DMD.27, 155 This milder phenotype occurs because the BMD mutations generally 
affect the centre of the gene and maintain the open reading frame, which in turn 
allows the production of a shorter but functional protein product.156  Clinical 
observations of BMD patients, who remained ambulant until old age or did not 
develop muscle weakness at all despite expressing 30-60% of dystrophin on 
muscle biopsy, fuelled the idea that restoring at least a partially functional 
protein can ameliorate the disease course of DMD. An approach to restore 
normal mRNA reading frame is by exon skipping, which can be induced by 
antisense oligonucleotides (AONs), synthetized fragments of nucleic acids, which 
modulate RNA splicing in the pre-mRNA at the proximity of the mutation, 
resulting in a shorted mRNA, which however carries a normal open reading 
frame and can produce a partially functional BMD-like protein (figure 11). Two 
types of chemistries have advanced into clinical trials: phosphorodiamidate 
morpholino oligomers and 2’-O-methyl RNA with a phosphorothioate backbone; 
a review of the chemical properties and differences has been published by 
Arechavala-Gomeza and colleagues.157   The recent drug developments have 
targeted exon 51 of the DMD gene, as this could be applied to approximately 14% 
of the mutations resulting in DMD (see table 9).20 Proof of concept studies 
showed dystrophin restoration by local and systemic administration.76-79 
Therapeutic efficacy and safety profiles have been established and reported in 
recently published phase II studies.80, 81  AONs targeting other exons (i.e. 44, 45, 
53, ) are also currently being developed, and both chemistries are now in phase I-
II clinical trials. 
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An alternative approach includes delivering an antisense sequence linked to a U1 
or U7 snRNA gene packaged into a recombinant adeno-associated virus vector, 
which showed promising results in animal models,154 and a clinical trial targeting 
exon 53 is currently being planned.  
 
 
Figure 11.  Schematic representation of the principal of exon skipping  
 
 
 
Figure 11: Schematic representation of the principal of exon skipping   
In the top image a deletion of exon 50 leads to the disruption of the mRNA 
reading frame. No protein is produced. 
In the bottom figure, an antisense oligomer targeting exon 51 in the pre-mRNA 
and preventing its inclusion into the mRNA restores the open reading frame 
leading to the production of a truncated but functional protein.  
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Table 9. Applicability of single exon skipping  
 
Exon Applicability for 
deletion 
Applicability for 
all mutations 
51 20.5% 14.0% 
45 13.1% 9.0% 
53 11.8% 8.1% 
44 11.1% 7.6% 
50 5.6% 3.8% 
43 4.5% 3.1% 
8 2.9% 2.0% 
55 2.5% 1.7% 
52 1.3% 0.9% 
11 1.3% 0.9% 
 
Table 9: Applicability of single exon skipping  
Deletions that can be corrected by skipping of either of the flanking exons (i.e: 
deletion exon 52) were not counted twice. Source20  
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Approximately 13% of subjects with DMD carry an intragenic nonsense mutation 
of the dystrophin gene.20 A nonsense mutation results in a premature stop codon 
within the protein-coding region of the corresponding mRNA and causes 
premature termination of translation, which therefore results in on of a non-
functional protein product.  An alternative strategy to exon skipping, which aims 
at restoring dystrophin in patients with eligible mutations, is ribosomal read-
through mutation suppression of the premature stop codon. As amino acid 
inclusion at the nonsense mutation-carrying codon is a chance process many of 
the dystrophin proteins thereby created are expected to carry missense 
mutations. A proof-of-concept phase IIa study demonstrated that ataluren/PTC 
124 produced dystrophin in patients with nonsense mutations;158 a subsequent 
Phase IIb registration-directed study showed patients receiving treatment at a 
lower dose experienced significantly slower progression when compared to 
placebo.82  Currently the compound is being evaluated in a phase III clinical trial.  
 
Gene replacement therapy 
Replacement of the defective dystrophin gene offers another promising 
approach, which can potentially be life-prolonging. This strategy is currently in 
pre-clinical phase of development and planned to go forward to the clinic in 
2017. 
The design of clinical trials in Duchenne muscular dystrophy 
The development of therapies for DMD and the rapid explosion of clinical trials, 
especially in the past 6 years, have triggered the requirement for some important 
considerations about the design of clinical trials.  
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The overall natural history of DMD has significantly changed in the recent years. 
With the introduction of glucocorticoid (GC) therapy and systematic 
implementation of the standards of care, age at loss of ambulation  (LOA) and 
life expectancy is gradually shifting to a later age, requiring continuous 
monitoring of the evolving clinical course DMD.43, 159-161 In addition, mutation-
specific therapeutic approaches, as discussed above, have generated the need for 
understanding the natural progression of the targeted genotype subgroups, 
especially if differences from the overall DMD population exist. It is recognised, 
for example, that some patients with mutations skippable by exons 44 or 45 may 
present an intermediate phenotype, due to an elevated number of revertant fibres 
and residual dystrophin expression;162, 163 however, the influence of the different 
genotypes on disease course appears to be modest according to a recent study.129  
Furthermore, the course of DMD can also be influenced by the age at starting GC 
and GC regimen42, 35 The standards of care suggest initiating GC in the plateau 
phase;32 33 the additional benefit of starting therapy at an younger age has been 
reported  on a small case-series of children135 which invites further exploration.  
 
Clinical trials design of rare progressive disorders, such as DMD, poses various 
challenges: 1) the number of patients who can be recruited into studies is often 
limited. In case of exon skipping recruitment is mutation-specific, making it 
problematic to run large and well-powered studies; 2) cohorts may be too small 
to allow for a placebo arm, and small cohorts may not be representative of the 
natural variability even within a genotype, thereby leading to skewed results; 3) 
validated outcome measures may only capture a snapshot of the progression of 
the disorder and not be applicable to different stages of the condition, further 
limiting the number of patients recruitable into studies (e.g. the 6-minute walk 
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distance test,164 a validated primary outcome measure in a number of clinical 
trials, can only be performed in ambulant individuals of at least 4 to 5 years); 4) 
most of the future genetic therapy approaches will target small cohorts due to 
high costs of experimental therapies and the challenges of running large 
multinational studies and will also need long-term follow-up to allow 
ascertainment of potential side effects, thereby emphasizing the need for precise 
subgroup characterization. 
Large natural history studies, if systematically conducted, can meaningfully 
inform the design of clinical trials, by offering an up-to-date description of the 
progression of the condition according to concurrent standards of care, and a 
valid platform of natural history data to guide both inclusion criteria and 
outcome measure selection.  
In this study, which focused on the NorthStar Ambulatory Assessment (NSAA) 
as a measure of motor function, our objectives were the following: 1) to assess the 
NSAA evolution in ambulant DMD boys in the UK treated according to the 
agreed standards of care; 2) to describe the rate of progression of a subgroup of 
young DMD boys in the UK treated with GC below five years of age; 3) to 
describe the NSAA rate of decline in DMD stratified for DMD genetic mutations 
including individuals in the UK and in the Italian neuromuscular clinical 
network . 
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A study on the NorthStar ambulatory assessment in Duchenne 
muscular dystrophy: considerations for the design of clinical trials. 
 
Methods 
Through the UK NorthStar Network and database, which encompasses 17 
neuromuscular centres, clinical data from 2004-2012 on 513 ambulant DMD boys 
between 3 and 16 years of age (mean age 9.5 years) were included in the analysis. 
The database systematically collects clinical information on DMD boys in UK. 
The diagnosis is confirmed in most cases by DNA diagnostic technique covering 
all DMD gene exons, and/or a muscle biopsy. Mutations were classified 
according to the Leiden Muscular Dystrophy database.123 All patients included in 
the analysis were treated according to the standards of care,32, 33 comprising 
therapy with GC administered ether as daily prednisolone/deflazacort or 
intermittently (ie: prednisolone 10 days on:10 days off or alternate days35, 42).   
For the analysis of the young DMD patient, I addressed the evolution in UK boys 
from 3 years onwards, comparing those who started GC before and after 5 years 
of age, as this would be a relevant population for future clinical trials.  
 
NorthStar Ambulatory Assessment  
The NSAA is a validated one-dimensional functional scale for ambulant DMD 
boys.124, 125 The scale is suitable for multicentric studies,124-126  and is widely used 
internationally, both in clinical setting and as secondary outcome measure in 
clinical trials.  Both traditional and modern psychometric (Rasch) analysis has 
confirmed this to be a robust scale.127 Recently an updated linearized version of 
the scale has been developed following in-depth Rasch analysis, to improve the 
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interpretation and capturing of clinical meaningful changes across the breadth of 
the scale.165  
 
Statistical methods for the UK dataset 
I used frequencies and percentages to describe the number of boys with each 
mutation. I described the median and other percentiles for age at LOA, along 
with 95% CI using the Kaplan-Meier method.  
Previous work showed a difference in the relationship between motor function 
and age, up to 7 years of age compared with later stages in childhood35, 43, 113, 129, 
160, 161, 166; therefore we decided to look at these 2 time periods separately for the 
purposes of this study.  
NSAA score was our primary outcome, additionally I converted the raw NSAA 
total scores into linearized scores. Using Rasch methodology recently reported165, 
the conversion was performed via a logit transformation, and this formed a 
linearized score on a 0-100 scale. I used this linearized transformation of the 
NSAA scale in all subsequent analyses and present the results in terms of this 
linearization. The benefit of this approach is that the change score means the 
same across the breadth of the scale. Furthermore analyses were repeated for the 
raw NSAA score scale and results are presented in brackets, as raw scores are 
perhaps more readily understood by clinicians. The transformed score was 
calculated using total NSAA score minus the score for lifts head (as this item 
poorly fits the construct of ambulation). With the number of items reduced from 
34 to 32, the raw scores were converted to 100 points on the new scale as 
reported.165 For some children the lifts head component of the NSAA scale was 
missing, therefore it was not possible to convert their total NSAA score to the 
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linearized score. I performed a sensitivity analysis considering several possible 
values for the missing lifts head score and derived the corresponding linearized 
scale.  I found the results from these analyses were robust and there was no 
impact on subsequent findings. We fitted a separate multilevel model for each 
time period (data over age 7 years and data under 7 years), with a random effect 
for patient nested within random centre. I modelled the relationship between 
NSAA and age and adjusted for age at start of GC, and treatment regimen. In 
addition, by including interaction terms in our models we explored whether the 
rate of deterioration after age 7 or improvement in motor function up to age 7 
varied according to the type of mutation: duplication, deletion or point mutation.  
For the early time period we explored whether there was a difference in 
improvement in NSAA between those boys who started treatment early (before 
age 5) and those who started later (between 5-6.5 years), by fitting an interaction 
term. Simple comparisons for items in the NSAA scale were made between early 
and late starters using t tests. Similarly, BMI z scores131 were compared between 
early and late starters. 
Fractional polynomials were used to check for any non-linearity in the 
relationship between independent factors and NSAA outcome. 
 
Populations with skippable deletions - UK and Italian dataset  
Genetic information was available for 442 of 513 UK boys (figure 12). Mimicking 
the setting of phase II and phase III clinical trials for the sub-analysis of the 
skippable genotypes, we included: 
1) All DMD boys >5 years of age; 2) with a transformed NSAA total score of 
52/100 or above at time 0/baseline (corresponding to ~ 230 metres 6MWD159; 3) 
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and on stable GC for a minimum of three months at baseline; 4) boys with at least 
24 months longitudinal data.  
This resulted in a reduced dataset of 223 DMD boys from UK, which was 
combined with 172 DMD boys followed-up by the neuromuscular Italian clinical 
network coordinated by the Department of Paediatric Neurology, Catholic 
University, Rome. Of the Italian DMD boys, 74 had specific skippable deletions: 
20 with deletions exons 44/46 skippable; 1 exon 44 skippable; 17 exon 51 
skippable, 1 exons 51 or 53 skippable; 25 exon 53 skippable; 8 exon 50 skippable; 
2 exon 52 skippable.  
 
Figure 12 . Genotype breakdown of individuals registered in the UK 
NorthStar database. 
 
 
Figure 12: Genotype breakdown of individuals registered in the UK NorthStar 
database. Genotype information was available for 442 UK DMD boys. 
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Statistical methods for skippable populations 
I compared the change in linearized NSAA over time between skippable exons 
for the UK and Italian data combined. For the Italian patients data was available 
at fixed time points, at 12 months and 24 months follow-up. We created a similar 
format of data from the UK NorthStar database using fixed data ± 1 month and 
combined the two datasets together (n=223+172=395 DMD). Since a small 
minority of DMD boys can benefit from skipping more than one exon, we fitted a 
series of multilevel models, each including two interaction terms to compare the 
rate of decline in NSAA between those boys with and without a particular exon 
skip. The first interaction term compared the decline over 12 months and the 
second the decline over 24 months. All models included a random effect for 
patient nested within country; we adjusted for age at follow-up and treatment 
regimen. 
All analyses were conducted in Stata  and for all tests a p-value of < 0·05 was 
considered statistically significant.132   
 
Results  
UK NorthStar dataset 
Age at loss of ambulation  
In the UK NorthStar database, ambulation was lost in 137/513 boys between 9.5 
and 16 years, including all GC treatment regimens. The median LOA was 13 
years (95% CI: 12.1, 13.5). We also calculated the 10th centile: 9.5 years (95% CI: 
9.1, 9.9); the 25th centile: 10.9 years (95% CI: 10.1-11.1); and the 75th centile: 16 
years (95 %CI: 15 -na). (Figure 13, table 11) 
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Figure 13.  Survival curve for loss of ambulation  
 
 
 
 
 
 
Table 10. Centiles for loss of ambulation 
 
 
Centiles LOA Age (years) SE 95% CI 
10
th
 Centile  9.5 0.1 9.1-9.9 
25
th
 Centile 10.9 0.2 10.1-11.1 
50
th
 Centile 13 0.3 12.1 – 13.5 
75
th
 Centile 16 0.7 15- 
 
 
  
86 
 
NorthStar Ambulatory Assessment slope of decline in boys > 7 years of age 
It was previously reported that DMD patients gain motor function up to age 7, 
after which they start to decline.35, 43, 113, 160, 164, 166 In our cohort, the overall slope 
coefficient was -7.8 (95% CI -8.8, -6.9) [-3.7, 95% CI -4.1, -3.3], meaning that our 
DMD population on average lost 8 linearized NSAA units/year, after age 7 
(figure 14). The estimated linearized NSAA score at age 7 was 73.4 (95% CI 70.3, 
76.5) [27.4, 95% CI 26.1, 28.6] (p<0.01). When compared to the whole DMD 
population, a positive interaction coefficient 0.7 (95%CI: -1.9, 3.3) [raw NSAA:0.5 
(95%CI -0.7, 1.7)] suggested a possible trend for a slower decline in boys with 
duplications (p=0.5), and a trend towards a more rapid decline in boys with 
point mutations (interaction coefficient= -1.5; 95% CI -4.1, 1.1; p=0.2) [raw 
NSAA:-0.3 95%CI -1.5, 1.0]; however neither of these differences was significant. 
In order to determine which NSAA score may best predict LOA within 24 and 12 
months, assuming mean LOA of 13 years, we estimated the mean linearized 
NSAA score from our model, which in our population was 41.9 units, (95%CI 
38.5, 45.3) [12.6, 95%CI 11.2, 14.1] 2 years prior to LOA, and 34.0 units (95% CI 
30.1, 38.0) [8.9, 95% CI 7.2, 10.7] 1 year prior to LOA.  
 
 
 
 
  
87 
 
Figure 14. Linearized NSAA total score in DMD boys > 7 years of age 
 
 
 
Figure 14. Linearized NorthStar Ambulatory Assessment slope of decline in boys 
> 7 years of age 
With an average linearized NSAA score of 73.4 (95% CI 70.3, 76.5) at age 7 [raw 
NSAA: 27.4, 95% CI 26.1, 28.6] the overall slope coefficient was -7.8 (95% CI -8.8, -
6.9) [raw NSAA: -3.7, 95% CI -4.1, -3.3], meaning that our DMD population on 
average lost 8 linearized NSAA units for each year, after age 7 (p<0.01). At 8 
years of age the mean linearized NSAA was 65.5 (95% CI 62.7, 68.4) [23.7, 95% CI 
22.6, 24.8], while at 10 years of age it was estimated to be about 49.7 units (95% CI 
46.8, 52.8) [16.3, 95% CI 15.1, 17.5]. The mean linearized NSAA score was 42 units 
34 units 24 and 12 months before losing ambulation [equivalent to 13 and 9 raw 
scores respectively].  
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NorthStar ambulatory assessment in young DMD boys 
Prior to age 7, young DMD improve their motor function, with an overall gain of 
4.0 linearized units/year (95%CI: 2.2, 5.8) (p<0.001) [1.4, 95%CI 0.6, 2.1], adjusting 
for treatment regimen. As part of this analysis we explored the impact that 
starting GC before age 5 may have on DMD as measured by the NSAA.  When 
comparing 78 DMD who started daily or intermittent GC early, before age 5 
(mean age at start =4.5 years) with 163 boys who started GC between ages 5 and 
6.5 (mean age at start =5.7 years) the coefficient of interaction was -2.7, (95%CI, -
6.8, 1.3, p=0.2), favouring early starters by almost 3 linearized units a year (figure 
15) [Raw NSAA:-1.3, 95%CI -3.0, 0.3, p = 0.1]. By age 7, the mean total NSAA was 
different between the two groups (p<0.01): 73.8 (95%CI 67.5, 80.1) [27.0, 95%CI 
24.6, 29.4] in early starters and 68.7 (95%CI 64.1, 73.4) [25.1, 95%CI 23.2, 26.9] in 
the late-starter group.  
A difference between the 2 groups was observed in the following items of the 
scale: standing on heels (p=0.002) jumping (p=0.004), hopping (p=0.001), lifting 
head (p=0.009), standing to sit (p=0.008) and the 10 metre run (p=0.05). The mean 
SD BMI for early starters and late starters showed no statistical difference at 7 
years (p=0.2). 
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Figure 15. Linearized NSAA total score in DMD boys <7 years of age  
 
 
 
 
Figure 15. NorthStar ambulatory assessment in DMD boys < 7 years of age. 
The interaction coefficient between 78 DMD boys who started daily or 
intermittent GC before the age of 5 (in blue) with 163 boys who started steroids 
between ages 5 and 6.5 (in orange) was -2.7, (95%CI, -6.8, 1.3, p=0.2) [raw NSAA:-
1.3, 95%CI -3.0, 0.3], p = 0.1 favouring early starters. By age 7, the mean total 
NSAA was 73.8 (95%CI 67.5, 80.1) in early starters and 68.7 (95%CI 64.1, 73.4) in 
the late starters (p<0.01) [raw NSAA: [27.0, 95%CI 24.6, 29.4 in early starters and 
25.1, 95%CI 23.2, 26.9 in late starters]. 
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NorthStar ambulatory assessment in UK and Italian skippable populations  
For this sub-analysis we included 395 DMD (ie: 223 UK +172 Italian) boys 
meeting the age/motor function and GC requirement for inclusion criteria in 
most of on-going clinical trials as described in the methods above. The whole 
population showed a decline of 5 units (95% CI -6.5, -3.5; p <0.001) at 12 months 
and 13.8 (95% CI:-15.7, -12.0; p <0.001) at 24 months. When compared to the 
whole DMD population, boys skippable for exon 44 (n=27) and 46 (n=34) showed 
a slower decline, which became significant at 24 months follow-up (table 11, 
figure 16). The interaction coefficient for the population skippable for exon 44 
was 2.5 (95% CI -3.2, 8.3) at 1 year (p=0.39) and 9.1 (95% CI 2.3, 15.9) at 24 months 
(p<0.001), suggesting that over the course of 2 years boys with exon 44 skippable 
deletions lost 9 points less on the transformed NSAA scale than the remaining 
DMD population (table 11a, figure 16). Similarly, boys skippable for exon 46 
showed a slower decline at 24 months with an interaction coefficient of 8.8 (95% 
CI 2.6, 15.1; p<0.01).  On the other hand, the negative interaction coefficient for 
the population skippable for exon 53 (n=41) was suggestive of an overall more 
rapid decline: -6.5 (95%CI -11.2, -1.7; p<0.01) at 12 months and – 14.2 (95%CI -
19.9, -8.5; p<0.001) at 24 months (table 11a, figure 16). Similarly boys skippable 
for exon 51 (n=61) showed an increased loss of 5.7 linearized NSAA units at 2 
years (interaction coefficient  -5.7, p=0.02). We report the raw NSAA scores and 
interaction coefficients in table 11b. All the above comparisons are adjusted for 
treatment and age at follow-up. I found no significant difference among the 
remaining populations. 
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Table 11. Linearized and raw NSAA total score 
A 
 Linearized NSAA 12 
months 
Linearized NSAA 12 + 24 
months 
ALL DMD (n=395) -5.0 (-6.5,-3.5) p<0.001 -13.8 (-15.7,-12.0) p<0.001 
Skip 44 (n=27) 2.5 (-3.2, 8.3) (p=0.39) 9.1 (2.3, 15.9) (p<0.001)** 
Skip 45 (n=31) 1.8 (-3.6, 7.4) (p=0.50) -3.2 (-9.7, 3.5) (p=0.35) 
Skip 46 (n=34) 2.8 (-2.4, 8.0) (p=0.29) 8.8 (2.6, 15.1) (p<0.01)* 
Skip 50 (n=8) 4.3 (-6.6, 15.2) (p=0.44) 8.3 -4.0, 20.7) (p=0.19) 
Skip 51 (n=61) -2.5 (-6.7, 1.8) (p=025) -5.7 (-10.6, -0.9) (p=0.02)* 
Skip 52 (n=9) 1.0 (-6.7, 8.8) (p=0.79) 9.2 (0.4, 18.0) (p=0.04)* 
Skip 53 (n=41) -6.5 (-11.2, -1.7) 
(p<0.01)* 
-14.2 (-19.9, -8.5) (p<0.001)** 
 
B 
 NSAA 12 months NSAA 12 + 24 months 
ALL DMD (n=395) -2.1 (-2.7,-1.5) p<0.001 -5.8 (-6.5,-5.1) p<0.001   
Skip 44 (n=27) 1.3 (-0.9, 3.5) (p=0.25) 3.9 (1.3, 6.5) (p<0.01)* 
Skip 45 (n=31) 0.3 (-1.8, 2.5) (p=0.75) -0.6 (-3.2, 1.9) (p=0.6) 
Skip 46 (n=34) 1.3 (-0.6, 3.3) (p=0.19) 3.5 (1.1, 5.9) (p<0.01)* 
Skip 50 (n=8) 1.9 (-2.2, 6.1) (p=0.37)  3.0( -1.8, 7.7) (p=0.22) 
Skip 51 (n=61) -1.0 (-2.6, 0.6) (p=022) -2.4 (-4.2, -0.5) (p=0.01)* 
Skip 52 (n=9) 0.4 (-2.6, 3.3) (p=0.80) 3.0 (-0.4, 6.4) (p=0.08) 
Skip 53 (n=41) -2.0 (-3.8, -0.1) (p=0.04)* -4.5 (-6.7, -2.3) (p<0.001)** 
 
Table 11. Linearized (a) and raw (b) NSAA total score: interaction coefficients for 
skippable genotypes at 12 and 24 months.  The overall slope of decline is 
described for the overall DMD population at 12 months and 24 months. 
Skippable genotypes are compared with all DMD, at 1 year and 2 years. 
Interactions coefficients (p value) suggest that boys skippable for exon 44 and 46 
decline at a slower rate over the course of 2 years, while boys skippable for exon 
51 and 53 decline faster.  
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Figure 16. Mean linearized NSAA total score mean and change from baseline 
for skippable genotypes at 12 and 24 months 
 
 
Figure 16: Mean (95% CI) Linearised NSAA total score mean (A) and change 
from baseline  (B) for skippable genotypes at 12 and 24 months. The overall slope 
of decline over 24 months is described in DMD boys > 5 years of age, with a 
minimum NSAA of 52/100 [raw NSAA: 17/34], and at least 3 months on 
glucocorticoids at baseline.  
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Discussion 
In this study I addressed a number of important issues regarding the progression 
of DMD, which inform patients/families, and the design and interpretation of 
experimental therapies.  
It was recently reported on the general characteristics of children followed in the 
UK NorthStar clinical network.35  In the current study I described the effect of age 
on disease progression on linearized NSAA scale; I explored the effect of 
initiating GC at a younger age than the current guidelines; in addition, I assessed 
the possible influence of DMD genotype on disease progression by gathering 
data from a very large group of UK and Italian DMD boys stratified by genomic 
mutations. 
The benefit of the linearized scores is that the change score means the same 
across the breadth of the scale. Whereas with the raw score a drop of several 
points at a mid-level of ability might actually mean a small loss of function 
(difficulty getting on and off a small step but still independently) and a drop of 
one point at either end of the scale might suddenly mean loss of independence in 
rising from the floor or loss of ability to run. 
To characterise the disease on linearized NSAA, through the collaboration of the 
UK NorthStar clinical network, I reported the course of DMD in >500 
glucocorticoid-treated UK boys. I described the slope of progression after age 7, 
when motor function starts to decline. With an average linearized NSAA score of 
73 at age 7 [=27/34 in the raw scale], I observed that the overall rate of decline on 
the transformed NSAA scale is 8 linearized units/year. Recent data suggest that 
in the linearized NSAA scale ~10 units are considered to capture a significant 
clinically meaningful change, irrespective of the scores along the scale that drive 
such a loss.165 This loss can mean the loss of the ability to stand on one leg or get 
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up from the floor independently. Therefore the linearized NSAA can reliably 
support clinical trials as a secondary outcome measure for ambulant DMD, with 
the potential to capture either stabilization from the predicted 8-unit loss, or 
potentially even an improvement from baseline during the course of a one-year 
study.  When conducting clinical trials for ambulant boys, one possible outcome 
is that the boys may lose ambulation during the course of the study, affecting the 
overall interpretation of the study. From our cohort of NorthStar-registered 
individuals, we found that in the 137 UK boys who lost ambulation between 9.5 
and 16 years, the median age was 13 years (95% CI 12.1, 13.5). However, as age 
alone cannot serve as a predictor of LOA, I also reported the estimated mean 
linearized NSAA score at 12 and 24 months prior to LOA (i.e. at ages 12 and 11 
years respectively), which in our database were 34 and 42 units [approximately 9 
and 13 in the raw scale respectively]. When selecting inclusion criteria for clinical 
trials in ambulant boys, a baseline total linearized NSAA score of 50 (~16 of the 
raw scale) would therefore give reassurance that the boys are very unlikely to 
lose ambulation over the course of a 2-year study. Mazzone et al. reported that in 
their Italian cohort followed for 24 months, the equivalent assurance was given 
by performing 330 metres in the 6MWD.159 Only 2% of the boys, who at baseline 
walked at least 330 metres, lost ambulation in the subsequent 2 years. Equally in 
their cohort of boys approximately 98% of boys with a NSAA score of 17/34 (~52 
units in the linearized NSAA) were ambulant after 2 years, confirming our 
observation.159  
If recruiting older DMD patients in clinical trials poses the problem that they 
may lose ambulation during the course of the study, recruiting younger 
individuals poses the opposite problem: a number of DMD patients improve 
their motor function up to the age 7,35, 113, 160, 161 thereby complicating the 
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interpretation of a potential drug effect against the natural disease course. In our 
study we report a functional gain of ~3 units/year between 4-7 years [~1.5 raw 
NSAA], with a mean NSAA score at age 7 of 73 (p=0.02) [=27/34]. We further 
report an improvement of 3 additional linearized units/year in 36 boys who had 
started GC <5 years (mean age: 3.4 years) when compared to boys who started 
GC >5, with a difference of 10 units by age 7 (p<0.01) but no difference in SD BMI 
at this early phase of therapy. We lack sufficient longitudinal data to conclude 
that this initial benefit is sustained also during the decline phase and that age of 
LOA is further postponed, although data from smaller cohorts also appear to 
substantiate an increased efficacy of early GC initiation.135  Additionally we lack 
sufficient longitudinal data to show if the cumulative GC therapy has an 
enhanced detrimental effect on the side effect profile. However, despite the 
limitation of our relatively small cohort (n=78), the positive impact of early 
initiation of GC therapy is of interest and demands future exploration. 
Furthermore, our analysis provides an insight on the motor function in this age 
group of patients, who are likely candidates for future clinical trials.  
As part of our study I also explored progression of disease in mutations 
amenable to genetic therapies. A number of current experimental approaches for 
DMD are mutation specific,78, 80, 152, 153, 158, 167 emphasizing the importance of 
investigating, within the disease spectrum, possible existing variations in the 
natural course of each genetic subtype, which could impact on clinical trials. 
Exon skipping by antisense oligomer is now in Phase III studies for exon 51; 
molecules targeting the exons 44, 45,and 53 are undergoing early clinical studies. 
In this study, I observed that individuals with duplications deteriorate minimally 
slower (~1 unit/year) when compared to individuals with point mutations and 
deletions, however this did not meet significance. In a sub-study, we combined 
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the Italian and UK datasets, to focus the analysis on skippable deletions and 
reproduce the setting of a clinical trial. I observed that boys skippable for exon 53 
do progress more rapidly losing additional 14 units over 2 years [~4-5 raw units], 
when compared to the whole DMD population (p=0.001). Similarly, individuals 
skippable for exon 51 declined faster loosing additional 5 units [2.5 raw units] 
(p=0.02). In contrast, boys with deletions skippable for exon 44 showed a less 
rapid decline measured as 9 linearized units over 24 months (p<0.001) [~4 raw 
units].  Within the spectrum of severity of DMD, variability in phenotype among 
skippable deletions has been previously reported. Pane et al. observed that boys 
skippable for exon 44 had better baseline results in the 6MWD and less drastic 
changes over the course of one year when compared to boys skippable for exon 
53.168  Despite a similar trend, their results at one year did not reach statistical 
significance. The results of the present study are consistent with this observation, 
as we could not detect a significant difference at 12, but only at 24 months. 
Similarly, Servais et al.169 reported that patients treatable by exon 53 skipping 
have a more severe phenotype when upper limb function was assessed in a 
cohort of 14 DMD; additionally loss of ambulation had occurred one year earlier 
in 90 boys who were 53 skippable when compared to 400 other DMD boys. 
Residual dystrophin level can partially explain such a phenomenon. Recent 
studies showed that a larger presence of revertant fibres and residual dystrophin 
expression, which may favour a better outcome, is found in patients with 
mutations in the region of exons 45-47,162, 163 when compared to levels of 
dystrophin found in patients with mutations in the region of exon 47-55.170  It is 
possible to attribute these higher levels of residual dystrophin proteins to 
spontaneous exon 44 skipping when surrounding exons are deleted.171 These 
“leaky” mutations can thus present with more variable phenotypes, which 
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highlight the limitation of an exclusively genetic diagnosis/prognosis and the 
value of accurate muscle pathology.   
Residual dystrophin levels can therefore play a role as a weak modifier of DMD 
progression, although further exploration in larger cohorts should be performed 
in order to power studies precisely. The size effect of these differences is small 
and in practice negligible for studies lasting 1 year or less, but should be 
considered for longer duration studies. This might be particularly important in 
clinical trials where a treatment arm is compared to natural history data or a 
subset of patients. In particular our data would discourage the recruitment of 
patients with deletions skippable for exon 44 as a comparator group for patients 
with 53 skippable deletions, and vice versa. Moreover, other disease modifiers 
are increasingly being reported in DMD, including polymorphisms in SPP1172, 173 
and LTBP4.174  This latter gene was very recently independently validated in 
separate DMD patient populations.175 When interpreting response to treatment 
the combination of disease modifiers should therefore be accounted for.  
Our study has some limitations: incomplete and partially missing data, adjusted 
for in the statistical analysis; patients of the same genotype sub-group were on 
different steroid regimens (i.e. daily or intermittent), also adjusted for in the 
analysis; although this study included the largest sample size ever studied when 
correlating phenotype to genotype, the number of patients included for the 
analysis remains relatively small; finally, also the early starters used different GC 
regimens and long-term effects, such as LOA and adverse events could not be 
evaluated because the follow-up is still ongoing.  
Despite its limitation, this study describes up-to date natural history data of the 
linearized NSAA scale in a large cohort of DMD boys in the UK and Italy. The 
NSAA is currently included in clinical trials as a secondary outcome measure. 
98 
 
Increased knowledge of the natural course of the disorder and its covariates (ie: 
age at starting GC and gene mutations), which can influence sensitivity of clinical 
trials, will help for the design of future studies and interpretation of their results. 
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CHAPTER 4: THE NEURO-PSYCHIATRIC PROFILE OF DMD  
 
 
 
 
 
 
 
Dystrophin and the brain 
 
Earlier clinical description of DMD, including descriptions by Duchenne himself 
in 1868 and by Gowers in 1879 had reported that a proportion of young males 
affected by DMD had some degree of intellectual impairment, however for 
almost a century, the neuropsychiatric aspects of DMD have been overlooked 
and poorly understood until more recently.   
Some studies in the 1950s had found that the incidence of cognitive impairment 
in DMD was the same as that among the general paediatric populations, 176, 177 
others explained the intellectual difficulties as a consequence of the chronic 
disability alone or in combination with low-socio economic status. 178, 179 
The work contained in this chapter has given rise to the following publication: 
Ricotti V, Mandy WP,Scoto M, Pane M, Deconinck N,Messina S, Mercuri E, 
Skuse DH,  Muntoni F. Neurodevelopmental, emotional and behavioural problems 
in Duchenne muscular dystrophy in relation to underlying dystrophin gene 
mutations. Dev Med Child Neurol. 2015 Sep 14. [Epub ahead of print] 
PMID:26365034 
 
My contribution to this work consisted of the following:  
I oversaw the design of the study. I led recruitment of patients into this study 
and contributed to data collection. In collaboration with William Mandy I 
analysed the data. I wrote the first draft of the manuscript, and contributed to 
the revision of the manuscript. 
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 However, more research started in the 1960s confirming the initial observations 
and establishing substantial evidence that DMD patients do suffer from 
decreased cognitive functions. Table 12 summarises the findings of these key 
initial studies.180-185 Of interest, Posser et al. also examined the IQ of 31 normal 
brothers and compared it with the IQ of their affected DMD siblings. A 
significant difference was reported with the normal siblings having a mean IQ in 
the normal range  (110.4 ±13.0 SD).185 
 
 
 
 
 
 
Table 12.  Early studies on cognitive function in DMD 
 
Study 
reference  
No. of 
subjects 
Age of 
subjects 
Mean IQ 
(ranges) 
IQ< 75  
Allen et al 
1960 
30 2-23 82 
(14-117) 
30% 
Worden et 
al 1962 
38 4-27 83 
(46-134) 
29% 
Shoer 1964 
 
28 5-28 n.a. n.a. 
Dubowitz 
1965 
27 8-16 68 
(42-118) 
70% 
Zellweger et 
al. 1965 
42 3-16 83 
(42-131) 
33% 
Zellweger et 
al.1967 
48 2-8 83 
(48-127) 
31% 
Prosser et al. 
1969 
52 2-18 87 
(51-113) 
30% 
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Serial testing of a sub-set of subjects also suggested that cognitive impairment, 
unlike motor deterioration, does not appear to be progressive. 184, 185 In the early 
1980s it was further recognised that in addition to cognitive impairment, DMD 
boys also suffer from a high rate of emotional disorders.186  
Only recently, there has been a substantial body of evidence showing the wide 
spectrum of neuropsychiatric disturbances in DMD and its growing recognition 
as a direct result of disruption of CNS dystrophin protein products.   
The large dystrophin gene (2.5 million bp) contains 79 exons plus seven 
promoters, each linked to a unique first exon. These tightly regulated internal 
promoters generate a range of different protein isoforms, with diverse expression 
in tissues. Mutations in the 5’ end of the gene (i.e. mutations from exon 1 to 31) 
only affect the 3 longest isoforms Dp427M, Dp427C, and Dp427P, expressed in 
skeletal and cardiac muscles, in the neurons in cortex, and in cerebellar Purkinje 
cells respectively. However, mutations progressively further along the gene 
affect more and more isoforms. Mutations in between exons 31-44, in addition to 
disrupting expression of the long isoforms, will also disrupt Dp260 (expressed 
mostly in the retina); mutation in between exon 45- 62 will in addition disrupt 
both Dp140 (expressed in the brain and kidneys), Dp116 (expressed in Schwann 
cells), while the rare mutations downstream of exon 63 will affect all dystrophin 
products including the shortest Dp71 (most abundant brain isoform) (figure 17).18  
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Figure 17.  Genomic organisation of the dystrophin gene 
 
 
 
Figure 17. Genomic organisation of the dystrophin gene. The various promoters 
along the gene are illustrated. Mutations along the gene progressively disrupt the 
various protein products, the expression of which varies in different tissues, 
including the brain  
(Adapted from Muntoni et al, Lancet Neurol. 2003) 
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In muscle dystrophin is a large sarcolemmal protein, part of the dystrophin-
associated protein complex, connecting the cytoskeleton to the extracellular 
matrix.187 A major function of dystrophin in muscle is to protect muscle fibres 
against the mechanical forces of contraction, thus its absence renders muscle 
fibres susceptible to stretch-induced damage and necrosis.188 Dystrophin has also 
been assigned a signalling role; while some of these activities are relevant for 
skeletal muscle function (e.g. modulation of adrenergic tone by nNOS)26, others 
are essential for dystrophin function in organs such as brain and retina. 26, 189-191 
The role of dystrophin isoforms in the brain remains largely unclear; nevertheless 
it is recognised that the brain is affected by the lack of dystrophin and notably 
that mutations disrupting the brain isoforms Dp140 and Dp71 are more 
frequently associated with lower IQ scores.66-68, 73 Furthermore, CNS involvement 
in DMD goes beyond disability arising from impaired intellectual development.  
A number of recent studies showed that DMD boys present with symptoms of 
neurodevelopmental disorders, with higher prevalence than in the general 
paediatric population including: Autistic Spectrum Disorder (ASD) reported 
between 3-19%69-71, 73; Attention Deficit and Hyperactivity Disorder (ADHD) 
between 12-31%70, 72, 73; and Obsessive Compulsive Disorder (OCD) in up to 5%.70 
In accordance with what was reported about cognitive function, higher 
prevalence of ADHD has been reported in association with mutations predicted 
to affect Dp140 and Dp71.72  
Autistic Spectrum Disorder  (ASD) describes a range of conditions classified as 
neurodevelopmental disorders in the fifth revision of the American Psychiatric 
Association's Diagnostic and Statistical Manual of Mental Disorders 5th edition 
(DSM-5). These conditions are characterized by social deficits and 
communication difficulties, stereotyped or repetitive behaviours and interests, 
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sensory issues, and in some cases, cognitive delays. The general population 
prevalence is estimated to be about 1-6%.192 
Attention Deficit and Hyperactivity Disorder (ADHD) is a neurodevelopmental 
disorder, in which there are significant problems with executive functions (e.g. 
attention control and inhibitory control) that cause attention deficits, 
hyperactivity, or impulsiveness that is not appropriate for a person's age. These 
symptoms must begin by age six to twelve and persist for more than six months 
for a diagnosis to be made. It affects about 6–11% of children.193 
An individual with inattention may have some (or al) of the following 
symptoms: 
 Be easily distracted 
 Have difficulty maintaining focus on one task 
 Become bored with a task after only a few minutes 
 Have difficulty focusing attention  
 Have trouble completing or turning in homework assignments 
 Not seem to listen when spoken to 
 Daydream 
 Have difficulty processing information as quickly and accurately as 
others 
 Struggle to follow instructions 
An individual with hyperactivity may have some (or all) of the following 
symptoms: 
 Fidget and squirm in their seats 
 Talk nonstop 
 Dash around, touching or playing with anything and everything in sight 
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 Have trouble sitting still during dinner, school, and story time 
 Be constantly in motion 
 Have difficulty doing quiet tasks or activities 
Emotional and behavioural disorders (EBD) are a broad category, which group 
together as a range of more specific perceived difficulties of children and 
adolescents. These are divided in internalising problems, such as depression and 
anxiety; and externalising problems such as aggression, under-control and acting 
out. It is very difficult to estimate their prevalence, however it is estimated that at 
least 10% of children and adolescents are affected at some stage of their life from 
childhood to adolescence.194   
Finally, Obsessive–compulsive disorder (OCD) is an anxiety disorder 
characterized by intrusive thoughts that produce uneasiness, apprehension, fear 
or worry (obsessions), repetitive behaviours aimed at reducing the associated 
anxiety (compulsions), or a combination of such obsessions and compulsions. 
The estimated prevalence is between 1 to 3% of children and adults.195 
 
A study on the neurodevelopmental, emotional and behavioural 
problems in Duchenne muscular dystrophy in relation to underlying 
dystrophin gene mutations  
 
In this multicentre international study, I aimed to elucidate the neuropsychiatric 
phenotype of DMD by using a comprehensive battery of standardised, well-
validated neurodevelopment assessments. In so doing we aimed to offer the 
most comprehensive picture to date of the neuropsychiatric elements of DMD, by 
capturing with parent reporting a wide array of CNS characteristics including: 1) 
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intellectual difficulties (ID), 2) neurodevelopmental disorders (i.e. ASD, ADHD,) 
3) emotional behavioural problems such as internalising and externalising 
behaviours. We aimed to ascertain how these different characteristics cluster in 
the same individual, exploring the possibility of a “DMD neuropsychiatric 
syndrome”. Finally, we aimed to learn about the association between the 
neuropsychiatric profile and genotype of DMD, in particular referring to those 
regions of interest disrupting the different dystrophin isoforms.  
 
Methods 
Patient population 
Families attending the neuromuscular departments in three counties (UK, Italy 
and Belgium) and four centres were recruited over 12 months. Inclusion criteria 
were as follows: (1) DMD boys with proven mutation in the dystrophin gene. 
Mutations were classified according to the Leiden Muscular Dystrophy database 
(http://www.dmd.nl): (2) aged between 5 and 16 years; and (3) willing to take 
part into the study and with good understanding of the language spoken in the 
country of the assessment.  
Ethic approval was obtained by all participating centres.  
 
Measures  
Social Communication Disorder Checklist  
Families attending the neuromuscular outpatient department were asked to 
complete a validated, 12-item measure, the Social Communication Disorder 
Checklist (SCDC), which is highly sensitive to neurodevelopmental disorders 
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especially in the social communication domain. 196, 197 The SCDC is a 3-point 
Likert scale, with each item scoring 0, 1 or 2, with higher scores indicating greater 
symptom severity. A total score of 8 is indicative of likely neurodevelopmental 
disturbance, whilst scores >15 are strongly suggestive of ASD.  
 
Cognitive assessment  
Intelligence was measured, where possible (n=92, 71%), with the Wechsler 
Intelligence Scales for Children- Fourth Edition (WISC-IV).198 A truncated version 
of the WISC-IV was administered (Vocabulary, Similarities, Matrix Reasoning, 
Block Design, Digit Span and Letter-Number Sequencing) to reduce participant 
burden. The Digit Span and Letter Number Sequencing subtests were used to 
produce a Working Memory Index (WMI) score; Similarities and Vocabulary 
subtests produced a Verbal Comprehension Index (VCI) score; and the Matrix 
Reasoning and Block Design subtests generated a Perceptual Reasoning Index 
(PRI) score. General intelligence was measured using the WISC-IV’s General 
Ability Index (GAI) score. This is a measure of overall intellectual ability that is 
particularly suitable for boys with DMD as, compared to the full-scale IQ score of 
the WISC-IV, it is less influenced by processing speed, working memory deficits 
and motor problems, which are common in this population.199 In addition, three 
boys (2%) who were aged five when they joined the study, and so were too 
young for the WISC-IV, were assessed using the Wechsler Preschool and Primary 
Scale of Intelligence – Third Edition (WPPSI-III).200  
In boys reluctant to complete a Wechsler intelligence test or those who were non-
verbal (n=20, 15%), general intelligence was assessed with the Raven’s Coloured 
Progressive Matrices (RCPM).201 RCPM is a widely used, well-normed cognitive 
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assessment for children aged 5-11. In the current study raw scores were 
converted to IQ scores with a mean of 100 and a SD of 15.202 Boys with a GAI or 
RCPM IQ score equal to or less than 70 were categorized as being in the ID 
range.203 An additional 15 boys (12% of overall sample) were able to complete 
neither a WISC-IV, WPPSI-III nor RCPM, due to being non-verbal and having 
developmental delay. After inspection of their clinical notes, they were all 
estimated to have an ID, based on reports of their language, functioning and 
presentation in clinic. 
 
Neurodevelopmental assessments  
ASD was assessed with the Developmental, Diagnostic and Dimensional 
Interview short version (3Di-sv).204 The 3Di-sv is a semi-structured, parent-
report, diagnostic interview comprised of 53 items. It has high inter-rater 
reliability and test-retest reliability coefficients.204 The clinical cut-off scores on 
the 3Di-sv indexes are reciprocal social interaction (RSI) impairment=11.5, 
repetitive and stereotyped behaviour (RSB)=5; and communication impairment 
(CI)=8. Children who score above the cut-off point on the RSI scale and either the 
RSB scale and/or CI scale are categorised as meeting criteria for ASD.  
In addition, parents completed the Conners’ Parent Rating Scale (Conners 3),  
The short version of the Conners’ Parent Rating Scale is a 45-item questionnaire 
addressing issues such as: aggression, learning problems, inattention, 
hyperactivity/impulsivity, executive functioning and peer relations. Children 
who had t-scores in the abnormal range (t<65) on the hyperactivity and/or 
inattention indexes were categorized as meeting criteria for ADHD by parent 
report.205   In the UK cohort alone, also teachers were asked to complete the 
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Conners’ Teacher Rating Scale (Conners 3), and return the questionnaire by pre-
stamped envelope.  
 
Emotional behavioural problems 
Parents completed the Child Behavioural Check List (CBCL). The CBCL is a 
parent-report measure, with scales measuring internalizing symptoms (anxiety 
and depression), and externalizing symptoms (aggression and hyperactivity). It 
is normed for use with young people between the ages of 4 and 18 years. In line 
with the CBCL manual, internalising, externalising and total t-scores greater than 
or equal to 63 were deemed to be in the clinical range. 206  
 
Statistical methods 
To compare the SCDC mean score of the current sample with published 
population norms, a one sample T-test was used. One-way ANOVA was used to 
compare mean scores on continuous measures in the three genotype-defined sub 
groups of the sample. Post hoc analyses were conducted using Gabriel’s 
procedure, which has been designed to accommodate for situations when sample 
sizes are very different. 207  Fisher’s exact tests were used to make group 
comparisons for categorical variables. Paired samples t-test was used to compare 
parents and teacher’s scores where available. 
 
Results 
We recruited 130 DMD boys in 4 centres: UK (n=73); Italy, (Rome n=29; Messina 
n=16); Belgium (n=12). Mean age was 9.8 (range: 5-16 years) including both 
ambulant and non-ambulant subjects. All boys were treated according to the 
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standards of care for DMD.32 The overall grouping for genotype was as follows: 
41 patients with mutations upstream of exon 30; 75 boys with mutations in 
between exons 31-62, and 14 boys with mutations downstream of exon 63. There 
was no difference in mean age between the genotype sub-groups.  
 
Social Communication Disorder Checklist (SCDC) 
The mean total SCDC score for 130 DMD boys was 7.9 (95% CI 6.8, 8.9), which 
was significantly higher (p<0.001) when compared to the mean score of normal 
controls (2.9, 95% CI 2.2, 3.6) previously reported208, indicating greater levels of 
impairment in this DMD sample.  The boys with mutations predicted to disrupt 
all short/brain dystrophin isoforms, including Dp71 (i.e. with mutations 
downstream exon 63), had a total mean score of 11.7 (95% CI 8.5, 15.4); boys with 
mutation disrupting Dp260, Dp140, Dp116 (i.e. between exons 31-62) had a mean 
score of 7.3 (95% CI 5.9, 8.6); and boys with Dp427 mutations (i.e. upstream exon 
30) had a mean score of 7.6 (95% CI 5.8, 9.3).  ANOVA confirmed a significant 
group effect (p=0.045). Post hoc testing using the Gabriel’s procedure showed 
that this reflected higher scores of boys with mutations downstream of exon 63, 
compared to those with mutations upstream of exon 30 (p=0.024). Also, we 
observed that boys with mutations downstream of exon 63 had higher SCDC 
scores than boys with mutations between exons 31 and 62, although these 
findings were of clinical importance, they did not reach statistical significance 
(p=0.071). 
Cognitive Function  
We observed that 34 out of 130 DMD boys (26%) were estimated to have an 
intellectual disability (ID). For 19 of these ID status was assigned on the basis of 
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an IQ score below 70 (table 2), and for 15 ID was estimated from clinical notes as 
they presented with too severe a language and developmental delay to complete 
an IQ test. WMI was on average strongly affected (table 13). Post hoc testing 
using the Gabriel’s procedure showed group effect was seen (p=0.011), with a 
more profound ID associated with mutations downstream exon 63 (table 13). 
Furthermore, nine out of 14 individuals with mutations affecting Dp71 (i.e. 
downstream exon 63) had intellectual disability (64%) compared to 25% (19 out 
of 75) of boys with mutations disrupting Dp260, Dp140, Dp116, and 15% (6 out of 
41) of boys with mutation disrupting only the long dystrophin isoforms Dp427 
(table 14).  
 
Neurodevelopmental disorders 
Of the 130 subjects, 87 completed the full assessment protocol (UK n=62, Italy 
n=13, Brussels n=12). There was no bias based on clinical presentation in 
selecting these 87 boys: the primary reason why the remaining boys did not 
undergo the full assessment was due to time restraint during the routine clinical 
appointment. The 87 boys were representative of the whole cohort: they did not 
differ significantly from the remaining individuals in relation to age, IQ, SCDC 
score and genotype (all p’s >0.09). The genotype grouping was as follows: 26 
subjects with mutations upstream of exon 30; 54 boys with mutations between 
exons 31-62, and 7 boys with mutations downstream of exon 63.  
In this entire cohort, we observed a high prevalence of individuals who were 
above the threshold scores on the standardised parent-report instruments 
employed. A fifth (21%, n=18) of the boys scored in the ASD range, 24% (n= 21) 
showed clinically significant hyperactivity and 44% (n=38) had severe difficulties 
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with inattention (table 14). The mean raw scores are also reported (table 13). With 
the exception of hyperactivity, where a group difference was observed, with 
mutations at the 3’end of the gene being more severely affected (p=0.039), we did 
not find any statistical difference between groups. However, of clinical interest, a 
higher proportion of boys with mutations affecting the shorter isoforms met the 
threshold scores for neurodevelopmental disorders as opposed to boys with 
mutations only affecting Dp427  (table 14).  
 
Conners’ 3 teachers 
Conners’ 3 (T) data was obtained for 41 out of 52 boys recruited in the UK (66%).   
Teachers gave 15 out of 41 boys (37%) scores that indicated ADHD 
symptomology. On paired samples correlations both the inattention (r= 0.590; 
p<0.001) and hyperactivity (r= 0.601; p <0.001) index scores of the parent and 
teacher measures were significantly correlated. There was no significant 
difference between the mean scores reported by parents and teachers on the 
hyperactivity index; however, a paired samples t-test revealed that parents 
reported a significantly higher mean score on the inattention index (mean= 62.61; 
SD =13.28) than teachers (mean = 55.78; SD = 10.73), t = 6.83, p=0.001. 
Emotional behavioural problems 
As is shown in table 14, emotional and behavioural problems were highly 
prevalent in our cohort of 87 DMD boys. Around a quarter (n=21) had scores in 
the clinical range for internalising problems (i.e. anxious, depressive, and over-
controlled); and approximately one in six (n=13) scored in the clinical range for 
externalising behavioural problems (i.e. aggressive, hyperactive, noncompliant, 
and under-controlled.). On the CBCL’s total problems scale, 15 boys (17%, 95 CI 
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10,26) scored above the conventional clinical threshold (t-score ≥ 63), and 13 
(15%, 95% CI 8,23) scored above a more stringent threshold (t-score ≥ 67), 
employed in previous research using the CBCL in a group of boys with DMD.209 
Unlike ID, and neurodevelopmental disorders, internalising and externalising 
problems were not related to genotype: they were common in the boys with 
mutations at the 3’end of the gene, and amongst boys with mutations predicted 
to affect the Dp427 alone, so they inversely correlated with ID (table 14). 
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Table 13 Raw scores for the 3Di-sv, Conners 3, CBCL and general intelligence 
in the total population and according to genotype sub-groups 
 
Assessment Mean score (95% CI) P-values 
Upstre
am 
exon 30 
Exon 31 
-62 
Down-
stream 
exon 63 
TOTAL p-
value 
Post-
hoc 
Cognitive 
function$ 
General 
Ability Index 
96.0 
(87.9, 
104.1) 
91.7 
(86.7, 
96.7) 
74.8 
(62.7, 86.9) 
91.8 (87.7, 
95.8) 
0.042*  31 > 63 
Working 
Memory 
Index 
86.6 
(78.2, 
94.9) 
81.7 
(75.8, 
87,5) 
57,5 ( 24,4, 
90.7) 
81.3 (76.2, 
86.3) 
0.011* 31,31-
62 > 63 
3Di-sv 
 
Social 7.6 (6.1, 
9.2) 
8.8  (7.3, 
10.3) 
10.5 (4.9, 
16.0) 
8.6 (7.5, 
9.7) 
0.396  
Communicat
ion 
7.8 (5.9, 
9.7) 
7.76 (6.2, 
9.2) 
10.20 
(4.35, 16.1) 
6.6 (6.9, 
9.7) 
0.516  
Repetitive 
stereotypical 
behaviour 
4.1 (2.8, 
5.7) 
3.2 (2.4, 
4.0) 
4.4 (1.5, 
7.6) 
3.6 (2.8, 
4.2) 
0.387  
Conners-3 
(Parents) 
Inattentive 62.1 
(57.3, 
66.9) 
59.5 
(57.2, 67) 
63.6 (47.5, 
79,6) 
60.6 (57.1, 
64.1) 
0.706  
Hyper-
activity 
53.4 
(50.1, 
56.9) 
53.4 
(49.5, 
58.3) 
63.1 (52.6, 
73.7) 
54.5 (51.5, 
57.5) 
0.240  
CBCL Internalising 
Problems 
9.4 (6.3, 
12.6) 
8 (7.3, 
11.7) 
6.3 (3.5, 
11.1) 
9.5 (7.8, 
11.3) 
0.998  
Externalising 
Problems 
8.31 
(5.2, 
11.3) 
9.98 (7.4, 
12.5) 
8.7 (1.5, 
15.9) 
8.6 (7.5, 
11.2) 
0.708  
 
Table 13: Raw scores for the 3Di-sv, Conners 3, CBCL and general intelligence 
(WISC-IV/RCPM) in the total population and according to genotype sub-groups.  
$Upstream exon 30 n=25; mutations between exon 31 -62 n=52; Downstream exon 
63 n=6.  Non-verbal patients were not included. ANOVA, p-values <0.05 were 
considered significant*.  
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Table 14 Prevalence of cognitive function, neurodevelopmental disorders and 
emotional behavioural problems for all mutations and according to genotype 
 
 Genotype subgroups (mutations)  
 
Total, n 
(%, 95% 
CI) 
 
Upstream 
exon 30 
(Dp427) 
 
 
 
 
Exon 31 -62 
(Dp260, 
Dp140, Dp116) 
 
 
Down-
stream 
exon 63 
(Dp71) 
 
 
 
P 
value 
Cognitive function (n=130)                                                                                                     
 Intellectual 
disability 
 
6/41  
(15%, 7, 29) 
 
19/75 
(25%: 17, 37) 
9/14  
(64%, 36, 
85) 
34 /130 
(26%, 
19, 34) 
0.002 
Neurodevelopmental disorders (n=87) 
 Scores above 
threshold for 
Autistic 
Spectrum 
Disorder  
4/26 
(15%; 6,35) 
11/54 
(20%; 11,34) 
3/7 
(43%; 13, 79) 
18/87 
(21%; 
13,31) 
0.264 
Scores above 
threshold for 
inattention 
13/26 
(50%; 31, 69) 
22/54 
(41%; 28, 55) 
3/7 
(43%; 13, 79) 
38/87  
(44%; 
33, 54) 
0.753 
Scores above 
threshold 
for hyperactivity 
3/26  
(11%; 4,31) 
14/54 
(26%; 16, 39) 
4/7 
(57%, 21, 87) 
21/87  
(24%; 
16, 34) 
0.046 
Emotional behavioural problems (n=87)                                                                                                     
 Scores above 
threshold for 
internalising 
problems 
6/26 
(23%, 10, 44) 
14/54 
(26%; 16, 39) 
1/7 
(14%; 2, 
63) 
21/87  
(24%; 
16, 34) 
0.929 
Scores over 
threshold for 
externalising 
problems 
2/26  
(8%; 2, 27) 
10/54  
(19%; 10, 31) 
1/7  
(14%; 2, 
63) 
13/87 
(15%; 9, 
24) 
0.404 
 
 
Table 14. Prevalence of impaired cognitive function, neurodevelopmental 
disorders and emotional behavioural problems for all mutations and according 
to genotype (Fisher’s exact tests).  P-values of <0.05 were considered significant. 
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Clustering of neurodevelopmental, behavioural and emotional symptoms  
In light of the multitude of neurodevelopmental, emotional and behavioural 
problems observed in our population, we looked at how many of these cluster in 
the same subject. We found a high prevalence of clustering of psychiatric 
symptoms: 37% of boys (n=32 of 87) scored in the clinical range on more than one 
measure of emotional, behavioural or neurodevelopmental problems (table 3). 
Twelve boys (14%) scored up on four or more of these measures. Compared to 
boys with mutations affecting only the long Dp427 isoforms  (n=3, 12%), those 
with a mutation affecting the short isoforms (n=17, 28%,) were more than twice 
as likely to have clinical problems on three or more measures, although this 
difference was not significant (p=0.162). In table 16 I report the correlation within 
psychiatric comorbidities. 
Despite the high prevalence of neuropsychiatric disturbances, it is also 
noteworthy that 32 (37%) DMD boys had no symptoms detected. 
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Table 15. Clustering of neurodevelopmental, emotional and behavioural 
problems for all mutations and according to genotype 
 
Symptoms Mutations 
between exon 
1-30, n (%, 95% 
CI) 
Mutations 
between exon 31 
– 79, n (%, 95% 
CI) 
All mutations, 
n (%, 95% CI) 
0 8 (31; 16, 51%) 24 (39%; 28, 52) 32 (37%; 27, 48) 
1 9 (35%; 19, 55) 14 (23%; 14, 35) 23 (26%; 18, 37) 
2 6 (23%; 11, 44) 6 (10%; 4, 21) 12 (14%; 8, 23%) 
3 2 (8%; 2, 27) 6 (10%; 4, 21) 8 (9%; 5, 18%) 
4 plus 1 (4%; 1, 24) 11(18%, 10, 30) 12 (14%; 8, 23%) 
 Total n=26 Total n=61 Total n= 87 
 
Table 15. Clustering of neurodevelopmental, emotional and behavioural 
problems for all mutations and according to genotype. 
These included: intellectual disability, ASD, ADHD, internalising and 
externalising problems. A total of 32 DMD (37%) boys across all mutations had a 
clustering of two or more symptoms. Boys with mutations affecting the short 
brain isoforms had a higher proportion of clustering of three or more symptom 
(28%, n=17) than boys with mutations at the 5’ end of the gene (12%, n=3), 
however this was statistically non-significant.  
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Table 16. Pearson Correlation between neurodevelopmental disorders, 
emotional behavioural problems and intellectual disability 
 
 1 2 3 4 5 6 7 8 
1.  
ASD 
(Social 
Domain) 
1 0.622** 0.558** 0.530** 0.506** 0.336** 0.520** 0.23* 
2. 
ASD 
(Communicat
ion domain) 
 1 0.463** 0.364** 0.307** 0.230* 0.363** 0.31* 
3.  
ASD 
(Stereotypical 
Behaviour) 
  1 0.340** 0.329** 0.227* 0.384** 0.03 
4.  
Inattentive  
 
   1 0.670** 0.370** 0.591** 0.18 
5. 
Hyperactive  
 
    1 0.476** 0.643** 0.05 
6. 
 Internalising 
problems 
     1 0.616** 0.09 
7.  
Externalising 
problems 
      1 0.07 
8. 
 Intellectual 
disability 
          
     1 
 
 
Table 16. Pearson Correlation between neurodevelopmental disorders, emotional 
behavioural problems and intellectual disability. *Upstream exon 30 n=25; 
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between exon 31 -62 n=52; Down-stream exon 63 n=6.  Non-verbal patients were 
not included (**p=0.002; *p=0.05)  
We observed a strong correlation between comorbidities, most strikingly 
between the social domain of ASD and externalising problems (r=0.52, p=0.002); 
ADHD and the social domain of ASD (r=0.5, p=0.002); internalising and 
externalising problems (r=0.6, p=0.002). Intelligence, where measured, did not 
show a strong correlation neither with neurodevelopmental disorders, nor with 
emotional problems.  
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Discussion 
I reported a large multicentre and international cohort study that used well-
validated parent-report measures of neurodevelopmental, behavioural and 
emotional difficulties to screen DMD boys with a wide spectrum of genetic 
mutations. 
This study found a significantly elevated mean total SCDC score, suggestive of 
high rates of neurodevelopmental disturbance in this DMD population.196 In 
relation to general intelligence, we confirmed previous findings reported in the 
literature: cognitive function was lower than in the general population with WMI 
most strongly affected.210 211 Including 15 boys who were non-verbal/profoundly 
delayed, we estimated that 26% (n=34) had ID. Based on detailed and 
standardised parent-report measures we observed a high prevalence of 
neurodevelopmental disorders: 21% of boys scored above the threshold for ASD, 
24% for hyperactivity, 44% for inattention. These figures are much higher than 
those in the general paediatric population.212-215 Our study fits with previous 
observations on the high prevalence of ADHD, reported as 32% in a cohort of 
Italian DMD boys assessed according to DSM-IV criteria.72 In relation to ASD, 
previous studies supported an association with dystrophinopathies: Hinton and 
colleagues 71 reported that 19% of DMD/BMD met the criteria for ASD in the 
Autism Diagnostic Interview-Revised. Our findings are based on a diagnostic 
interview with parents; although the 3Di is a reliable, highly sensitive and 
specific tool for ASD, it may overestimate the diagnosis; therefore these findings 
need further exploration with in-depth objective assessments which include 
direct observation with tools such as the Autism Diagnostic Observation 
Schedule. However, it is undisputable that ADHD and ASD have traditionally 
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been an under-diagnosed co-morbidity of DMD, which is a concern given the 
high levels of functional impairment associated with both disorders.   
Emotional behavioural problems, such as anxiety, affective disorder, and 
oppositional/aggressive behaviour have also been recognised in DMD.209, 216 One 
study reported that on a screening behavioural questionnaire, 32% of DMD 
families responded with scores above the normal cut-off, when compared to 0-
2% of other disabling neuromuscular disorders, including spinal muscular 
atrophy.217 Only a small proportion of these DMD patients had been investigated 
for neurodevelopmental disorders.  In our large DMD cohort, we observed that 
families reported also a high prevalence of internalising and externalising 
problems, 24% and 15% respectively. These findings reflect the high level of 
anxiety and mood disorders, alone or in combination, observed in clinical 
practice.  
Although it is not uncommon for neurodevelopmental disorders to cluster 
together212, in our DMD cohort we observed a high prevalence of combination of 
neuropsychiatric symptoms: over a third of boys presented with ≥2 co-
morbidities, and 8% of DMD boys with ID (n=7) scored in the range all four 
disorders assessed. Such striking patterns of clustering of symptoms suggest the 
existence of a “dystrophin-specific neurodevelopmental syndrome”, which in clinical 
practice has a significant impact on the condition and its management. In future, 
it will be important to further evaluate DMD with objective neuropsychiatric 
inventories, and to use non-DMD neurodevelopmental control group to see if 
there is any distinctive pattern of clustering observed in DMD.  
Mean life expectancy for DMD is now in the late 20s, with many individuals 
surviving into the 4th and even the 5th decade of life; it is anticipated this will 
further shift in the new generations. Therefore, improving neuropsychological 
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wellbeing is of paramount importance for participation and quality of life. 
Intervening from early stages, during the crucial initial years of schooling, 
targeting specific ID and/or behavioural issues, first of all requires prompt and 
appropriate recognition and understanding of the disorder.  
In our study we explored further a relationship between genotype (i.e. mutation 
location along the gene) and the neuropsychiatric profile. On the 12-item SCDC 
questionnaire completed by the families, we found that boys with Dp71 
mutations (i.e. downstream exon 63) had overall the highest SCDC mean total 
score (=11.7), with more than half of the boys scoring in the abnormal range of 
8.  In relation to intelligence, confirming previous reports, 67, 218DMD boys with 
mutations affecting an increasing number of shorter isoforms had a higher 
frequency of ID (p=0.002), with 63% of Dp71 mutations being most severely 
affected. WMI also showed a significant group effect (p=0.011), with the group 
missing the short isoform being worst affected. In relation to the detailed 
neurodevelopmental assessment of a subsample (n=87), our analyses were 
somewhat limited by the small numbers of boys with mutations affecting the 5’ 
end of the gene, which meant we only had the statistical power to detect very 
large effects. Nevertheless, in common with previous findings for ADHD, we 
observed higher levels of hyperactivity amongst boys with the 5’ mutation. 
Clinically, these same boys to have a higher incidence of ASD, and this will be 
worth investigating in larger samples.  
In contrast to neurodevelopmental problems, emotional behavioural problems 
were evenly distributed across the genotype subgroups. Our findings support 
the notion that mutations towards the 3’end of dystrophin, which disrupt not only 
the long products, but also in turn the short brain-expressed isoforms Dp140 and 
Dp71, have a more devastating effect on the neurocognitive phenotype (table 
123 
 
14).66, 67 Furthermore, the long dystrophin products Dp427 also must play a 
significant role in the association of CNS comorbidities.  Proximal mutations are 
sufficient to cause cognitive and neurobehavioral problems, hence Dp427 is also 
important for the neurodevelopment of the brain. This should not be surprising 
considering that Dp472 is largely expressed in the cortex, hippocampus and 
cerebellum, localizing to neuronal GABAergic synapses. In the mdx mouse, lack 
of Dp427 is associated with reduced receptor clustering, impairing specific 
amygdala GABAergic transmission and enhancing defensive behaviour in 
response to danger.219 In contrast, Dp140 localizes in glial cells and Dp71 is 
expressed in the perivascular astrocytes and Dp71 is required for the anchoring 
of aquaporin-4. Loss of Dp71 is associated with reduced levels of aquaporin-4, 
therefore altering trans-membrane water permeability.220, 221 
We could speculate that, when in addition to Dp472 also the short dystrophin 
products are disrupted, a “compensatory/protective” mechanism produced by 
these abundantly CNS-expressed isoforms may be lost, increasing the risk of 
associated neuropsychiatric disorders and accounting for the more devastating 
profile observed in boys with Dp71 mutations.  
Yet much remains unclear of the effects of dystrophin disruption in the CNS, and 
how different isoforms contribute to pathology. Structural abnormalities in the 
brain have been recently described: changes in the cerebral grey matter volume 
and white matter microstructure in boys with DMD have been described using 
quantitative MRI.222 Previous studies using MR spectroscopy have indicated 
altered phosphorous metabolite ratios in the cerebral cortex of 19 DMD boys.223 
In the mdx animal model, disrupted cerebral diffusivity was demonstrated 
associated to lack of dystrophin.224  
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Finally, novel pharmaco-gene therapies aiming at restoring dystrophin 
expression and delaying the course of the disease progression are currently in 
different phases of experimentation. Some of these compounds, such as the 
tricyclo-DNA antisense molecules, are also capable of crossing the blood brain 
barrier and restoring dystrophin expression through exon skipping in the CNS. 
This approach demonstrated clinical benefit and behavioural amelioration in the 
mdx mouse model, after receiving systemic antisense administration, indicating 
that at least some aspects of the dystrophin-associated neurodevelopmental 
syndrome might be reversible upon brain dystrophin restoration.225  
Our study has some limitations: although a large cohort of patients was 
recruited, the distribution between genotype sub-groups was not equal, this was 
adjusted for in post-hoc analysis; we did not have reports from the school to 
match observations from parents, with the exception of 41 Conners from 
teachers; parents’ reported measures may have overestimated 
neurodevelopmental problems, therefore a more in depth assessment is required 
for diagnostic purposes; both the 3Di and the SCDC were used for the first time 
outside the UK, therefore normative data does not exist for Italian and Belgian  
populations;  finally, we have speculated that that our findings are secondary to 
dystrophin deficiency in the CNS, however such speculation requires further 
studies elucidating the nature of this relationship. 
Despite its limitation, this study fuels the growing interest in unravelling the yet 
unclear role that the disruption of different dystrophin isoforms may play in the 
brain development and function, and provides a baseline to evaluate if these 
events can be reversed and to what degree, with emerging dystrophin- restoring 
therapies. 
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CHAPTER 5: MANIFESTATIONS OF DYSTROPHIN DISRUPTION IN THE 
DMD RETINA 
 
 
 
 
The human retina 
The human retina is a complex layered structure with a large diversity of cells 
and an intricate circuit and connections, which work in parallel and combination 
to produce a composite visual output.  
The retinal layer encompasses 5 major neuronal cell classes (figure 18) : 1) Rods 
and cone photoreceptors,  2) Horizontal cells;  3)Bipolar cells; 4) Amacrine cells;  
5) Ganglion cells. In addition Müller glial cells provide metabolic and 
homeostatic support. Photoreceptors are classified into rods and cones; with rods 
having exquisite sensitivity to light, thus responsible for dim-light vision; and 
cones being much less sensitive than rods, but exhibiting much faster response 
The work contained in this chapter has given rise to the following publication: 
Ricotti V, Jägle H, Theodorou M, Moore AT, Muntoni F, Thompson DA. 
Ocular and neurodevelopmental features of Duchenne muscular dystrophy a 
signature of dystrophin function in the central nervous system. Eur J Hum Genet. 
2015 Jun 17. [Epub ahead of print] PMID: 26081639 
 
My contribution to this work consisted of the following:  
I oversaw the design of the study. I led recruitment of patients into this study 
and contributed to data collection under the supervision of Dorothy 
Thompson. In collaboration with Dorothy Thompson I analysed the data. I 
wrote the first draft of the manuscript, and contributed to the revision of the 
manuscript. 
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during photo transduction, therefore responsible for bright-light, high acuity 
colour vision. Moreover, each cone photoreceptor type is most sensitive to a 
specific wavelength of light. 
Coding of visual information happens with conversion of light energy to 
membrane potential changes in these photoreceptors, which by the use of 
glutamate alters neurotransmitter release. Cones and rods synapse onto second 
order glutamatergic bipolar cells at the outer plexiform layer (OPL).  Bipolar cells 
are either rod or cone connected, and are further divided into 2 functional 
groups:  those that depolarise (i.e. ON) and those that hyperpolarise (i.e. OFF) in 
response to augmentation in light intensity. Bipolar cells in contact with rods are 
exclusively ON, whereas cone bipolar cells can be of either type.  Moreover, 
horizontal cells modulate such synaptic transmission: they possess dendritic 
connections between cones, and in addition have an axon with extensive terminal 
arborisation with rods. Despite the modulating effect of horizontal cells, most of 
the signal compression and information processing is done by the amacrine cells 
in the inner plexiform layer (IPL). Cone bipolar cells synapse with retinal 
ganglion cells and amacrine cells forming the IPL. Amacrine cells receive signals 
from a very large number of connecting bipolar/ horizontal cells and directly 
modulate the excitation of retinal ganglion cells through either direct or indirect 
inhibition pathways, largely mediated by GABA and glycine. Within the IPL, 
synaptic connections are further organized in two distinct layers. The inner 
lamina of the IPL comprises synapses between ON-bipolar cells and retinal 
ganglion cells and amacrine cells, whereas the outer lamina contains synaptic 
connections of OFF-bipolar cells.226 
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The last cells in this complex circuit are the ganglion cells, which come in several 
varieties and sizes. Ganglion cells are the sole output neurons of the retina, 
projecting their axons to higher visual centres.227, 228  
Finally, the Müller glial cells, which span across the entire thickness of the 
neuronal retina, are essential for supporting neuronal cell metabolism. However, 
a recent study has shown that the enhancement of signal by Müller glial cells 
greatly contributes to increase the clarity of vision by channelling green and red 
colours, mostly needed for day vision to the cones and scattering blue light, 
mostly needed for night vision to the neighbouring rods, therefore further 
optimising day and night vision.229 
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Figure 18. Retinal layers and cells 
 
 
(Graphic by Gabriella Codastefano) 
 
Figure 19. The electroretinogram 
 
Figure 19.  The human electroretinogram: the two components that are most 
often measured are the a- and b-waves. The a-wave (negative) =physiological 
response of photoreceptors in the outer retina; b-wave (positive) = inner layers of 
the retina 
  
 
129 
 
 
The electroretinogram 
The electroretinogram (ERG) offers a way of measuring combined electrical 
responses of the various retinal cell classes. The basic method of recording the 
electrical response (full-field ERG) is by stimulating the eye with a bright light 
source. The flash of light elicits a biphasic waveform recordable at the cornea. 
The two components that are most often measured are the a- and b-waves (figure 
19). The a-wave is the first large negative component, and reflects the 
physiological response of photoreceptors in the outer retina. This is followed by 
the b-wave which is corneal positive and usually larger in amplitude, and reflects 
the response of the inner layers of the retina (including the ON bipolar cells) and 
the Müller glial cells. The 2 principal measures of the waves recorded are the 
amplitude and the time. Furthermore the wavelets, which occur on the rising 
phase of the b-wave, are known as oscillatory potentials (OPs), and are thought 
to reflect activity in amacrine cells.226, 227 
By manipulating adaptation level and background illumination, flash intensity, 
color of the flash and rate of stimulation, rod and cone activity can be 
significantly isolated and recorded. 226 
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Dystrophin and the retina 
As discussed in Chapter 4, the DMD gene is a very large gene with 79 exons and 
tightly regulated internal promoters, which make a range of protein isoforms, 
identical at the C-terminus, but with unique N-termini. These include 3 full-
length dystrophin isoforms (Dp427) and the shorter products Dp260, Dp140, 
Dp116 and Dp71. A major function of dystrophin in muscle is to protect muscle 
fibres against the mechanical forces of contraction, thus its absence renders 
muscle fibres susceptible to stretch-induced damage and necrosis.188 Dystrophin 
has also been assigned a signalling role; while some of these activities are 
relevant for skeletal muscle function (e.g. modulation of adrenergic tone by 
nNOS)26, others are essential for dystrophin function in organs such as brain and 
retina.189, 190 Furthermore, different dystrophin isoforms are localised in distinct 
regions of the CNS and the retina (figure 17, chapter 4). As discussed in chapter 
four, Dp140 and Dp71 are largely expressed in the brain, and the lack of both 
these isoforms is well recognised to be associated to higher incidence of cognitive 
impairment and neurodevelopmental disorders in patients with mutations 
downstream exon 45.67, 68, 72 All dystrophin isoforms, with the exception of 
Dp116, are expressed highly in the retina (figure 20).  Dp427, Dp260 and Dp140 
are located in photoreceptor terminals, while Dp71 is expressed in Muller glia 
cells.230-235  Recently Dp427, Dp260 and Dp140 expression have been identified in 
inner retinal layer neurons as well; Dp427 was expressed proportionately more at 
cone than rod synapses, in bipolar cells and some amacrine cells.233  These recent 
findings suggest that Dp260 and Dp71 are not redundant protein products in the 
retina. Their location in different sites within the retina suggests that their 
contribution to retinal electrophysiology is indeed distinct.235  
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It is well recognised in the literature that absence of dystrophin from the retina 
gives disturbances in retinal electrophysiology.236  More specifically, mutations 
downstream of exon 30, which affect Dp260 expression, are associated with an 
abnormal scotopic ERG waveform, as demonstrated both in mouse models190, 237-
239 and in individuals with Duchenne/Becker Muscular Dystrophy.191, 240  
Pillers et al. reported that DMD subjects with normal ERGs had mutations 
predominantly at the 5’ end of the DMD gene (n=7/14), whilst all subjects 
studied with mutation predicted to disrupt production of Dp260 (n=50) showed 
marked reduction of b-wave amplitude.191  
More recently Barboni et al. tested 19 DMD patients and 7 heterozygous DMD 
carriers with deletions, duplications, and point mutations against 19 age-matched 
controls.240 The study showed a reduction in scotopic positive peaks of the ERGs 
across the genotype in DMD subjects; however more severe changes were found 
in patients with mutations downstream exon 30, hence affecting Dp260. At 
photopic level alterations were of similar extent both in patients mutated 
downstream and upstream exon 30. Furthermore, some alterations were also 
observed in DMD carriers but these findings were not significant when 
compared to controls. Finally contrast sensitivity was also tested and found to be 
significantly lower in DMD subjects.240  
Red-green colour vision impairment was also reported in DMD and in 
association with Dp260 disruption. 241  Costa et al. evaluated colour vision in 44 
DMD patients against a control group of 70 age-matched healthy males: over half 
of patients with mutations downstream exon 30 had red-green colour vision 
impairment as measured with the Cambridge Colour Test, while subjects with 
mutations upstream exon 30 had normal colour vision. 241 
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Figure 20. Schematic representation of expression of Dystrophin in the retinal 
layers  
 
 
(Graphic by Gabriella Codastefano) 
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A study on ocular and neurodevelopmental features of Duchenne 
muscular dystrophy: a signature of dystrophin function in the 
central nervous system 
In light of the recent retinal expression studies, this study sought to explore the 
clinical ERG as a potential biomarker of CNS dystrophin expression associated 
with different DMD genotypes and recorded ERGs to a wide range of flash 
strengths in a cohort of individuals with a range of mutations across the DMD 
gene. A subsidiary, but important, aim was to assess in this population whether a 
validated non-invasive paediatric ERG protocol would provide results 
comparable to those from a more demanding international standard method.242 
Finally, we explored a potential relation between ERG and the neuropsychiatric 
profile using validated psychometric inventories. 
 
 
Methods 
Participants 
Sixteen DMD boys attending the neuromuscular outpatient Department at Great 
Ormond Street Hospital (GOSH) were recruited according to their genotype, 
ensuring balanced distribution of mutations downstream and upstream of exon 
30 (table 17), but also tolerability of the assessment.  The diagnosis was 
confirmed by finding an out-of-frame-frame mutation in the DMD gene, using 
Multiplex Ligation-dependent Probe Amplification (MLPA).  Where DMD 
deletions or duplications were not identified, all 79 exons and the adjacent 
introns were analyzed through PCR amplification and direct sequencing to 
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screen for point mutations. Mutations were classified according to the Leiden 
Muscular Dystrophy database.123 
Seven boys had mutations involving exons 3-13 (affecting expression of Dp427 
isoforms); 7 boys had mutations involving exons 44-57 (disrupting Dp427, and 
progressively also Dp260, Dp140 and Dp116); 2 boys had mutations downstream 
exon 63 (disrupting all dystrophin isoforms, including the shortest Dp71). All 
patients were fully cooperative and able complete the examination, with the 
exception of the 2 boys with Dp71 mutation who had a profound intellectual 
disability, as expected for this genotype,67 and could only complete the paediatric 
protocol. The mean age was 11 years (range 4-15). All the boys were on 
prednisolone given at 0.5- 0.75 mg/kg/day daily or intermittently (10 days on:10 
days off).32, 33, 243  
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Table 17. General Characteristics of DMD subjects in this study 
 
ID Age at 
assess
ment  
(years) 
Mutation Dystrophin 
isoforms 
predicted to 
be affected* 
Neuro-
behavioural 
problems  
 
GAI 
1  7 Deletion 
exon 3-7 
Dp427 SCDC = 7 
Internalising 
behavioural 
problems  
98 
2  10 Deletion 
exons 3-7 
 
Dp427 SCDC = 2 
No 
 
102 
3 15 Deletion 
exons 5-7 
Dp427 SCDC = 7 
Attention deficit 
and anxiety 
90 
4 11 Deletion 
exons 8-13 
Dp427 SCDC = 4 
No 
110 
5 10  Deletion 
exons 3-11 
Dp427 SCDC = 4 
No 
119 
6 10 Deletion 
exons 8-13  
Dp427 SCDC =16 
Inattention, 
internalising 
behavioural 
problems and 
ASD 
83 
7 8 Duplication 
exon 2 
Dp427 SCDC = 3 
No 
90 
8 13 Duplication 
exons 56-57 
Dp427, Dp260, 
Dp140, Dp116 
SCDC =10 
Internalising 
behavioural 
problems and 
anxiety 
119 
9 8 Duplication 
exons 56-57 
Dp427, Dp260, 
Dp140, Dp116 
SCDC = 9 
Attention deficit 
 
96 
10 8 Deletion 
exons 51-54 
Dp427, Dp260, 
Dp140 
SCDC = 9 
Internalising 
behavioural 
problems 
119 
11 12 Deletion 
exons 48-50 
Dp 427, Dp 
260, Dp 140 
SCDC = 0 
No 
116 
12 11 Deletion 
exon 44 
Dp 427, Dp 
260, Dp 140 
SCDC = 2 
No 
99 
13 14 Deletion 
exons 51 
Dp 427, Dp 
260, Dp 140 
SCDC =1 
No 
 
106 
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14 10 Deletion 
exons 49-54 
Dp 427, Dp 
260, Dp 140 
SCDC =1 
Attention deficit 
 
90 
15 11 Deletion 
exon 70 
Dp 427, 
Dp260, Dp 
140, Dp116, 
Dp 71 
SCDC =17 
ASD 
N/A* 
16 4 Nonsense 
mutation 
exon 70 
Dp 427, Dp 
260, Dp 140, 
Dp 116,  Dp 71 
SCDC =16 
ASD 
 
N/A*  
 
 
Table 17: General Characteristics of DMD subjects in this study 
A total score on the Social and Communication Disorder Checklist (SCDC) ≥ 8 is 
suggestive of emotional socio-communicative behavioural problems; a total 
SCDC score of >15 is invariably associated with a diagnosis of Autistic Spectrum 
Disorder (ASD). IQ is expressed as a General Ability Index (GAI) score and 
calculated from a truncated version of the WISC-IV. Behavioural problems are 
reported as meeting the threshold scores in the Parents’ Conners 3, Child 
Behavioural Check List and the short version of the Developmental Diagnostic 
and Dimensional Interview (3Di-sv). 
* Severe speech delay/non-verbal 
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Experimental protocol 
All patients underwent eye examinations: visual acuity, Ishihara colour vision 
assessment, intra-ocular pressure (IOP) measurement, fundoscopy and 
electrophysiology examination of the retina using Electroretinograms (ERG).  
ERGs were recorded both to international standards (ISCEV)244 and with a 
modified paediatric protocol developed and validated at GOSH. 245, 246 The 
paediatric GOSH protocol does not require lengthy dark adaptation, dilation, or 
corneal electrodes and therefore has greater applicability in uncooperative 
children.  ERGs are recorded from peri-orbital skin electrodes in response to flash 
stimuli delivered by a hand held Grass strobe under photopic and scotopic 
conditions (figure 21). This method elicits ERGs which are of smaller amplitude, 
but physiologically comparable to the diagnostic International Society of Clinical 
Vision Society (ISCEV) standard protocol. 
The range of flash luminance presented in the dark and light were extended to 
more specifically probe slow and fast signalling pathways in the retina.  Images 
of retinal macula structure and retinal nerve fibre layer thickness were taken 
when possible with a high resolution Fourier optical coherence tomographer 
(OCT) (Heidelberg Spectralis) device. The intellectual quotient (IQ), where 
possible, was assessed with a truncated version of the Wechsler Intellectual 
Scales for Children-Fourth Edition (WISC-IV)198, which included Vocabulary, 
Similarities, Matrix Reasoning, Block Design, Digit Span and Letter-Number 
Sequencing. The IQ was expressed as a General Ability Index (GAI) score247.  The 
boys’ families were asked to complete the Social and Communication Disorders 
Checklist (SCDC).196 The SCDC is a validated 12-item measure for 
neurodevelopmental disorders.  A total score of 8 is indicative of 
neurodevelopmental disturbances, especially in the social communication 
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domain, whilst scores >15 are strongly suggestive of autistic spectrum disorders 
(ASD).197 Families who reported behavioural problems were asked to participate 
in further assessments including: the Developmental, Diagnostic and 
Dimensional Interview short version (3Di-sv) to assess Autistic Spectrum 
Disorder (ASD)204, Conners’ Parent Rating Scale (Conners 3)205 to assess Attention 
Deficit Hyperactivity Disorder (ADHD); and the Child and Behavioural Check 
List (CBCL)205 to assess internalising and externalising emotional problems. 
 
 
Figure 21. Patient assessment using the modified paediatric GOSH ERG 
protocol 
 
 
(Courtesy of the Academic Department of Ophthalmology, Great Ormond Street 
Hospital for Children, London, UK) 
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Statistics  
The amplitudes and peak times of ERG a- and b-waves from the patients were 
compared with clinical laboratory age-matched normative data for the ISCEV 
and GOSH protocols expressed as 5th and 95th centiles. The ratios of a:b wave 
amplitudes to scotopic and photopic standard flash stimuli obtained with the 
GOSH and ISCEV recording techniques were compared using a Pearson 
correlation.  A one-way ANOVA comparing ERGs and SCDC scores between the 
genotype groups was performed using GraphPad Prism.248 P-values <0.05 were 
considered significant. 
 
Results 
The ERG waveform has a negative a-wave due to the photoreceptors 
hyperpolarizing in response to light followed by a positive b-wave that depends 
upon signalling between photoreceptors and bipolar cells depolarizing the 
bipolar cell.  Across all genotypes cone photopic b-wave amplitudes were 
subnormal, especially to high flash luminances, whilst photopic a-wave 
amplitudes were ≥5th centile, indicating normal cone photoreceptor function 
(figure 22).  In contrast scotopic a-wave amplitudes were subnormal falling 
below the 5th centile in 6/16 (40%) of tested patients (figure 23, bottom graph).  
Individual scotopic ERG a- and b-wave amplitude are plotted against normative 
data (figure 23).  Boys with mutations downstream of exon 30, affecting both 
Dp427 and Dp260 (individuals 8-16, table 1), showed subnormal scotopic b-wave 
amplitudes to all flash strengths. As the amplitude of the preceding a-wave was 
larger than the b-wave the a:b amplitude ratios were >1 and the resulting 
waveform is called electronegative (figure 22). 
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Individuals with mutations affecting only Dp427 (individuals 1-7, table 17) 
showed milder scotopic b-wave amplitude reduction, with a:b ratios of 1 (normal 
a:b ~1:2) (figure 22). The only exception was individual 6, who had a deletion of 
exons 8-13, yet showed a similar scotopic ERG profile to boys with mutations 
affecting Dp260.  
Boys with mutations affecting all protein products, including Dp71 (individuals 
15-16, table 17), showed the most profoundly electronegative scotopic ERGs 
(figure 24).  
When comparing photopic and scotopic mean a:b ratios we found a significant 
difference between mutations upstream and downstream of exon 30 (p<0.001). 
Furthermore, the a:b ratio data obtained by the ISCEV corneal electrode protocol 
were comparable with the GOSH skin electrode protocol (r=0.87, p=0.01) (Figure 
25). 
The scotopic and photopic ERGs were filtered to reveal 4 oscillatory potentials. 
Boys with Dp427 mutations had a small cone OP2, but normal rod OPs. Those 
with mutations downstream exon 30 had an absent rod OP2, but surprisingly 
cone OPs in some were normal (figure 26). 
OCT axial sections performed randomly in 6 individuals, showed normal retinal 
lamination and macular profiles. The retinal nerve fibre layer thicknesses were 
within normal limits across genotypes (figure 27). 
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Figure 22. ISCEV ERG trace examples. 
 
 
 
Figure 22. Examples of rod and cone ISCEV full field ERGs from patients with 
mutations at 5’ and 3’ end of the gene are compared with normal waveforms, in 
which the a-wave is smaller than the b-wave and the a:b ratio is 1:2. The upper 
traces from a boy with a mutation affecting Dp427 alone (i.e. exons 8-13) show a 
DA 3 rod ERG in which the b-wave is reduced to the same size as the a-wave 
giving an a:b ratio of 1. Below, an individual with a mutation affecting Dp427 
and Dp260 (i.e. exon 44) with a DA 3 rod ERG b-wave that is smaller than the a-
wave giving an electronegative ERG.  The cone ERG LA 10 waveforms show a 
similar pattern with normal a-waves, but small b-wave amplitudes altering the 
overall ERG waveform. 
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Figure 23. ISCEV scotopic dark-adapted ERG measurements 
 
Figure 23: ISCEV scotopic dark-adapted ERG measurements 
Top graph: Dark-adapted b-wave amplitude is plotted against flash strength. It 
shows a dichotomy of Dp427 (filled symbols) and Dp260 (open symbols) 
response, accentuating the subnormal amplitude when expression of Dp260 is 
compromised. The b-wave time to peak is also distinctive, falling below normal 
range i.e. shorter time to peak, to high increasing flash strength when only the 
Dp427 expression is affected. 
Lower graph: a-wave amplitude is plotted against flash strength. Dp427 (filled 
symbols), are more often seen below the 5th centile at high flash strengths than 
Dp260 (open symbols), but the time to peak for both fall within normal range.  
The exception, shown as a grey filled symbol, is from a patient with deletion of 
exons 8-13. 
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Figure 24. Skin ERG trace examples 
 
 
Figure 24. Skin ERG trace examples. Examples of skin ERGs are shown to 
illustrate responses from individuals with mutations affecting each isoform. The 
absent b-wave, (marked with *), in association with a mutation in exon 70 results 
in a profoundly electronegative ERG waveform. The trace time base is extended 
to 250ms to show that eventually the polarity of the ERG recovers and the trace 
re-joins the baseline.    
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Figure 25. Scotopic and photopic a:b ratios ISCEV standardised protocol and  
GOSH protocol  
 
Figure 25: Scotopic and photopic a:b ratios ISCEV standardised protocol (top) 
and skin GOSH protocol (bottom). These bar charts show the ratio of a:b-wave 
amplitudes for each patient. These are arranged according to the isoform 
affected. The horizontal lines indicate the normal reference ratio. Data falling 
above the line indicates a low b-wave amplitude and abnormal a:b ratio. The top 
left graph shows the strong association of Dp260 (open bars) with electronegative 
DA ERGs as the a:b ratio is greater than 1. The top right graph abnormal cone 
ERGs a:b ratios occur mildly across all mutations. Patients with mutations 
affecting Dp71 managed skin ERGs (GOSH protocol) only depicted on the lower 
graphs, not requiring formal dark adaptation; these are electronegative for both 
photopic and scotopic conditions. The exceptional case (individual 6) is 
highlighted next to the Dp260 patients: although his mutation is predicted to 
affect only Dp427, the ERGs suggest Dp260 expression is also affected. 
Importantly, the same profile of a:b ratio with genotype is seen for the skin 
145 
 
GOSH ERG data as ISCEV ERG data  (r= 0.87, p= 0.01) i.e. ratios fall above the 
line for the same patients. 
 
 
Figure 26. Oscillatory potentials 
 
Figure 26. The oscillatory potentials (OPs) are high frequency wavelets revealed 
by filtering the ERG trace between 100-300Hz. These are numbered for 
identification, though loss includes the possibility of OP delay and consequent 
merger with other OPs. The photopic OP2 in the patient with a mutation at the 5’ 
end of the gene is subnormal, but the scotopic OPs are normal.  Scotopically the 
greater effect of Dp260 is seen and these scotopic OP2 and OP3 are subnormal, 
yet unexpectedly this patient has normal photopic OPs.  
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Figure 27. Retinal structure 
 
 
Figure 27: Optical coherence tomography (OCT) show normal retinal structure 
with resolution of 7-10 microns). 
(Courtesy of Dorothy Ann Thompson Clinical and Academic Department of 
Ophthalmology, Great Ormond Street Hospital for Children, London, UK) 
 
 
 
Clinically, all boys had normal fundi and normal visual acuity. One boy with a 
nonsense mutation in exon 70 had a red/green colour vision defect. IOPs were 
mildly elevated in two boys (22-24mmHg). 
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Explorative relation between ERG findings, behavioural problems and intellectual 
disability 
All the subjects recruited in this study were cooperative and with normal range 
GAI, with the exception of the 2 boys with Dp71 mutations, who had a profound 
speech delay. Nine of the 16 boys had neurobehavioural problems: 5/6 boys who 
scored high in the SCDC had mutations downstream of exon 30 and scored 
above the threshold for ADHD, ASD and emotional problems (table 17). Two of 
seven boys with mutations upstream of exon 30, whose families reported mild 
behavioural disturbances, had scores above the threshold for inattention and 
anxiety (table 17).  The two boys with mutations downstream of exon 63 and 
profound speech delay, scored in the ASD range according to both to the SCDC 
and the 3Di-sv. These two boys only managed the GOSH ERG skin protocol. 
Interestingly, the same boy (individual 6), with 5’-end mutation, but with a 
Dp260, 3’-end mutation type of ERG profile also presented with a neurocognitive 
profile (i.e. inattention, emotional problems and ASD) comparable to that of 
children with 3’-end mutations. In this subject we therefore suspected a second 
mutation in addition to the deletion of exons 8-13 identified by MLPA and we 
carried out a full dystrophin gene sequencing, which however did not reveal 
other mutations.  
Exploring a possible relationship between ERG and neurobehavioural outcomes 
we compared the SCDC scores as an overall index of neurodevelopmental 
impairment with scotopic a:b ratios. Although our analysis did not meet 
statistical significance (p=0.1), we observed that boys with electronegative 
scotopic ERGs to score more likely in the abnormal range for the SCDC (6 out of 
10), whilst none of the six boys with electropositive scotopic ERGs had abnormal 
scores (figure 28).  
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Figure 28. Social and Communication Disorders Checklist (SCDC) score 
according to ERG findings 
 
 
 
Figure 28. ANOVA comparing SCDC scores in electronegative and 
electropositive scotopic ERG groups (Graph pad Prism)248. SCDC scores above 8 
are abnormal and highly indicative of neurodevelopmental disorders. Boys with 
electronegative ERGs were more likely to have abnormal scores (p=0.01). 
P value< 0.05 was considered significant.  
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Discussion 
In collaboration and with the support of the ophthalmology department at 
GOSH, I studied the retinal physiology and neurodevelopmental profile of 16 
DMD boys, with a range of mutations around a ‘pivot’ region of interest at exon 
30, which enabled us to segregate CNS/retinal expression of shorter isoforms 
Dp260, Dp140, and Dp71 from the full-length dystrophin isoforms Dp427 which 
are predominantly expressed in muscle18.  We examined the retina functionally 
with the ERG, and structurally with OCT imaging. We found ERG changes 
corresponding with the recently reported differential expression of Dp isoforms 
between retinal sub-networks in animal models, with Dp427 allied more with 
cone pathways and Dp260 with rods.233 
We now recognise that ERG b-wave amplitude mainly depends upon 
depolarisation of on-bipolar cells249, rather than potassium channels on the 
Muller glial cells,250 which are altered in the Dp71 null mouse models of DMD. 
This explains why ERGs reported in DMD patients differ from some previously 
predicted DMD mouse knockout models.231, 237  
In this study DMD patients selectively lacking expression of Dp427 isoforms 
showed a preponderance of changes in cone b-waves indicating a disruption of 
signalling between normally functioning cone photoreceptors and cone on-
bipolar cells.   In contrast, rod a-wave amplitude was subnormal, indicating 
altered rod photoreceptor function in 5/7 of patients with mutations affecting 
Dp427 alone.  This has not been reported before and may be due to the brighter 
flash used in our study. Expression of the Dp260 isoform, between rod 
photoreceptors and rod on-bipolar cells, was necessary for slow rod pathway 
function.  Altered expression of Dp260 caused subnormal b-wave amplitude and 
hence electronegative scotopic ERG waveforms. This characteristic signature was 
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exacerbated if Dp71 was additionally compromised, as shown in figure 24. In our 
study we showed that, indeed, mutations affecting Dp71 have the most profound 
and uniquely electronegative scotopic ERG (figure 24), alongside showing most 
severe cognitive-neuropsychiatric profile disturbances.  
This study highlighted only one exception in such patterns: a boy with a 
mutation of exons 8-13 (i.e. affecting Dp427 alone) showed both an 
electronegative scotopic ERG, severe speech delay and a neuropsychiatric profile 
in the autistic spectrum domain. Additional DMD mutations were not identified; 
the combined ERG and neurodevelopmental phenotype of this child remain 
unexplained. 
Retinal signalling depends upon the structural alignment of proteins at the 
synapses.  Dystrophin is considered a developmental determinant of structural 
apposition of photoreceptors with bipolar cells.251  It was anticipated that patients 
with DMD might show altered patterns of retinal lamination, but high-resolution 
spectral domain OCT axial images of the in vivo retina did not show any 
irregularity of the outer plexiform lamina nor abnormal lamina thicknesses in a 
comparison with normal.  
As retinal lamination is normal, the observed ERG changes are more likely due to 
altered synaptic transmission and membrane polarisation. This implies a role for 
dystrophin isoforms in retinal signalling.  Our novel evidence of isoform-specific 
loss of rod and cone oscillatory potentials supports this contention as OPs are 
generated by spiking amacrine and ganglion cells.  
In relation to the neuropsychiatric profile, an important consideration is 
required: in order to facilitate electrophysiological assessments, the recruitment 
was biased towards DMD boys with good understanding and co-operation. With 
the exception of the two Dp71 boys, who had profound delay, the GAI scores 
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were within normal ranges.  Nevertheless neurobehavioural problems were 
observed in nine boys and including ADHD, ASD and emotional problems. 
Although three boys with Dp427 mutations presented with some behavioural 
problems, overall boys with mutations progressively affecting the shorter 
dystrophin isoforms were more commonly and more severely affected. This is 
not surprising, as the full length isoforms are also expressed in the neuro-cortex, 
hippocampus and cerebellum. However, the shorter isoforms are most 
abundantly expressed in the brain, with the pivot region of interest for the brain 
in exon 45. Indeed, Dp140 has been amply localized in glial cells,252 and 
disruption of this isoform in mutations affecting exons 45-62, has been implicated 
with cognitive impairment, higher incidence of ADHD and delayed milestones.12, 
68, 72 Mutations affecting Dp71, a brain isoform implicated in trans-membrane 
permeability,220 although rare are recognized in association with severe cognitive 
impairment.68, 213  The two boys with Dp71 mutations, indeed had the most 
severe profile with ASD and profound speech delay. Our findings, in line with 
previous reports in the literature, suggest a possible cumulative effect on 
neurodevelopment caused by the progressive loss of the shorter dystrophin 
isoforms, with mutations towards the 3’-end of DMD being associated with the 
most devastating outcomes.  
 
In our cohort, of clinical importance, we observed that scotopic electronegative 
ERGs were more likely to be associated with neurodevelopmental disorders. 
However, the spectrum of neuropsychiatric morbidities in dystrophinopathies is 
vast, complex and multifactorial; our sample population was relatively small; 
and our observations were based on validated questionnaires/interviews rather 
than extensive neuropsychological assessments. Therefore, an association 
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between retinal electrophysiology and neurodevelopmental disturbances needs 
further exploration in much larger cohorts.  
Experimental treatments with antisense-mediated exon skipping or drugs that 
allow read-through of nonsense mutations are currently being tested in human 
clinical trials, demonstrating successful partial restoration of dystrophin 
expression in muscle.78, 79 A new class of therapeutic agents, have recently shown 
to be able cross the blood brain barrier in animal models and to restore 
dystrophin also in the CNS,225  therefore there is both the need to better 
understand the DMD CNS changes and to identify the treatment response with 
quantifiable biomarkers.   
This study shows that retinal electrophysiology is a tool sensitive to dystrophin 
protein absence in the CNS; it provides an individual patient pre-treatment 
retinal response profile as a signature of protein disruption. In absence of 
structural defects in the eye of DMD boys, we can speculate that the 
electrophysiological signature may change towards normal as protein is restored 
also in the CNS, however this model requires further exploration in the retina, 
while it was demonstrated in the brain.253 The ophthalmic manifestations of 
myopathies have recognised importance as potential biomarkers,254  and in DMD 
the retina characteristics may offer a portal to the CNS. 
Two boys with severe neurocognitive profile could only manage the GOSH skin 
protocol. This technique offers a tolerable, child-friendly assessment of retinal 
physiology if the neurobehavioural profile is severely affected, which is often the 
case in DMD, especially in boys with mutations at the 3’end of the gene.  
In conclusion, these data further refine the characteristics of the retinal function 
of DMD. The frequently reported electro-negative scotopic ERG associates with 
mutations downstream of exon 30 and is profound when Dp71 is additionally 
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affected. Selective stimulation of slow and fast rod pathways shows a 
dependence of slow rod pathways upon Dp260.  Also we have highlighted 
anomalies of the amacrine oscillatory potential circuits, and cone pathways 
associated with Dp427 and Dp71.  The most severe b-wave changes reflect the 
most severe neurocognitive profile and likely reflect abnormal dystrophin 
isoform CNS expression.   
Our study has several limitations: the sample size was small, therefore these 
results need to be explored in larger cohort of patients especially with mutations 
in the 3’-end of the gene;  we have speculated that our electrophysiological 
findings are secondary to dystrophin disruption in the retina, however further 
studies are required to understand the underlying signalling mechanisms in 
humans, which determine these electrophysiological abnormalities, and to what 
extent they can be reversed; finally, any relationship between 
neurodevelopmental problems and retinal electrophysiological abnormalities 
requires further systematic investigation in larger cohort of patients.  
In conclusion, while further investigating the intricate and yet poorly understood 
role of dystrophin and its isoforms, retinal electrophysiology could offer a non-
invasive portal into understanding protein disruption and potential restoration 
in the CNS.  
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CHAPTER 6: NUCLEAR MAGNETIC RESONANCE INVESTIGATIONS IN 
DMD 
 
 
 
 
Imaging and the muscle  
The use of imaging for the assessment of muscle disease raised interest in the 
neuromuscular community when in 1980 Heckmatt, Dubowitz and Leeman 
carried out a pilot study on use of muscle ultrasound, which was published on 
the Lancet.255 Subsequently the same group reported the appearance of the 
quadriceps muscle of the thigh in 60 children affected by different 
neuromuscular conditions and in 60 control children. The authors could show a 
very good visualization of bone echo, which stood out clearly against the 
The work contained in this chapter has given rise to the following publication: 
Ricotti V, Evans MRB, Sinclair CDJ, Butler JW, Ridout DA, Hogrel JY, Emira 
A, Morrow JM, Reilly MM, Hanna MG, Janiczek RL, Matthews PM, Yousry 
TA, Muntoni F and Thornton JS. Evaluation of upper limb in Duchenne muscular 
dystrophy: fat-water quantification by MRI, muscle force and function define 
endpoints for clinical trials. (Under review)  
 
My contribution to this work consisted of the following:  
In collaboration with the Institute of Myology, UCL and GSK I oversaw the 
design and analysis of the study. I contributed in the development of the 
upper limb modules used to asses patients in this study. I recruited patients. I 
contributed to data collection. In collaboration with the Statistical Department 
I analysed the data. I wrote the first draft of the manuscript, and contributed 
to the revision of the manuscript.  
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background of echo-free muscle tissue, whilst muscle of boys with muscular 
dystrophies was associated with an increase in the intensity of echo reflected 
from the muscle tissues, with corresponding loss of bone echo. Changes in 
muscle echo were also reported in children with congenital myopathies, whilst 
children with non-neuromuscular conditions, such as hypotonia, had normal 
findings.   
Ultrasound imaging has proved a very useful, non-invasive screening tool in the 
investigation of children with neuromuscular disease, and it is currently widely 
used in clinics to identify muscle involvement, and also as an aid in the selection 
of muscle biopsy sites. In the recent years magnetic resonance imaging (MRI) and 
spectroscopy (MRS) have rapidly increased in importance in the neuromuscular 
field both in assisting the diagnostic pathway but also as very promising 
outcome measures in experimental studies. 
The advantage conferred by MR technology is that it is a non-invasive method 
without ionizing radiation, with high resolution of muscle fat and connective 
tissue, and capable of measuring tissue characteristics (MRI) and muscle 
metabolites (MRS) in a quantitative way.  
MRI works by creating around the area to be imaged, a strong magnetic field, 
which can range from 1 to 7 tesla. Hydrogen atoms in tissues containing water 
molecules are used to create a signal that is processed to form an image of the 
target tissue or organ. First, energy from an oscillating magnetic field is 
temporarily applied to the patient at the appropriate resonance frequency. The 
excited hydrogen atoms emit a radio frequency signal, which is measured by a 
receiving coil. The radio signal can be made to encode position information by 
varying the main magnetic field using gradient coils. The contrast between 
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different tissues is determined by the rate at which excited atoms return to the 
equilibrium state.  
MRS is also a non-invasive biochemical sampling technique, which can be used 
to infer further information about cellular activity to quantify certain metabolites 
in the target tissues such as lipids or ATP in skeletal muscle.  
 
MRI in neuromuscular diseases 
The use of MRI largely contributed to shift from a diagnostic approach based on 
muscle biopsy to clinical and MRI pattern recognition in support of a targeted 
genetic investigation.256 Imaging has shown how different muscle diseases affect 
muscles selectively, and consistently, therefore creating a disease distribution 
pattern, which facilitates diagnosis. A TREAT-NMD workshop held in Rome in 
2011 summarised the characteristic findings for the different muscle diseases.257 
The MRI muscle study group in addition extensively reported pattern 
recognition in early onset neuromuscular disorders with full body MRI 
protocols.258 
 
MRI studies in Duchenne muscular dystrophy  
For Duchenne muscular dystrophy, numerous studies have shown the ability of 
MRI to detect alterations in skeletal muscles and its composition.256, 259-274   
Matsuma et al. in 1988 reported T1 values in DMD to rapidly decrease with time 
as disease progresses, secondary to replacement of muscle by fat.260 The group 
also showed that the pattern of T1 reduction was not the same for all muscles, as 
it was most prominent in the gluteus maximus and least prominent in the 
sartorius and gracilis muscles. The authors reported that both regenerating and 
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degenerating muscle fibres showed an increased muscle water content, resulting 
in high T1 value in the early stages of DMD, whereas in the advanced stages of 
the condition replacement of muscle by fat caused decrease in T1 values.259  
Another pioneering study reported increased T2 values of anterior tibial muscle 
in DMD patients when compared to healthy controls, and this was explained by 
the increased fatty infiltration in DMD patients.261 Furthermore, in weaker DMD 
patients, the width of the muscle T2 peak increased and the peak shifted toward 
the fat peak. In addition, the T1 values decreased with increasing fatty 
infiltration. The authors concluded that quantitative T1 and T2 maps could be 
used to assess muscle status and monitor DMD progression.261 
Mercuri et al.256 subsequently developed a six step staging system to qualitatively 
characterise disease severity based on visual inspection of the skeletal muscle, the 
so called “Mercuri score”: 
 Stage 0: normal appearance 
 Stage 1: Scattered small areas of increased density 
 Stage 2a: numerous discrete areas of increased density ≤ 30% of the 
volume of the muscle 
 Stage 2b: Numerous discrete areas of increased density with early 
confluence, 30-60% of the volume of the muscle 
 Stage 3: Numerous perimysial and endomysial adipocytes with 
loss/partial loss of fascicular structure 
 Stage 4: Pronounced fatty replacement throughout with fascicle structure 
loss. 
Although this score was recently used to screen DMD subjects recruited into a 
clinical trial for local administration of antisense oligomer nucleotides,77 and was 
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also used in a comparative study of muscle histology with MRI, its limitation is 
that it relies on quality inspection rather than quantification of muscle 
pathology.262 
A number of quantitative methodologies have been applied to DMD including: 
T1-weighted imaging,259 T1-weighted imaging and gadolinium enhancement,263 
muscle cross sectional area;264 T2-weighted imaging;256, 265, 268, 273, 275  Fat 
suppression sequences;266 3-Point Dixon technique;267, 269, 270 and finally MR 
Spetroscopy.268, 271, 272 
As an example, T1-weighted (T1W) with gadolinium contrast-enhanced images 
have been used to quantify the differences between normal controls and 
corticosteroid-treated DMD boys in the lower limb muscles and to explore the 
effect of exercise.263 Eight of nine muscles studied showed a significant increase 
in T1-W signal intensity in DMD as compared to normal muscle, suggestive of 
increased fat infiltration in DMD muscle. The DMD boys were also imaged 
before and after stepping exercise: and as exercise effect an increased gadolinium 
uptake was observed only in the tibialis anterior muscle.263 
T1-weighted images at 3 time points were used to assess fat replacement in the 
thighs of 8 DMD ambulant boys on corticosteroids.267 This study showed that as 
early as 9 months and over 18 months the fat replacements in the thigh muscle 
increases significantly, especially in the biceps femoris, rectus femoris and vastus 
lateralis. This study proved MRI to be able to demonstrate the specific fat 
changes over time and also the variability between different muscle groups.267  
Another study focused on T2-weighted imaging to establish quantifiable 
measures, which would allow correlation with clinical evaluations and with the 
“Mercuri score” assessment.265 The study, which was carried out on the upper leg 
of 34 DMD boys (mean age of 8.5 years) quantified the degree of muscle 
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involvement by T2 mapping methodologies. The study showed that the highest 
T2 values, reflecting fat degeneration, were observed in the gluteus maximus, 
and these values correlated with the Mercuri scores, as well as with clinical 
assessment (i.e. time rising from the floor and the 30 feet run).265  
A large multi-centre cross-sectional study has been recently published evaluating 
MRI and MRS in the lower extremities of 123 DMD boys and 31 healthy 
controls.268 This study supported the validity and reproducibility of an imaging 
protocol across centres;276 furthermore it showed how MR-T2 measures of the 
lower limb muscles are sensitive at differentiating DMD patients who are still 
ambulant from healthy controls, and these values deteriorate with age and 
pathology progression.  
 
Dixon technique 
The Dixon technique has been originally been described by Thomas Dixon, who 
in 1984 proposed a chemical shift imaging capable of separating MRI signal 
intensity for the distinct contributions of water and fat.277 In his original 
technique two sets of spin echo images were acquired with slightly different echo 
times: the first with fat and water signals in phase and the second with the echo 
times adjusted by a few milliseconds so that the fat and water signals were out-
of-phase. This technique results in high-resolution water and fat maps. During 
the 1990s numerous modifications of the Dixon technique were proposed, 
including 3-point methods:278, 279 this requires three gradient echo images at three 
different echo times to be acquired with the echo times determined by the field 
strength of the magnet.258 Usually two of the acquisitions are done with water 
and fat in phase whilst a third acquisition is out of phase. This technique has 
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been recently used by Wren and colleagues269 in nine boys with DMD, MRI 
measures of fat infiltrations in the thigh were compared with functional grades 
according to the Brooke Scale280  showing a strong correlation between the 2 
parameters. More recently the lower limbs of 16 DMD patients and 11 controls 
were imaged with the 3-point Dixon technique.270 This study described fat 
fraction percentage values in all the muscle groups of the upper and lower leg, 
with values significantly higher than in controls. The mean age of the DMD 
patients was 11.4 years (± 2.2 y.), 7 of them fully ambulant and the others 
wheelchair users/dependant.  The most affected muscles included abductor 
magnus, biceps femoris (long head and rectus femoris, with f.f.% in the range of 
40-60. Furthermore this study demonstrated that although the total cross 
sectional area of the muscles did not differ significantly between controls and 
DMD, on the other hand, the contractile muscle cross sectional area was 
significantly smaller in DMD, particularly the quadriceps femoris and 
hamstrings. Maximal voluntary isometric contraction was obtained using a fixed 
myometry. All muscle groups showed decreased strength when compared to 
controls.270 
 
MR Spetroscopy 
In recent years various approaches of  MR spectroscopy (MRS) have been 
explored to study muscle pathology in DMD. Although MRS focuses on a limited 
area of the muscle, it can provide accurate information on the muscle 
metabolites. 31Phosphorus spectroscopy (31P MRI) has been reported in patients 
with DMD281, 282 and has been evaluated and described in in the soleus and 
tibialis anterior muscles of healthy subjects by Kan et al.271 The idea behind 31P 
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MRI is that it can be used to measure cellular energy in organs; to assess 
mitochondrial content and function in skeletal muscles; and to evaluate muscle 
perfusion and acidification.283  
31P MRI, and most specifically phosphodiesters to phosphocreatine  (PDE/PCr), a 
single sensitive index for membrane metabolism analysis, have been recently 
used to describe improvement in muscles of Golden Retriever Muscular 
Dystrophy (GRMD) dogs treated with AVV-delivered exon skipping, alongside 
histopathology and muscle strength.154  
Furthermore, proton spectroscopy (1H-MRS) has been evaluated in muscles. 
Torriani et al.272 measured 1H-MRS lipid fraction in the soleus and tibialis anterior 
of 9 DMD subjects and 8 matched healthy controls. In this study a relationship 
between muscle lipid composition and the 6-minute walk test (6MWT) was 
observed. The same study found a positive correlation between 1H-MRS 
measures which were part of the imaging protocol and the 10 metre run. 272 
However, these correlations need to be interpreted with caution given the cross-
sectional nature of the study and the small sample size.  
In their large cross-sectional multicentre study involving 123 ambulant DMD and 
31 healthy controls, alongside MRI-T2, Forbes et al. described also 1H-MRS 
measures acquired for the assessment of lipid fraction in the lower extremities. 
The fat fraction, which is given by the ratio lipid/(lipid + water) was significantly 
higher in DMD subjects and as for the MRI-T2 measures, these values increased 
with age,268 therefore providing a potential biomarker for monitoring disease 
progression and therapeutic intervention.  
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MRI as an endpoint for clinical trials 
MRI continues to be largely investigated both in animal models,154, 284 in natural 
history studies 275, 285 and in interventional studies.286, 287   
International collaborations supported by TREAT-NMD have facilitated the 
standardization of operating procedures and the harmonization of protocols for 
clinical trials in DMD.258 Furthermore, a multicentre study carried out in the 
United States has validated MRI and MRS protocols for DMD ambulant 
subjects.276  
As discussed above, MRS has been explored as a biomarker sensitive to response 
to pharmaco-genetic therapy in GRMD dogs.154 A recent study evaluated both 
MRI and MRS of the legs in response to steroid therapy.286 MRI and MRS 
measures of fat infiltration favoured DMD subjects on steroids when examined 
cross-sectionally; in addition imaging detected therapeutic effects of steroid 
treatment in reducing inflammation over the course of one year.  With a number 
of potential therapeutic interventions under development for DMD, MRI/MRS 
seem to offer potential non-invasive and non-motivational-dependent 
biomarkers for monitoring disease progression and response to treatment. 
Muscle biopsy is currently used to demonstrate dystrophin expression in clinical 
trials that aim at restoring truncated yet functional protein products. 78, 79, 82  
However, this is an invasive procedure, which carries the risks of exposing the 
subjects to general anaesthetics and can only be carried out a limited number of 
times in the same subjects. A study by Kinali et al. showed a correlation between 
MRI changes based on the Mercuri scoring system evaluated by two observers, 
and histopathologic changes on muscle biopsy of the extensor digitorum 
brevis.262  
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MRI not only allows to evaluate muscle pathology non-invasively but also to 
evaluate an overall progression of the pathology. It is well recognised that DMD 
pathology varies between muscles and within the same muscle, dystrophin 
expression may not be uniform.288 Hence, MRI may offer a more global view of 
the pathology.  
As discussed in chapters 3, a number of promising novel experimental therapies 
are at different stages of clinical trials, e.g. antisense oligomer (AO) mediated 
exon skipping, which aims to restore semi-functional protein products; and 
drugs to induce read-through of nonsense mutations.78, 79, 82 The 6-minute-walk 
test (6-MWT) has been utilized as a primary outcome end-point in phase II-III 
clinical trials;80-82 however limitations of this functional test include that it is 
motivation dependent289 and can only be used for ambulant boys. As discussed 
above, recent studies showed that MRI and MRS provide sensitive markers of 
muscle pathology and disease progression in the lower limbs of DMD subjects,267, 
268, 273 however to date very limited data exists about upper limb imaging in non-
ambulant subjects.  
 
A study on evaluation of upper limb in Duchenne muscular dystrophy: fat-water 
quantification by MRI, muscle force and function define endpoints for clinical trials.  
 
The aim of my study was to examine the ability of MRI, specifically MRI fat 
quantification, to detect disease progression in the upper limb of non-ambulant 
DMD boys and to compare the responsiveness of quantitative MRI measures to 
muscle strength and validated functional assessments.  
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Methods 
Participants 
I recruited 15 non-ambulant DMD boys with a mean age of 13.3 y, (range: 10.8-
17.3 years) mean duration of non-ambulation 20.2 months (range: 4.7- 41.6) and 
mean BMI 26.5, range: 20.8-41.7). Assessments were performed at baseline, 3, 6 
and 12 months; 6 subjects withdrew from the study due to the frequent hospital 
visits, which were challenging to sustain in absence of therapeutic intervention. 
At the time of the study, all but one subject were receiving glucocorticoids at the 
time of the study.  Ten age and gender-matched healthy control subjects were 
scanned once (mean age: 14.6y, range: 13-17; mean BMI 21.5, range: 16.5-25.4).  
To assess measurement reproducibility 4 of these individuals were re-tested at 6 
weeks. 
Approval from the local research ethics committee was obtained for this study, 
which was performed in compliance with the Declaration of Helsinki.  
 
MRI acquisition and data analysis 
Unilateral upper-limb MRI was performed at 3T (Siemens, Erlangen, Germany) 
using a flexible surface matrix coil (4-Channel Flex Coil) wrapped around the 
dominant forearm. Subjects lay in the scanner in the head-first supine position, 
with the dominant arm to be imaged lying in a comfortable position on the 
scanner bed alongside the torso.  Three-point-Dixon278 images were acquired. 
Images were post-processed offline with a Python programming language 
pipeline according to Glover and Schneider’s algorithm279 and separated fat (f) 
and water (w) images were used to calculate pixel-wise fat fraction (f.f.) maps 
according to f.f.(%)= 100*f/(w+f). 
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Observers blinded to diagnosis manually defined individual muscle-group 
regions of interest (ROI) on the TE=3.45ms Dixon image to encompass each 
muscle-group boundary to the fascia using the ITK Snap software290. For 
consistency all ROI definitions were subsequently reviewed by a single blinded 
observer (based at the Institute of Neurology). For each subject 3 of the 9 
available baseline image slices were chosen for analysis: a central slice defined as 
the first axial slice distal to the supinator muscle, and proximal and distant slices 
centred  74mm relative to the central slice.  For consecutive longitudinal data 
from the same subject, the slices selected for analysis were carefully matched to 
the baseline slices by visual inspection and reference to a coronal scout image.  
On each slice ten forearm muscle-group ROIs were defined: the (extensor carpi 
ulnaris (ECU), extensor digiti minimi (EDM), extensor digitorum (ED), extensor 
pollicis longus (EPL), abductor pollicis longus (APL), extensor carpi radialis 
longus/brevis and the brachioradialis (ECRLB Br), flexor digitorum profundus 
and flexor pollicis longus (FDP), flexor digitorum superficialis and palmaris 
longus (FDS), flexor carpi ulnaris (FCU), flexor carpi radialis (FCR) 
muscle/muscle groups (figure 29). 
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Figure 29. Muscle segmentation and raw 3-point Dixon of the central slice in 
the dominant forearm of a healthy control 
 
 
 
 
Figure 29. Muscle segmentation (A) and raw 3-point Dixon (B) of the central slice 
in the dominant forearm of a healthy control . 
Extensor carpi ulnaris (ECU), extensor digiti minimi (EDM), extensor digitorum 
(ED), extensor pollicis longus (EPL), abductor pollicis longus (APL), extensor 
carpi radialis longus/brevis and brachioradialis (ECRLB Br), flexor digitorum 
profundus and flexor pollicis longus (FDP), flexor digitorum superficialis and 
palmaris longus (FDS), flexor carpi ulnaris (FCU), flexor carpi radialis (FCR). 
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For each consecutive image at the same level in the same subject, ROI were 
drawn with reference to the baseline ROI, to maintain equivalent anatomical 
coverage.  The segmented ROI were transferred to the co-registered f.f. maps, 
and visually inspected for placement errors or the presence of gross artefact and 
adjusted if necessary.  For all individual ROIs, custom-written software extracted 
individual muscle-group mean f.f. and muscle cross-sectional area (CSA) in mm2, 
and also calculated for each subject at each of the 3 slice levels the summary 
measures overall muscle  f.f. calculated as the mean of the individual muscle-
group mean f.f.s weighted by their respective CSAs, total cross-sectional muscle 
area calculated as the sum of the individual muscle CSAs, and total remaining 
muscle area calculated as total cross-sectional muscle area (100 – overall muscle 
%f.f.)/100.  
 
Functional assessment  
Each subject was assessed as follows: 1) performance of upper limb (PUL) 
module, a validated 74 point functional scale for motor performance relating to 
everyday life activity;291, 292  2) muscle strength  for shoulder flexion, elbow 
extension and flexion, and wrist extension was measured in lbs using a hand-
held myometer (Microfet, Hoggan, UT)   3) MyoSet (Myopinch, Myogrip and 
Moviplate), a suite of recently validated novel tools to assess strength and 
fatigability of the upper limb;293, 294  4) Egen Klassification (EK2) interview version 
2, which is used to determine performance of tasks in daily life (total score=51)295 
5) spirometry and peak cough flow by using Vitalograph Pneumotrac 6800; and 
6) the time to loss of ambulation (LOA) in months was also recorded. 
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Statistical methods 
Baseline MRI measures were compared between the DMD and control groups 
using unpaired t-tests. In the DMD group, changes in clinical measurements and 
MRI scores were compared within boys over the 3 follow-up time points, using 
mixed model regression analysis. A separate model was fitted for each outcome 
measurement and an adjustment was made for length of time non-ambulant; 
results are presented as adjusted mean changes for the 3 month, 6 month and 12 
month periods with 95% confidence intervals (CI). The Normality assumption of 
the models was checked using the Shapiro-Francia W dash test.128 The Shapiro-
Francia normality test performs a formal test of Normality for a single variable. 
The null hypothesis of the test assumes the population is normally distributed 
and a resulting significant p value would suggest there is evidence of non-
Normality. 128 For measurements where there was some evidence of non-
normality we investigated the use of appropriate transformations. 128  Findings 
were found to be very similar therefore we have presented results for 
untransformed data. To account for multiplicity a P-value < 0.01 was considered 
significant. The statistics package Stata132 was used for the analysis.  
 
Results 
Out of the 15 subjects initially recruited, combined MRI and clinical assessment 
data were obtained for 9/15 subjects at 3 month (mean age 13.2y; range: 11.1-
17.6) follow-up and 7/15 at both 6 the month (mean age 13.9y; range: 11.6-17.9) 
and 12-month (mean age 14.2y; range: 11.8-18.2) time points. Although MRI was 
overall well tolerated, the remaining 6 subjects found the commitment to the 
study too demanding to sustain.  
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Muscle MRI- fat infiltration, cross-sectional area, and remaining non-fat area 
The overall mean central slice muscle f.f. (95% CI) in the DMD subjects was 
significantly higher than for healthy controls (14.1%, 95% CI 9.1, 19.1 in DMD; 
0.9% 95% CI 0.8, 1.0 in healthy controls; p<0.001), as were individual muscle-
group mean  f.f. (table 18). The central slice mean total cross-sectional muscle 
area was reduced in DMD (1473 mm2, 95% CI 1289.3, 1654.7 mm2) relatively to 
the healthy controls (2389 mm2, 95% CI 1878.9, 2899.0 mm2; p=0.006). The 
extensor carpi radialis longus/brevis and the brachioradialis (ECRLB Br) group  
showed the greatest differences in f.f. between DMD and the healthy controls 
(table 18), with an overall  mean f.f. 31.1 (95% CI 22.5; 39.7%) in the DMD group.  
 
 
 
Table 18 (A&B). Individual muscle-group mean fat fraction (%) for the central 
slice in each DMD and healthy control (HC) subject at baseline (A) and mean 
(95%CI) changes from baseline  (B). 
A 
 
Subjects ECU 
f.f. 
EDM 
f.f. 
ED 
f.f. 
APL 
f.f. 
EPL 
f.f. 
ECRLB 
Br f.f. 
FCU 
f.f. 
FDP 
f.f. 
FCR 
f.f. 
FDS & 
PL f.f. 
1 DMD 3.41 1.14 3.50 4.58 3.40 26.41 5.88 4.99 4.90 7.09 
2 DMD 5.44 2.95 5.27 10.98 9.49 55.10 E 12.94 26.15 46.72 
3 DMD 8.56 12.69 9.86 19.26 7.56 13.36 49.10 16.69 24.19 34.17 
4 DMD 2.25 3.45 4.03 4.48 5.81 43.67 11.64 2.65 5.16 6.18 
5 DMD 1.73 2.44 4.47 3.21 4.10 9.76 22.81 7.74 34.73 13.39 
6 DMD 2.87 1.23 1.87 1.93 2.43 14.58 3.82 1.32 4.19 5.81 
7 DMD 2.21 7.72 40.36 25.28 22.94 54.52 6.97 35.21 24.01 47.72 
8 DMD 91.92 88.59 68.19 84.76 75.76 46.23 75.94 91.95 87.61 94.56 
9 DMD 0.77 0.00 0.03 0.29 0.66 7.84 3.97 1.58 0.48 1.52 
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10 DMD 7.94 14.24 17.23 16.11 13.13 52.27 31.68 11.07 30.58 12.68 
11 DMD 12.69 11.53 25.37 23.47 30.19 30.69 32.30 22.78 38.58 47.92 
12 DMD 2.57 2.24 3.68 2.01 2.25 22.12 6.03 1.93 21.74 15.85 
13 DMD 2.15 3.18 4.93 4.96 5.93 22.34 6.40 3.66 6.92 1.99 
14 DMD 5.39 11.54 12.56 25.14 12.51 32.43 12.08 3.61 27.84 11.97 
15 DMD 12.96 13.33 24.29 35.66 19.79 37.66 36.40 27.24 56.73 41.59 
 
Subjects ECU 
f.f. 
EDM 
f.f. 
ED 
f.f. 
APL 
f.f. 
EPL 
f.f. 
ECRLB 
Br f.f. 
FCU 
f.f. 
FDP 
f.f. 
FCR 
f.f. 
FDS & 
PL f.f. 
1 HC 0.09 0.47 1.50 0.72 0.00 1.67 2.42 0.50 1.34 0.93 
2 HC 1.48 0.63 0.95 0.28 1.40 1.03 1.58 0.59 0.07 0.24 
3 HC 0.13 0.52 1.01 0.53 1.19 1.20 0.20 0.11 0.46 0.58 
4 HC 1.14 0.68 2.07 0.64 0.68 0.78 2.41 0.58 1.84 0.88 
5 HC 4.37 1.39 4.39 0.06 -1.55 4.70 0.40 0.16 0.01 0.01 
6 HC 2.35 1.18 2.47 0.19 0.99 1.31 2.25 0.73 2.04 1.82 
7 HC 0.66 0.80 0.98 0.48 0.38 0.25 3.31 0.44 0.91 0.93 
8 HC 1.66 0.60 1.65 0.14 3.58 4.30 0.85 0.86 0.65 0.61 
9 HC 1.69 1.31 1.23 0.98 2.09 1.50 1.15 0.37 2.03 0.68 
10 HC 1.22 1.04 1.01 0.70 0.34 1.34 -0.07 0.57 0.57 0.38 
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B 
 3 months 6 months 12 months 
ECU FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
0.7 
(-0.3, 1.8) 
0.7 
 (-0.4, 1.8) 
1.6 
 (0.6, 2.7) 
No. of subjects 9 7 8 
P value 0.17 0.19 <0.01 
EDM FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
0.1 
 (-2.2, 2.5) 
2.2 
(-0.4, 4.6) 
3.8 
(1.4, 6.3) 
No. of subjects 9 7 8 
P value 0.92 0.10 <0.01 
ED FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.2 
 (-0.7, 3.2) 
2.3 
(0.2, 4.4) 
2.9 
(0.9, 4.9) 
No. of subjects 9 7 8 
P value 0.21 0.03 <0.01 
APL FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.2 
(-2.1, 4.5) 
4.3 
(0.8, 7.9) 
6.6 
 (3.2, 10.0) 
No. of subjects 9 7 8 
P value 0.48 0.02 <0.001 
EPL FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.2 
 (-0.8, 3.2) 
1.0 
(-1.1, 3.1) 
1.3 
(-0.8, 3.3) 
No. of subjects 9 7 8 
P value 0.23 0.35 0.22 
ECRLB Br FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.7 
(-1.1, 4.5) 
6.1 
(3.1, 9.2) 
7.0 
(4.1, 10.0) 
No. of subjects 9 7 8 
P value 0.24 <0.001 <0.001 
FCU FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
3.6 
(0.6, 6.6) 
3.9 
(0.6, 7.1) 
6.0 
 (2.9, 9.1) 
No. of subjects 9 7 8 
P value 0.02 0.02 <0.001 
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FDP FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
0.05 
 (-2.4, 2.5) 
1.3 
(-1.3, 3.9) 
4.8 
(2.3, 7.3) 
No. of subjects 9 7 8 
P value 0.97 0.32 <0.001 
FCR FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
2.0 
(-1.9, 5.9) 
2.6 
(-1.6, 6.8) 
7.1 
(3.1, 11.1) 
No. of subjects 9 7 8 
P value 0.31 0.22 <0.01 
FDS & PL FAT FRACTION (%) 
 Mean change from baseline (±SD) 2.7 
(0.3, 5.0) 
6.0 
(3.5, 8.6) 
7.1 
 (4.7, 9.6) 
No. of subjects 9 7 8 
P value 0.03 <0.001 <0.001 
 
Table 18: Extensor carpi ulnaris (ECU), extensor digiti minimi (EDM), extensor 
digitorum (ED), abductor pollicis longus (APL), extensor pollicis longus (EPL), 
extensor carpi radialis longus/brevis and brachioradialis (ECRLB Br), flexor carpi 
ulnaris (FCU), flexor digitorum profundus and flexor pollicis longus (FDP), 
flexor digitorum; flexor carpi radialis (FCR); superficialis and palmaris longus 
(FDS & PL). P value < 0.01 was considered significant. 
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Longitudinally we observed a significant increase in central slice overall muscle 
f.f. at 6 months, with a mean increase of 3.8% (95% CI 1.9, 5.7%) above baseline in 
7 DMD (p<0.001).  At 12 months the mean increase for central slice overall 
muscle f.f. was 5.0 (95% CI 3.2, 6.9) above baseline (n=7). Examples of 3-point 
Dixon images are shown on figure 30.  Group mean changes from baseline are 
reported on table 19. Individual trajectories of DMD subjects are shown in figure 
30a.  
Proximal and distal slice mean increases also were significant at 12 months: 6.5% 
(95%CI 3.9, 8.9%; p<0.001) and 4.3% (95%CI 2.0, 6.6%; p<0.001) respectively (table 
19, figure 31 b&c). 
At 12 months, the dorsal compartment was more affected than the volar 
compartment, with, at the central-slice level, a mean increase of 6.3 % (95%CI 3.6, 
9.1; p<0.001) compared to the volar compartment (3.4 %, 95% CI 0.9, 5.7; p<0.01) 
(table18). All individual muscle groups showed a significant increase in f.f. over a 
year (all p<0.001, e-table 1b) with the ECRLB Br remaining the most affected 
muscle group, with a mean increase of  f.f. equal to 7.0% (95% CI 4.1, 10.0; 
p<0.001) (table18 B) 
Mean central slice total cross-sectional muscle area in the DMD subjects 
increased above baseline by 140 mm2 (95% CI 50.9, 229.1 mm2) at 12 months 
(p<0.01); however the total remaining (i.e. non-fat) muscle area, which at baseline 
was 1472 mm2 (95% CI 1289.3, 1654.7 mm2) remained overall unchanged at 12 
months (mean change in 7 subjects was = 22.0 mm2, 95% CI -48.2, 92.3 mm2, 
p=0.5). 
The mean f.f. (95% CI) central slice overall mean muscle f.f. change between 
baseline and 6 weeks in healthy controls was 0.8% (95% CI 0.6, 0.9%; p=0.67).   
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Figure 30. Three-point Dixon fat-fraction maps of dominant forearm central 
slice at baseline and 12 months  
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Figure 30. 3-point Dixon fat-fraction (f.f.) maps of dominant forearm central slice 
at baseline (left images) and 12 months (right images) of DMD subjects (A-D) and 
healthy control (E). Normal muscle appears black, in contrast with fat which is 
white, for example the sub-cutaneous fat and bone marrow. In DMD patients, fat 
infiltrated muscles are also white. Fat-fraction maps allow fat quantification 
(expressed in %, weighted for the area) in the regions of interest of the muscles 
which are evaluated. 
Top (A&B): 13 y.o. DMD, non-ambulant for 40 months, and on daily steroids. 
Overall mean f.f.  at baseline= 7.6%  (A) and 12 months = 9.7% (B).  Middle 
(C&D): 11 y.o. DMD, non-ambulant for 14 months, who was discontinued from 
steroid therapy. Mean f.f. at baseline= 30.7%(C) and 12 months =43.3%(D). (Grey-
level bars represent f.f. from 0 to 100%). Bottom (E): gender-matched healthy 
control (13 years), mean f.f.= 0.7% 
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Table 19. MRI and clinical indices mean changes from baseline from analysis 
of variance. 
 
 3 months 6 months 12 months 
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.4 
 (-0.3, 3.2) 
3.9 
(1.9, 5.7) 
5.0 
(3.2, 6.9) 
No. of subjects 9 7 7 
P value 0.11 < 0.001 < 0.001 
PROXIMAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 
 Mean change from baseline (95% 
CI) 
2.1 
(0.5, 3.7) 
4.5 
(2.7, 6.3) 
6.9 
(5.2, 8.7) 
No. of subjects 9 6 7 
P value 0.01 < 0.001 < 0.001 
DISTAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 
 Mean change from baseline (95% 
CI) 
2.18 
(0.06, 4.29) 
2.23 
(-0.05, 4.52) 
4.29 
(2.01, 6.58) 
No. of subjects 9 7 7 
P value 0.04 0.06 < 0.001 
CENTRAL SLICE DORSAL COMPARTMENT FAT FRACTION (%) 
 
 Mean change from baseline (95% 
CI) 
1.7 
 (-0.9, 4.4) 
5.5 
(2.7, 8.3) 
6.3 
(3.6, 9.1) 
No. of subjects 9 7 8 
P value 0.20 <0.001 <0.001 
CENTRAL SLICE VOLAR COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.3 
(-1.0, 3.7) 
0.7 
(-1.8, 3.3) 
3.4 
(0.9, 5.7) 
No. of subjects 9 7 8 
P value 0.27 0.58 <0.01 
ECRLB Br FAT FRACTION (%) 
 
 Mean change from baseline (95% 
CI) 
1.7 
(-1.1, 4.5) 
6.1 
(3.1, 9.2) 
7.0 
(4.1, 10.0) 
No. of subjects 9 7 8 
P value 0.24 <0.001 <0.001 
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CENTRAL SLICE TOTAL MUSCLE COMPARTMENT CROSS-SECTIONAL MUSCLE AREA (mm
2
) 
 Mean change from baseline (95% 
CI) 
-5.4 
(-88.1, 77.4) 
42.1 
(-47.0, 131.2) 
140 
(50.9, 229.1) 
No. of subjects 9 7 7 
P value 0.90 0.36 < 0.01 
CENTRAL SLICE TOTAL REMAINING  (NON-FAT) MUSCLE AREA (mm
2
) 
 Mean change from baseline (95% 
CI) 
-28.4 
(-93.6, 36.83) 
-32.1 
(-102.6, 38.1) 
22.0 
(-48.2, 92.28) 
No. of subjects 9 7 7 
P value 0.39 0.37 0.54 
MYOPINCH (Kg) 
 Mean change from baseline (95% 
CI) 
-0.1 
(-0.27, 0.03) 
-0.38 
(-0.53, -0.22) 
-0.50 
(-0.66, -0.34) 
No. of subjects 10 9 8 
P value 0.12 < 0.001 < 0.001 
MYOGRIP (Kg) 
 Mean change from baseline (95% 
CI) 
-0.22 
(-0.70, 0.27) 
-0.50 
(-1.01, 0.002) 
-1.04 
(-1.56, -0.51) 
No. of subjects 10 9 8 
P value 0.38 0.05 < 0.001 
PERFORMANCE OF UPPER LIMB (Total score=74) 
 Mean change from baseline (95% 
CI) 
-0.5 
(-2.8, 1.9) 
-2.6 
(-5.2, -0.03) 
-9.2 
(-11.9, -6.4) 
 
No. of subjects 14 11 9 
P value 0.69 0.05 < 0.001 
PERFORMANCE OF UPPER LIMB ( Shoulder domain score =16) 
 Mean change from baseline (95% 
CI) 
-0.7 
(-2.6, 1.1) 
-1.0 
(-2.9, 0.9) 
-6.9  
(-9.0, -4.9) 
No. of subjects 14 11 10 
P value 0.42 0.32 < 0.001 
MOVIPLATE (taps in 30 seconds) 
 Mean change from baseline (95% 
CI) 
2.3 
(-0.02, 4.6) 
4.7 
(2.01, 7.4) 
1.7 
(-0.8, 4.3) 
No. of subjects 11 7 8 
P value 0.05 0.001 0.19 
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Table 19. MRI and clinical indices mean changes (95%CI) from baseline from 
analysis of variance. P value <0.01 was considered significant 
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Figure 31. Plots of individual trajectories 
 
 
 
 
 
Figure 31. Plots of individual trajectories for (A) central slice overall muscle %fat 
fraction, (B) proximal slice overall muscle %fat fraction, (C) distal slice overall 
muscle %fat fraction, (D) MyoPinch, (E) total score for Performance of Upper 
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limb, (F) PUL Shoulder domain score, (G) MoviPlate and(H) MyoGrip. F.f.= fat 
fraction; PUL= Performance of upper limb 
Excluding the DMD boy who was not receiving steroids from the analysis did 
not change the statistical conclusions (table 20). 
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Table 20. MRI and clinical indices: mean changes from baseline; analysis of 
variance excluding the DMD subject not taking steroid therapy. 
 
 3 months 6 months 12 months 
CENTRAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.40 
 (0.06, 2.73) 
3.53 
(2.07, 4.98) 
3.90 
(2.45, 5.35) 
No. of subjects 8 6 6 
P value 0.04 < 0.001 < 0.001 
PROXIMAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.79 
(0.30, 3.26) 
4.46 
(2.81, 6.10) 
6.03 
(4.42, 7.64) 
No. of subjects 8 5 6 
P value 0.02 < 0.001 < 0.001 
DISTAL SLICE TOTAL MUSCLE COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.71 
(-0.30, 3.71) 
1.63 
(-0.55, 3.81) 
3.20 
(1.02, 5.38) 
No. of subjects 8 6 6 
P value 0.10 0.14 < 0.01 
CENTRAL SLICE DORSAL COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.5 
 (-1.4, 4.3) 
5.0 
(1.9, 8.1) 
5.4 
(2.5, 8.4) 
No. of subjects 8 6 7 
P value 0.32 <0.01 <0.001 
CENTRAL SLICE VOLAR COMPARTMENT FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.3 
(-0.6, 3.3) 
0.06 
(-2.0, 2.2) 
2.1 
(0.1, 4.1) 
No. of subjects 8 6 7 
P value 0.18 0.95 0.04 
ECRLB Br FAT FRACTION (%) 
 Mean change from baseline (95% 
CI) 
1.3 
(-1.6, 4.1) 
4.8 
(1.8, 7.9) 
5.9 
(3.0, 8.8) 
No. of subjects 8 6 7 
P value 0.38 <0.01 <0.001 
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CENTRAL SLICE TOTAL MUSCLE COMPARTMENT CROSS-SECTIONAL MUSCLE AREA 
(mm2) 
 Mean change from baseline 
(95% CI) 
-17.93 
 (-99.68, 
63.83) 
18.15 
(-70.70, 
106.97) 
101.47 
(12.65, 190.29) 
No. of subjects 8 6 6 
P value 0.67 0.69 0.03 
CENTRAL SLICE TOTAL REMAINING (NON-FAT) MUSCLE AREA (mm2) 
 Mean change from baseline 
(95% CI) 
-38.65 
(-110.08, 
32.79) 
-46.26 
(-123.86, 
31.34) 
15.19 
(-62.41, 92.79) 
No. of subjects 8 6 6 
P value 0.29 0.24 0.70 
MYOPINCH (Kg) 
 Mean change from baseline 
(95% CI) 
-0.16 
(-0.31, -0.004) 
-0.39 
(-0.55, -0.23) 
-0.52 
(-0.68, -0.36) 
No. of subjects 9 8 8 
P value 0.04 < 0.001 < 0.001 
MYOGRIP (Kg) 
 Mean change from baseline 
(95% CI) 
-0.20 
(-0.72, 0.32) 
-0.43 
(-0.97, 0.12) 
-1.01 
(-1.56, -0.47) 
No. of subjects 9 8 8 
P value 0.45 0.13 < 0.001 
PERFORMANCE OF UPPER LIMB (Total score=74) 
 Mean change from baseline 
(95% CI) 
-0.48 
(-2.84, 1.88) 
-2.60 
(-5.18, -0.03) 
-9.19 
(-11.96, -6.42) 
 
No. of subjects 13 10 8 
P value 0.69 0.05 < 0.001 
PERFORMANCE OF UPPER LIMB ( Shoulder domain score =16) 
 Mean change from baseline 
(95% CI) 
-0.37 
(-2.79, 2.05) 
-2.70 
(-5.37, -0.03) 
-8.37 
(-11.26, -5.48) 
 
No. of subjects 13 10 8 
P value 0.77 0.05 < 0.001 
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MOVIPLATE (taps in 30 seconds) 
 Mean change from baseline 
(95% CI) 
2.42 
(-0.05, 4.90) 
5.08 
(2.14, 8.02) 
1.86 
(-0.82, 4.55) 
No. of subjects 10 6 8 
P value 0.06 0.001 0.17 
 
Table 20. MRI and clinical indices: mean (95%CI) changes from baseline; analysis 
of variance excluding the DMD subject not taking steroid therapy. P value < 0.01 
was considered significant. 
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Clinical assessment 
At 6 months mean MyoPinch-measured pinch force decreased significantly from 
baseline by 0.38 kg (95% CI -0.22, -0.53; p<0.01) (table 19, figure 31e) in the DMD 
group (n=8).  Grip force measured by MyoGrip in 8 DMD subjects, significantly 
decreased at 12 months from baseline by 1.0 kg (95% CI -1.56, -0.51) over the 
duration of the study (p<0.001).  The group average PUL total score and shoulder 
domain index deteriorated significantly at 12 months, with a mean drop of  9.2 
(95% CI -11.9; -6.4; p<0.001) and  –6.9 (95% CI -9.0; -4.9; p<0.001)  respectively. 
Lower arm functional assessment using the MoviPlate detected a significant 
improvement of function at 6 months (4.69, 95% CI 2.0, 7.4; p=0.001) with 
subsequent decline (table19, figure 31 g). These conclusions remain unchanged 
by excluding the subject not treated with steroids (table 20). All other evaluations, 
including spirometry and muscle strength measurement with myometry, failed to 
reach statistical significance. Individual trajectories of some of these measures 
are shown in figure 32.  
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Figure 32. Plots of individual trajectories 
 
 
Figure 32: (A) Individual trajectories for central slice total cross sectional muscle 
area in mm2 and (B) total remaining muscle area in mm2 , (C) wrist extension 
with microfet myometer, (D) Egen Klassification (EK2), (E) Forced vital capacity 
(ltr) (F), Peak cough flow(ltr/sec)  
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Discussion 
This study suggests that MRI fat quantification in the upper limb forearm is a 
sensitive biomarker for disease progression in non-ambulant DMD boys. Not 
only was MRI capable of discriminating DMD from healthy controls (p=0.002), 
but it also allowed detection of increased forearm muscle-fat infiltration in the 
dominant forearm of DMD subjects as early as 6 months from baseline (p<0.001). 
At one year, the DMD group mean central slice muscle f.f. increase was 5.0% 
(95% CI 3.2, 6.9%) above a baseline value of 14.1% (95% CI 9.1, 19.1%; p<0.001). 
In addition, we demonstrated that whilst in the patient group mean total muscle 
compartment cross-sectional area increased over 12 months, the remaining total 
non-fatty muscle area within the muscle compartments did not change. We 
speculate that this reflects the process of fat infiltration or transformation in 
DMD, which, in the lower limb has been associated with hypertrophic changes. 
All muscle groups showed a significant increase in f.f. over one year (all 
p<0.001), with the dorsal compartment more affected than the volar. The ECRLB 
Br was the most severely affected muscle group at baseline (mean f.f. 31.1, 95% 
CI 22.5; 39.7%) and progressed more rapidly over the course of the study with a 
mean f.f. increase of 7.0% (95% CI 4.1, 10.0; p<0.001) at 12 months. The fat 
transformation of muscle extended over the whole length of the lower arm: 
proximal and distal slices showed a similar relative progression of fat 
transformation, although the proximal slice was more severely affected. Even 
within individual muscles, fat transformation showed more rapid progression in 
the more proximal segments.  
In relation to the clinical evaluation, at 6 months we observed significant 
decrease from baseline in pinch strength of 0.38 kg (95% CI -0.22, -0.53; p<0.001) 
as measured by the MyoPinch. This was sustained at one year (-0.50 kg 95% CI -
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0.22, -0.53 kg from baseline, p<0.001). Over 12 months handgrip strength was 
also significantly reduced by 1.0 kg (95% CI -1.56, -0.51 p<0.001). In line with 
previous publications,293, 294 the MoviPlate, a tapping device designed to measure 
endurance of upper limb, showed a modest improvement over 6 months 
followed by a decline. This phenomenon has been observed in the early non-
ambulant phases (i.e. boys who are wheelchair-bound < 3years)294 and can 
possibly be explained by a functional training effect of the distal upper limb 
following loss of ambulation and increase demands on arm function. The 
functional scale PUL showed highly significant disease progression and loss of 
function at 12 months (p<0.001), with a mean drop of 9.2 scores (95% CI -11.9; -
6.4) out of 74; this effect was predominantly driven by the loss of function in the 
shoulder domain. Interestingly, the loss of shoulder-girdle muscle function is 
associated to a progressive fatty transformation of lower arm muscles, suggesting 
that the changes we observed are not limited to the forearm muscles. Muscle 
strength of specific muscle groups was measured including shoulder extension, 
elbow flexion and extension, and wrist extension; however these assessments did 
not yield any significant results within the time frame studied and in this 
relatively small cohort of patients. None of the other assessments, including 
spirometry and a patients’ reported questionnaire showed significant changes 
over 12 months.  
When designing clinical trials for rare disorders, critical issues need to be taken 
into account and these include:  selecting an endpoint which is as observer and 
subject-motivation independent as possible; reducing the burden of participation 
in clinical trials favouring non-invasive endpoints; and selecting an endpoint 
capable of identifying clinically meaningful changes in a small cohort of patients.  
MRI technologies are increasingly applied to neuromuscular disorders, not only  
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in defining phenotype257,  but also in providing biomarkers responsive to 
therapies.286, 287  Studies have already demonstrated the suitability of MRI to 
characterise pathology in DMD, 268, 296  monitor disease progression in the lower 
limbs 267, 273, 297 and in the upper limb of non-ambulant subjects.285 Further studies 
have explored imaging in combination with strength and/or functional 
assessment of the lower extremities.270, 274, 298-301A recent study has shown that 
MRI and MRS can also effectively detect the beneficial effect of glucocorticoid 
therapy both in cross-sectional comparison and at 3 months.286 Furthermore, MRI 
combines the advantages of being overall well tolerated: unlike muscle biopsy, it 
is not an invasive procedure, and also allows the simultaneous quantitative 
assessment of multiple muscles. 
Workshops were held by international experts under the auspices of the TREAT-
NMD with the objective to harmonize the protocols for MR-based outcome 
measures in skeletal muscle studies.258 Moreover, a multicentre study evaluated 
the reproducibility among centres of MRI and MRS in lower limbs of DMD 
boys,276 facilitating recruitment in multicentre studies. In recent studies the 3-
point-dixon technique278, 302 has been evaluated as possibly the best methodology 
to be able to globally measure fat transformation in DMD,258, 269, 270 since fat 
transformation has been associated with disease progression in DMD, also 
supported by muscle pathology. Indeed, MRI and MRS have been included as 
exploratory endpoints in clinical trials for ambulant boys in patients treated with 
Drisapersen287 and in the on-going EU FP7 funded SKIP-NMD programme, 
which aims to restore dystrophin with morpholino antisense oligomer exon 
skipping for patients with deletions skippable by exon 53, and which will yield 
results by 2016.287, 303  
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To my knowledge, our pilot study provides longitudinal data on fat 
transformation in the forearm of non-ambulant DMD with 3-point Dixon 
imaging in the context of detailed clinical evaluation measurements for the first 
time. MRI and Myopinch sensitively detected changes at 6 months and in that 
case they both qualify as endpoints; however, these are highly complementary 
endpoints. MRI allows assessing individual muscles, and allows a 
comprehensive view across different muscle groups at different locations, 
whereas Myopinch specifically measures a function of strength, which reflects a 
joint effort of one distinct group of muscle. Furthermore, our results support the 
notion that f.f. determined by MRI could provide a reliable objective and 
clinically-meaningful marker for disease monitoring in DMD. The progression in 
fat transformation as measured by MRI in our cohort resulted not only in a 
decline in strength (for pinching at 6 months, and gripping at 12 months), but 
also in a functional impairment as measured by the PUL at 1 year; we therefore 
conclude that the increase in f.f. is clinically meaningful.  
The high sensitivity for change in DMD, which can detect significant disease 
progression as early as 6 months in a small cohort of patients, would allow 
design of clinical trials with shorter duration and limit the need for the larger 
sample sizes associated with conventional clinical end-points. For example, in 
our study we observed a mean change in total cross-sectional muscle f.f. at 6 
months from baseline of approximately 4% (± 3%) in 7 DMD subjects. In clinical 
trials, if this change was compared with an expected mean change of 
approximately 0.5% in a treated group,286 assuming a similar SD, a power of 90% 
and significance level of 5%, a minimum of 16 patients per group would be 
required. This would considerably reduce the sample size and duration of the 
study compared to studies designed with, for example, the 6-MWT as a clinical 
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end-point. Furthermore, these data also supports the feasibility of recruiting non-
ambulant DMD subjects into clinical trials under the assumption that a response 
to treatment should also be observed in the upper limb.   
This study protocol was well tolerated overall, allowing adequate rest between 
the image acquisition and physiotherapy assessment. The 6 subjects who 
withdrew from the study reported that the frequent hospital visits (i.e. 4 in 12 
months) were difficult to sustain in absence of therapeutic intervention. 
Although cooperation in lying still in the scanner is indispensable for image 
acquisition, on the whole this is not regarded as motivational-dependent as for 
conventional endpoints such the 6-MWT, for which performance may be affected 
by the level of tiredness or motivation on the day. 
Limitations of this study include the sample size being small, with a selected 
population (i.e. non-ambulant and below 18 years of age). It is likely that the 
measures explored in our study may vary according to age at baseline and length 
of time non ambulant, and it would be of interest to adjust for these factors in a 
future larger study. Furthermore, although it was not our objective here to 
explore the effect of treatment including steroids on MRI response, this may be 
important. However, excluding from the analysis the single patient not on 
steroid therapy did not alter our broad findings. Finally, our MRI coverage was 
limited to the dominant forearm, and the fat transformation analysis to three 
slices; further studies should address pathology and disease progression in limb 
regions and muscle groups not included here.  
In conclusion, the results of our study provide novel data to inform rational 
imaging endpoint incorporation and trial design for studies in non-ambulant 
Duchenne cohorts. I documented objective changes in MRI measures of muscle 
fatty transformation and suggested their clinical meaningfulness by 
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demonstrating a strong correlation with measures of muscle force, function and 
disease progression. The time course of response to deterioration observed 
suggests detection of disease stabilization or improvements over periods as short 
as 6-12 months is readily achievable. The complementarity of the methods 
suggests a mechanistic relationship between fat transformation of muscle tissues, 
muscle force production and overall function.   
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CHAPTER 7: FINAL DISCUSSION AND CONCLUSIONS  
Challenges of clinical trial design for DMD  
 
The changing natural history of DMD 
The natural history of Duchenne Muscular Dystrophy (DMD) is undoubtedly a 
shifting target, as shown by the work of my thesis and reported by numerous 
recent studies.29, 35, 304 And by “natural history” it is intended DMD-with-all-the-
intervention-available-to-date, which are summarised and elucidated in the 
standard of care documents published by Bushby and colleagues.32, 33 The natural 
history of this disorder goes hand in hand with the on-going evolution of 
therapies; hence this phenomenon needs to be respected and factored into the 
design of clinical trials.  Applying metrics based on old knowledge of the 
condition without taking into account new interventions risks making clinical 
trial design poorly adapted or obsolete and recruitment into studies very 
challenging.  For example, most ambulant patients are now on glucocorticoid 
therapy, and the age of starting steroids is indeed shifting towards a younger age 
as shown in the UK clinical practice;305 hence, designing studies with steroid 
therapy as an exclusion criterion in the young ambulant population risks making 
recruitment virtually impossible in most specialised centres. This could in turn 
skew recruitment and introduce recruitment biases. Furthermore, cardiac 
medications used prophylactically (i.e. beta blockers and ACE-inhibitors) are 
increasingly supported by evidence that their use is beneficial for DMD 
patients,52, 53, 306 although a consensus on what is the optimal age for commencing 
therapy is lacking. An on-going 5-year long clinical trial funded by the British 
Heart Foundation testing ACE-inhibitor (perindopril) combined with beta-
blocker therapy (bisoprolol) is targeting DMD boys 7-12 years of age who have 
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not developed signs of cardiomyopathy (EudraCT number: 2007-005932-10). This 
study will likely strengthen the body of literature in support of early 
intervention51 and indeed prevention; hence clinical trial design will have to 
become permissive towards heart medication given prophylactically. However, 
at least in animal models medications targeting angiotensin not only impact on 
cardiac load, but appear also beneficial for skeletal muscle307 making it difficult to 
assess if such medications introduce a bias into skeletal muscle-based trial 
outcome. A similar scenario will apply to anti-oxidative treatment such as 
ibedenone; with the recently published study146 supporting the beneficial effect 
on respiratory function it is expected that soon enough many patients will be 
treated on ibedenone alongside steroids although the study results were obtained 
on steroid-naïve patients and it is unknown to what degree the two drugs are 
complementary.  
 
Targeting the multisystem nature of DMD 
While current efforts are mainly focused on improving the skeletal muscle 
function, and some also cardiac function, it is becoming increasingly clear that , 
the evolving therapeutic interventions for DMD should ideally also reflect the 
multisystem nature of this disorder. This requires a shift in thinking: the target of 
experimental therapies should therefore not be solely the muscle but should 
ideally include other tissues and organs, such as smooth muscle, and the brain, 
also affected in this disorder.  Such interventions are indeed under development, 
for example with novel chemistries such as the modified antisense 
oligonucleotides peptide conjugated morpholinos (PPMO) and the tricyclo-DNA, 
not only target efficiently skeletal and cardiac muscle but also the brain in animal 
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models.308, 309 If proven to be beneficial in patients, these therapies have the 
potential of prolonging life span even further, as currently the most important 
cause of premature mortality in DMD is cardiomyopathy. Furthermore it is 
conceivable that therapies could also ameliorate the emotional/behavioural 
problems associated with disrupted dystrophin protein products in the brain. 
Indeed systemic administration of the tricyclo-DNA chemistry showed complete 
correction of behavioural features in the treated mdx mouse, yielding promising 
perspectives for future intervention also in humans; some of the most recently 
developed PPMOs also appear to be effective in crossing the blood brain barrier 
(M. Wood, F. Muntoni, M. Gait, personal observation).  If proven to be beneficial 
in patients, these novel class therapies have the potential of not only prolonging 
life span even further, as currently a very important cause of premature mortality 
in DMD is cardiomyopathy, but could potentially also address some of the issues 
related to deficiency of dystrophin in the CNS. 
 
The spectrum of phenotype within DMD 
The current clinical trials and natural history studies have also brought to surface 
further heterogeneity in the DMD population. For example, when plotting a 
functional scale score such as the North Star Ambulatory Assessment versus age 
it becomes evident that the motor function varies even in a cohort of patients 
assessed and treated with uniform protocols.159, 168, 305 A wide phenotypical 
spectrum is also a feature in other multisystem manifestations of DMD, such as 
the neuro-cognitive profile and is strongly influenced by the genotype 71, 72, 310, 311 
Similarly, response to treatment may vary from one subject to the other, 
including the response to corticosteroid therapy.35 With this in mind, in-depth 
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zoom on the inter-individual variability also begged the question: what are the 
determinants of variable disease course and manifestation?  It was described by 
the work of my thesis 305 and recent publications 168, 169 that different DMD 
mutations can follow a variable course, showing that genotype bears some role in 
phenotype expression. Even within cohorts amenable to exon skipping those 
deletions skippable by exon 44 clearly follow a milder course than those 
skippable by exons 51 or 53.  Although these differences may only become 
evident after 2 years of observation, clinical trial design needs to account for such 
variability. Novel techniques of dystrophin quantification 288, 312-314 have recently 
allowed to accurately quantifying the resulting protein product also across 
laboratories.315 This has facilitated the use of dystrophin quantification as a 
treatment-response-related biomarker in the setting of clinical trials; 76-81 
furthermore it allowed also to understand the role that even low residual protein 
expression may have in contributing to a less severe phenotype.162, 170, 316 Recently 
described gene disease modifiers also play a role in prolonging ambulation174, 175 
and influence treatment response to steroids.172 However, these results may need 
to be reproduced and further explored in larger scale populations, as their 
specific role especially in different ethnicities still needs to be fully evaluated. 
Finally, in spite of the efforts made to standardize treatment approaches such as 
steroid therapy, different regimens are currently being used and therapy is 
introduced at different ages, impacting on the effect that steroids can have on the 
disease course during the ambulant phase35 but possibly also after the age of loss 
of ambulation.44, 317  
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Impact of clinical trial design and outcome measures. 
With all these considerations in mind the design of clinical trials for DMD needs 
to take the dynamic variables of this condition into account. In such a panorama, 
biomarkers play a very important role. Biomarkers can be used to demonstrate 
pharmacodynamics proof of concept, as for example dystrophin quantification in 
dystrophin replacement therapies. Biomarkers can also be used to stratify 
patients, for example genetic disease modifiers (e.g. LTBP4, SPP1)172-175, 318 could 
guide stratification of less/more severely affected subjects if cohorts are 
sufficiently large. In addition, imaging biomarkers, such as the assessment of 
fatty transformation of skeletal muscle by MRI and MRS can be implemented to 
explore the variability of the phenotype and in future to create more 
homogenous cohorts for clinical trials. Finally, these novel biomarkers can 
potentially be used to monitor treatment response. For-example, fragments of 
myomesin-3, a myofibrillar structural protein, which are measured at abnormal 
levels in the sera of DMD subjects, have been found to be sensitive to monitor 
response to therapy in in mdx mice treated with morpholino AON.319 Similarly, 
longitudinal data on serum matrix metalloproteinase-9 showed increased levels 
with age and disease progression in DMD patients.320  In relation to the brain, 
monitoring of the bioelectrical response of the retina by ERG may be a 
convenient and non-invasive biomarker for monitoring the effects of CNS 
dystrophin restoration in retinal neurons.321 This is also pertinent for AAV-based 
gene correction therapy because AAV9 has previously been shown to effectively 
transduce the retina after systemic injection.322  A recent publication 154 reported 
improvement in skeletal muscle MR indices in Golden Retriever Muscular 
Dystrophy dogs injected with AVV- mediated U7snRNA-coupled antisense 
sequences promoting exon skipping. The injected limb after three months 
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showed improvement in T2w intensity; 31P NMS demonstrated a decrease in 
phosphodiester (PDE) signal and decrease in phosphocreatine (PCr) signal. The 
PDE/PCr ratio has been described to characterise muscle membrane metabolism 
and could potentially represent an effective biomarker of sarcolemma integrity.283 
Moreover, it was recently reported that the determination of the skeletal muscle 
fat fraction by MRI/MRS was able to detect the beneficial effects of steroid 
therapy in DMD subjects within 3 months of treatment.286  
MRI and MRS are currently included as an exploratory endpoints in clinical trial 
protocols for Duchenne Muscular dystrophy (http://www.skip-nmd.eu) and are 
able to monitor the relentlessly progressive fatty transformation, now 
documented for lower 267, 268 and upper extremities 285 as also described in the 
work of my thesis. These can be used as a baseline ruler of the disease 
progression. It is foreseeable that in future MRI/MRS may become a primary 
endpoint for clinical trials in DMD and other myopathies. 
 
The use of poly-therapies and a place for registries   
In neuromuscular disorders, specifically DMD, we are now most certainly 
entering an era when speeding-up of therapies is required. Clinical trial design 
needs to be adapted to the new disease course, and novel outcome measures 
need to be developed and implemented to reflect such an evolution.  It is 
predictable that within the next decade the treatment approaches for DMD will 
substantially alter the disease course; at the same time none of the approaches 
under development will cure the disease and likely this will be the scenario 10 
years from now. It is also predictable that medications now developed as single 
therapy need to be combined for a successful therapeutic approach in DMD (e.g. 
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gene therapy, AON, steroids, anti-oxidative medication). However concepts for 
developing combined therapeutic protocols such as in cancer treatment are still 
largely lacking for DMD and time-scales of decades are simply not acceptable. Of 
course the time pressure of a rapid malignancy versus that of a chronic 
progressive handicapping disease is different, hence fuelling different strings of 
research. This is why regularly and systematically updated registries and 
national databases may serve as useful platforms to capture the effect of 
combined treatment approaches and thereby modernise medicine even more so 
for rare and chronic disorders. National registries/database will be able to fulfil 
demands that are unlikely to be fulfilled by industry-sponsored studies. A 
successful example is the NorthStar clinical network and database in the UK, 
which allowed addressing questions such as long-term effects of different steroid 
regimens before any clinical trials could do;35 furthermore it advised the UK 
neuromuscular community on bone protection guidelines and on the disease 
course of different mutations.305 Likewise, the US-based clinical network CINRG 
and the Italian clinical network provided valuable and informative long-term 
natural history data on large cohorts of ambulant and non-ambulant subjects 43, 
116, 117, 159, 160 and also allowed to define disease-influencing genetic modifiers 
polymorphisms.318 I envisage that in the future similar and larger platforms 
could offer the opportunity to address other questions, for example in relation to 
poly-therapy (e.g. combined idebenone and steroids in the ambulant population) 
or the optimal age of starting cardiac medication prophylactically, or long term 
side effects of dystrophin replacement therapy (e.g. PTC). The use of national 
databases to define impact of therapeutic strategies today remains not readily 
accepted for regulatory purposes, with the exception of post-marketing follow 
up.  However, industry is frequently not willing to finance trials for preventive 
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treatment where follow-up longer than 5 years may be necessary to document a 
treatment effect, notably for medications already in use for common disorders. 
Furthermore, industry is even less willing to document cumulative positive or 
negative poly-treatment effects where part of the cocktail is conflicting with their 
interest. In this emerging panorama national and international 
databases/registries can play a critical role for the advancement of therapies and 
their development in DMD.  
 
Final conclusion 
 
In conclusion, with DMD as an example, I illustrated that multiple and combined 
strategies are required to accelerate therapeutic developments for neuromuscular 
disorders. This should include disease-specific and -sensitive outcome measures, 
which advance hand in hand with the evolving natural history of the condition; 
clinical trial design, which takes into account the variables and dynamics of the 
disorder; and finally integrate through intelligent use of registries/databases the 
collection of broad-based evidence to strengthen knowledge building and 
modernise clinical care for DMD.  
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